EP01.01. Adenocarcinoma and Small Cell Lung Cancer Risk Associated with Occupation in Women - PDF(Abstract)

EP01.01. Prognostic Analysis and Nomogram Establishment of Synchronous Dual Primary Lung Cancer: Based on Multicenter Data - PDF(Abstract)

EP01.01. Postoperative Course of Surgically Resected Lung Cancer Patients in Preserved Ratio Impaired Spirometry - PDF(Abstract)

EP01.01. Poor Sleep Quality in Lung Cancer Patients - PDF(Abstract)

EP01.01. Casual Effects of Some Chronic Respiratory Diseases on Squamous Cell Lung Cancer: A Mendelian Randomization Study - PDF(Abstract)

EP01.01. Sex Difference Indicate Survival Disparity in Resected NSCLC, from a Large Chinese Cohort - PDF(Abstract)

EP01.01. Histopathological Risk Factors Correlation in Patients with Non-Small Cell Lung Cancer - PDF(Abstract)

EP01.01. Radiation Exposure in Intraoperative Navigation for Peripheral Small Pulmonary Nodule - PDF(Abstract)

EP01.01. Long-term Survivals Associated with High Levels of Na+ and Ca2+ in the Blood of Patients with Stage IV Lung Cancer - PDF(Abstract)

EP01.01. Familial Aggregation in Non-small Cell Lung Cancer - PDF(Abstract)

EP01.01. Binge-Watching Frequency and Tobacco Use in Adolescents: Data from “Blaam Smoke-Free Movie” Program - PDF(Abstract)

EP01.01. Awareness and Perceptions of Compliance with the Nigerian Tobacco Control Law Among Young Adults in Lagos, Nigeria - PDF(Abstract)

EP01.01. Gender Differences in Clinical Course and Patient-Reported Outcomes among Patient with Early-Stage Non-Small Cell Lung Cancer - PDF(Abstract)

EP01.01. Osteoporotic Vertebral Fractures in Non-small Cell Lung Cancer : A Cracking Connection - PDF(Abstract)

EP01.01. Genomic Alterations of Lung Cancer: Experience in Peru - PDF(Abstract)

EP01.01. Impact of Smoking on Survival in NSCLC Patients Treated with Chemoimmunoimmunotherapy or Chemotherapy: A Real-world Data Study - PDF(Abstract)

EP01.01. Evaluation of Perioperative Nintedanib for Lung Cancer with Idiopathic Pulmonary Fibrosis - PDF(Abstract)

EP01.01. Respirable Crystalline Silica Exposure and Lung Cancer Risk: A Review of Cut-off Points - PDF(Abstract)

EP01.01. Risk Factors of Intraoperative Air Leakage in Anatomical Pulmonary Resection - PDF(Abstract)

EP01.01. Provider Perspectives on a Navigational Pilot Study for Cancer Patients within a Tobacco Treatment Program - PDF(Abstract)

EP01.01. Median Age at Lung Cancer Diagnosis in 60 Countries: An International Comparative Study - PDF(Abstract)

EP01.01. Occupational Exposure and Lung Cancer Risk in Women: A Pooling Study - PDF(Abstract)

EP01.01. Association between ACEI-Induced Cough and the Risk of Lung Cancer: A Mendelian Randomization Study - PDF(Abstract)

EP01.01. Gender and Lung Cancer (LC): Preliminary Data from a Prospective, Woman-Centered Local Registry - PDF(Abstract)

EP02.01. Differing Cell Cycle Responses for Alectinib and SHP099 in Variant 1 and Variant 3 ALK+ Non-Small Cell Lung Cancer Cell Lines - PDF(Abstract)

EP02.01. Novel Therapeutic Vulnerabilities in SOX2-dependent Squamous Cell Lung Cancer - PDF(Abstract)

EP02.01. Suppression of Telomerase RNA Component Induces Autophagy and Ferroptosis in Lung Cancer via Regulation of AMP-actived Protein Kinase - PDF(Abstract)

EP02.01. Androgen Receptor Suppresses Lung Cancer Invasion and Cisplatin Resistance via Decreasing TPD52 Expression - PDF(Abstract)

EP02.01. Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases - PDF(Abstract)

EP02.01. TP53 Mutation Has Significant Impact on Other Driver Genes in Lung Cancer - PDF(Abstract)

EP02.01. DEPDC1 Expression and Mechanisms in Lung Adenocarcinoma : Insights into Proliferation and KIF2C Regulation - PDF(Abstract)

EP02.01. SOX2 Deregulated Squamous Carcinomas Are Vulnerable to AKT3 Inhibition - PDF(Abstract)

EP02.01. Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma - PDF(Abstract)

EP02.01. Dysfunction of FBXL5-mediated Ferrous Iron Homeostasis Suppresses Lung Cancer Growth - PDF(Abstract)

EP02.01. CSNK1D and CSNK1E Inhibition Regulates Autophagy by Promoting Autophagic Flux in Lung Cancer - PDF(Abstract)

EP02.01. PEG2000-PLA-Based Nanoscale Polymeric Micellar Reduces Paclitaxel-Related Toxicity in Beagles - PDF(Abstract)

EP02.02. Genomic Correlates with Ancestry in Lung Squamous Cell Carcinoma - PDF(Abstract)

EP02.02. Transcriptomic Response to Tumor Treating Fields (TTFields) Across Tumor Types - PDF(Abstract)

EP02.02. Combination of Radiotherapy and PD-L1 Blockade Induces Abscopal Responses in EGFR-mutated Lung Cancer - PDF(Abstract)

EP02.02. Microbiome in Lung Cancer: Culture-Based Analysis Using Transthoracic Needle Biopsy (TTNB) - PDF(Abstract)

EP02.02. Radiation-induced SERPINE2 Expression Inhibit Abscopal Effect in Non-small Cell Lung Cancer via Exosomes - PDF(Abstract)

EP02.02. Machine Learning for Multi-Omics Data Identifies Vulnerabilities in a Subset of Squamous Cell Lung Cancers - PDF(Abstract)

EP02.02. Identification of COL5A2+ Cancer-Associated Fibroblast in Solid Subtype of LUAD by Integrated Analysis of WGCNA and Single Cell RNA-seq - PDF(Abstract)

EP02.03. ADAR1 Knockout Results in Loss of Tumorigenicity in a Syngeneic Murine Model of Non-small Cell Lung Cancer. - PDF(Abstract)

EP02.03. Defining Genetic Instability at Tetranucleotide Repeats (EMAST) In a Non-small Cell Lung Cancer - PDF(Abstract)

EP02.03. The Functional and Mechanistic Role of PA28α in Lung Cancer - PDF(Abstract)

EP02.03. Silencing of Long Non-coding RNA LINC00265 Triggers Autophagy in Lung Canerby Reducing Protein Stability ofSIN3A Oncogene - PDF(Abstract)

EP02.03. Circular RNA-mediated ceRNA Network was Indentified in Human Lung Adenocarcinoma by High-throughput Sequencing - PDF(Abstract)

EP02.03. Suppression of the Long Non-coding RNA LINC01279 Triggers Autophagy in Lung Cancer by Regulating SIN3A - PDF(Abstract)

EP02.03. LINC00629 Regulates Cell Proliferation, Migration, Invasion and Apoptosis of Lung Adenocarcinoma - PDF(Abstract)

EP02.04. The Suppressed Peritumoral Immune Microenvironment Enhances the Progression of Primary Lung Cancer And Metastatic Liver Tumor - PDF(Abstract)

EP02.04. A Nanoplatform Based on an in Situ Tumor Vaccine and Activation of STING and TLR7/8 Pathways for Enhanced NSCLC Immunotherapy - PDF(Abstract)

EP02.04. Frequency of the Number of Myeloid Derived Suppressor Cells in Patients with Lung Cancer According to Tumor Pathohistological Type - PDF(Abstract)

EP02.04. PHLPP2 Enhances Anti-tumor Immunity by Promoting M1 Polarization of Macrophages via STAT3-related Pathway in NSCLC - PDF(Abstract)

EP02.04. Xenotransplanted Lung Tumors Display Variable Pleomorphic Patterns in Immunosuppressed BALB/c Mice - PDF(Abstract)

EP02.04. Integrative Single Cell RNA Sequencing Reveals New Insight in Lung Cancer Microenvironment - PDF(Abstract)

EP03.01. Genetic Alterations as Independent Prognostic Factors to Predict Organ-Specific Metastases of Lung Cancer - PDF(Abstract)

EP03.01. Molecular Characterization of Non-small Cell Lung Cancer in People Living with HIV or Solid Organ Transplants - PDF(Abstract)

EP03.01. Differences in Glucose and Energy Metabolism between Lung Squamous Cell Carcinoma and Lung Adenocarcinoma - PDF(Abstract)

EP03.01. The Role of Microenvironmental Biomechanics in Lung Cancer Development and Metastasis - PDF(Abstract)

EP03.02. EGFR T790M Detection Differences by Original Mutation Types and Detection Samples - PDF(Abstract)

EP03.02. miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in NSCLC cells by targeting USP37 - PDF(Abstract)

EP03.02. High-Throughput Screening Reveals Ceritinib as a Sensitizer for Cafs-Induced Osimertinib Resistance in Non-small Cell Lung Cancer - PDF(Abstract)

EP03.03. IS1160 Transposon Mycobacterium Tuberculosis Detection in Lung Cancer - A Preliminary Study - PDF(Abstract)

EP03.03. Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer - PDF(Abstract)

EP03.03. Comprehensive Analysis of Primary Immunotherapy-resistant Genes with Regard Immune Infiltration and Prognosis in Lung Adenocarcinoma - PDF(Abstract)

EP03.03. Decoding the Immune Dysfunction of Cancer Cachexia in Lung Cancer Patients - PDF(Abstract)

EP03.03. Immunological Profiling of PD-1-Treated Murine Model Reveals Meyloid-Enriched Phenotypes - PDF(Abstract)

EP03.03. The Involvement of Tumor Endothelial Cells in the Regulation of PD-L1 and Tregs in the Immune Microenvironment of Early-stage Lung Adenocarcinoma - PDF(Abstract)

EP03.03. T-Cell Receptor Repertoire Profiling as a Predictive Biomarker for Immunotherapy in Unresectable Stage III Non-small Cell Lung (NSCLC) - PDF(Abstract)

EP03.03. Single-nucleus RNA Sequencing Dissecting the Tumor Microenvironment of Liver Metastasis of Non-small Cell Lung Cancer - PDF(Abstract)

EP03.03. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS CoV2 Vaccination in Patients with Non Small Cell Lung Cancer - PDF(Abstract)

EP03.04. Detection of Possible Targets in Aggressive Lung Cancer Using Molecular Abundances and Catalytic Action of Serine Hydrolases - PDF(Abstract)

EP03.05. Aberrant Methylation of ZNF577 As a Potential Prognostic Biomarker for Lung Adenocarcinoma - PDF(Abstract)

EP03.05. Genomic Landscape Features of Minimally Invasive Adenocarcinoma and Invasive Lung Adenocarcinoma - PDF(Abstract)

EP03.05. Hollow-MnO2 Nanofabricated Platform Equipped with Carbon Monoxide Gas Combined with SDT Enhanced ROS Generator for Lung Cancer Treatment - PDF(Abstract)

EP03.05. RNA Sequencing to Characterize Pathways in Patients with EGFR-mutated Non-Small Cell Lung Cancer - PDF(Abstract)

EP03.05. Non-Small Cell Lung Cancer: Artificial Intelligence, Complex System Analysis and Computer Simulation for Best Management. - PDF(Abstract)

EP03.05. Identification of Oncogenic Non-coding Regions Inducing the ANKZF1 Expression in Lung Cancer by a Multi-omics Website Omics3D - PDF(Abstract)

EP03.06. Differential Anticancer Compound Response of Filipino Patient-derived Lung Adenocarcinoma Cells (GL01) Against A549 Cell Line - PDF(Abstract)

EP03.06. The Landscape of NF1 Alteration in Chinese Non-Small-Cell Lung Cancer Patients - PDF(Abstract)

EP03.06. Development of an Inhibitor for the Treatment of Lung Cancer - PDF(Abstract)

EP03.06. Synthetic Lethality Targeting Programmed Cell Death Reverses the Osimertinib Resistance Induced by ARID1A Deficiency in LUAD - PDF(Abstract)

EP03.06. KRAS-B: Molecular Epidemiology and Clinical Outcomes of KRAS-Mutant Non-small Cell Lung Cancer (NSCLC) in Brazil - PDF(Abstract)

EP04.01. The PneuVision Test Detects Both Lung Squamous Cell Carcinoma and Adenocarcinoma from Cells in Sputum - PDF(Abstract)

EP04.01. Volatile Organic Compounds in Exhaled Breath as Biomarkers for Lung Cancer. A Screening-Based Study in High-Risk Participants - PDF(Abstract)

EP04.01. Advancing Malignancy Risk Stratification for Early-Stage Cancers in Lung Nodules by Combined Imaging and Electrical Impedance Analysis - PDF(Abstract)

EP04.01. Detecting KRAS Mutations in Peripheral Blood Extracellular Vesicles in Non-Small Cell Lung Cancer Using Digital Droplet PCR - PDF(Abstract)

EP04.01. True Abnormal Cells in Normal Cases Detected by the PneuVision Test for Early-Stage Lung Cancer - PDF(Abstract)

EP04.01. Double Blind Evaluation of Circulating Cancer Associated Macrophage Like (CAML) Cells for Detection of Cancer in Pulmonary Nodules - PDF(Abstract)

EP04.01. Optimal Predictors for Lung Cancer Using High-Resolution CT - PDF(Abstract)

EP04.01. The Combination of a Seven-Autoantibody Panel with Computed Tomography Scanning Can Enhance the Diagnostic Efficiency of Lung Cancer - PDF(Abstract)

EP04.01. AI-based Detection on Low-Dose CT: A Focus on Augmenting Model Performance - PDF(Abstract)

EP04.01. METTL7A Inhibits Cell Proliferation and M2-Like Polarisation of Tumor-Associated Macrophage in Lung Adenocarcinoma - PDF(Abstract)

EP04.02. Impact of an Urban Based Lung Cancer Screening Program: Seven Year Follow-up - PDF(Abstract)

EP04.02. Implementation of an Integrated Lung Cancer Screening Program at a Large Academic Community Health System in the U.S. - PDF(Abstract)

EP04.02. Cost-Consequence Analysis of Artificial Intelligence Assisted Image Reading in Lung Cancer Screening - PDF(Abstract)

EP04.02. Screening Success: A Review of Outcomes from Lehigh Valley Health Network’s Multi-Disciplinary Lung Cancer Screening Program. - PDF(Abstract)

EP04.04. Delay in Lung Cancer Diagnosis as a result of being Diagnosed as Pulmonary Tuberculosis in Riau Province - PDF(Abstract)

EP04.04. Incidental Lung Nodule Identification and Subsequent Diagnosis of Lung Cancer in a University Hospital in Hong Kong - PDF(Abstract)

EP04.04. Impact of a Lung Nodule Program in a Tertiary Care Academic Center in the United States - PDF(Abstract)

EP04.04. Relevance of AI (qCT ) In Automated Progression Monitoring of Pulmonary Nodules in Follow-up Lung CT Scans - PDF(Abstract)

EP04.04. Ten-year CTNB Data Indicate Its Usefulness and Safety, Especially Salvage Situation after Bronchoscopy without Diagnosis - PDF(Abstract)

EP04.04. Low-Dose CT Iterative Reconstructions can Impact Lung Nodule Measurements and Type Classification - PDF(Abstract)

EP04.04. The Frequency of Incidental Lung Cancer Detected in Thorax CT During the COVID-19 Pandemic Process in Turkey - PDF(Abstract)

EP04.05. Comparison of Two Enrolment Criteria in Lung Cancer Screening Pilot Project in Estonia - PDF(Abstract)

EP04.05. Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening. - PDF(Abstract)

EP04.05. Perspectives of Potentially Eligible Indigenous Māori on a Lung Cancer Screening Programme - A Qualitative Study - PDF(Abstract)

EP04.05. Impact of Magnitude of Lung Cancer Screening Benefit on Uptake - PDF(Abstract)

EP04.05. Singapore Lung Cancer Screening through Integrating CT with Other Biomarkers (SOLSTICE), A Single Arm Lung Cancer Screening Study - PDF(Abstract)

EP04.05. Centralized Shared Decision Making in Lung Cancer Screening: Unexpected Consequences - PDF(Abstract)

EP04.05. Improved Efficiency with Lungflag vs Opportunistic Selection in a Theoretical East Asian Lung Cancer Screening Program - PDF(Abstract)

EP04.06. Compliance with Lung Cancer Screening Guidelines Among At-Risk Patients at a Rural Teaching Hospital in West Texas - PDF(Abstract)

EP04.06. Multimodal Intervention Strategies to Improve Lung Cancer Screening for Women Undergoing Breast Screening - PDF(Abstract)

EP04.06. Qualitative Study Using Focus-Group Interviews on Cognition of Lung Cancer Screening and Symptom - PDF(Abstract)

EP04.06. Impact of a Navigational Program on Lung Cancer Screening at a Community Health Center Serving an Urban Diverse Population - PDF(Abstract)

EP04.07. Message from the Patients: What If I Wasn’t COVID 19 - PDF(Abstract)

EP05.01. An Analysis of Lymph Node Metastasis Patterns in Surgical Cases of Non-small-Cell Lung Cancer - PDF(Abstract)

EP05.01. Cryobiopsy for Peripheral Pulmonary Lesions Using a 1.1 mm Cryoprobe and Guide Sheath without Fluoroscopy: The Initial 400 Cases - PDF(Abstract)

EP05.01. A Retrospective Study on the Efficacy and Safety of Flexible Bronchoscopy in Elderly Patients with Suspected Primary Lung Cancer - PDF(Abstract)

EP05.01. Predictive Factors for Hemoptysis Following CT-guided PCNB : The Role of Post-procedure CT Findings and Cough after Biopsy - PDF(Abstract)

EP05.01. Propective Study: Usefulness of D-Dimer Determination for Thromboembolic Disease Screening in Patients with Metastatic Lung Cancer. - PDF(Abstract)

EP05.01. Observation of Peripheral Airways Using Ultra-Thin Fiberscope - PDF(Abstract)

EP05.01. Lung Cancer in Combined Pulmonary Fibrosis and Emphysema Syndrome Patients. A Complication or a Comorbidity? - PDF(Abstract)

EP05.01. Multi-scale Generator with Channel-wise Mask Attention to Generate Synthetic Contrast-enhanced Chest Computed Tomography - PDF(Abstract)

EP05.01. Lung Cancers Diagnosed in a Retrospective Cohort of Lung Nodule Patients in Singapore - PDF(Abstract)

EP05.01. A Retrospective Audit of Lung Nodules with Validation of the Brock Tool in a Singaporean Cohort - PDF(Abstract)

EP05.01. Time to Lung Cancer Diagnosis and Treatment in the Era of the COVID-19 Pandemic - PDF(Abstract)

EP05.01. Survival in Patients with Malignant Pleural Effusion Treated with a Tunneled Pleural Catheter Compared to the Lent Prognostic Score Scale - PDF(Abstract)

EP05.01. Prognosis in Terms of Invasive Non-mucinous Adenocarcinoma Grading System - PDF(Abstract)

EP05.01. Re Evaluation of a Larger Sample: Anatomical Variation Analysis of Left Upper Pulmonary Based on 3Dreconstruction of Chest CT - PDF(Abstract)

EP06.01. Concordance Between Generative AI GPT-4 and NCCN Guidelines: Biomarker-Driven Treatment Strategies in NSCLC - PDF(Abstract)

EP06.01. A Circulating Tumor Cell-based Artificial Neural Network of Patients with Advanced Non-Small Cell Lung Cancer - PDF(Abstract)

EP06.01. Evaluation of Unstained Cytology Slides for Artificial Intelligence Rapid On-Site Evaluation - PDF(Abstract)

EP06.01. Deep Learning Based Quality Assessment of DAPI Stained Nuclei Images Obtained from Routine FISH Test for Lung Cancer - PDF(Abstract)

EP06.02. Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective - PDF(Abstract)

EP06.02. Enrichment for PD-L1 High Tumors in AXL-Expressing Advanced Non-small Cell Lung Cancer (NSCLC) - PDF(Abstract)

EP06.02. PD-L1 Expressions in Non-small Cell Lung Cancer and its Correlation with Imaging Findings - PDF(Abstract)

EP06.02. The Relationship between Pathologic and Molecular Characteristics and PD-L1 Expression in Surgically Resected Non-small Cell Lung Cancer - PDF(Abstract)

EP06.02. Agreement among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer. - PDF(Abstract)

EP06.02. Pan-cancer Analyses Reveal Immune Infiltration and Clinical Outcomes of IL7R - PDF(Abstract)

EP06.02. Tertiary Lymphoid Structures Predict Clinical Outcomes of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC - PDF(Abstract)

EP06.03. Genetic Characterization of Driving Metastasis in TP53-Mutant Non-small Cell Lung Cancer Patients - PDF(Abstract)

EP06.03. Elucidating Tumor Heterogeneity from Spatially Resolved Transcriptomics in ALK-Rearranged Non-small Cell Lung Cancer - PDF(Abstract)

EP06.03. Molecular Alterations in Non-Small Cell Lung Cancer Arising in Emphysematous and Fibrotic Lungs - PDF(Abstract)

EP06.03. EGFR Exon 20 Insertion Mutations in NSCLC: The Need for Accurate Naming Conventions and Implications for Personalized Therapy - PDF(Abstract)

EP06.03. Clinical Impact of EGFR vs KRAS Mutations in Multifocal Lung Adenocarcinoma - PDF(Abstract)

EP06.03. Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience - PDF(Abstract)

EP06.03. Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma - PDF(Abstract)

EP06.03. Characteristics of Insufficient Samples for EGFR Mutation Testing at the Lung Center of the Philippines - PDF(Abstract)

EP06.03. HER3 Expression in Archived Tissue Samples from Patients with NSCLC Across Various Genomic Subtypes and Characteristics - PDF(Abstract)

EP06.03. Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center - PDF(Abstract)

EP06.03. Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2) - PDF(Abstract)

EP06.03. HRR Gene Mutations- A New Biomarker for Precision Genomics Based Testing in Metastatic Lung Cancer - PDF(Abstract)

EP06.03. Genomic Alterations in Advanced Lung Cancer Patients Compared via CGP and Hotspot Panel Test in a Bangladeshi Tertiary Hospital - PDF(Abstract)

EP06.03. Predicting ROS1 Fusions and Targetable Mutations in Non-small Cell Lung Cancer through H-score Pathological Analysis - PDF(Abstract)

EP06.03. Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations - PDF(Abstract)

EP06.03. The Prognostic Impact of Postoperative EGFR Mutation Status in Lung Cancer Patients with Stage II - III - PDF(Abstract)

EP06.03. Atlas: Italian Knowledge Based Database for Biomarkers Analysis In NSCLC Patients - PDF(Abstract)

EP06.03. Genomic Landscape of Non-Small Cell Lung Cancer in the Republic of Ireland - PDF(Abstract)

EP06.03. Molecular Testing of Pulmonary Adenosquamous Cell Carcinoma for EGFR Mutation and ALK Gene Rearrangement - PDF(Abstract)

EP06.03. Usefulness of Immunohistochemistry for the Detection of BRAFV600E in Lung Cancer: A Multicenter Retrospective Study in China - PDF(Abstract)

EP06.03. Implementing Next Generation Sequencing for Lung Cancer Patients in Mexico: A Real-World Study from Puebla - PDF(Abstract)

EP06.04. Challenge to Detect CTC-derived EGFR Mutation of Non-small Cell Lung Carcinoma by Unique Blood-Filtration Device - PDF(Abstract)

EP06.04. FLUIDIndia:Liquid "First" Approach is a "Solid" Solution in NSCLC - PDF(Abstract)

EP06.05. Molecular, Clinicopathological Characteristics of Thoracic SMARCA4‑defcientUndifferentiated Malignant Tumor -5 Cases Review- - PDF(Abstract)

EP06.05. Accuracy of Postoperative Thoracic Malignancy Diagnosis in National Respiratory Center Persahabatan Hospital - PDF(Abstract)

EP06.05. Subpleural Cystic Mesenchymal Neoplasm with Endometrial-type Stromal Proliferation: A Report of 3 Cases - PDF(Abstract)

EP06.05. SMARCA4/BRG1 Deficient Thoracic Neoplasms: Spectrum Encompassing Carcinomas to Undifferentiated Tumors - PDF(Abstract)

EP06.05. Molecular Characteristics of Lung Signet Ring Cell Carcinoma in the Chinese Population - PDF(Abstract)

EP06.05. Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients - PDF(Abstract)

EP06.05. Non Small Cell Lung Cancer Associated to Dipnech: A Clinico-Pathological Analysis of 32 Cases - PDF(Abstract)

EP06.05. Efficacy of Preoperative Biopsy in Predicting the Newly Proposed Histologic Grade of Resected Lung Adenocarcinoma - PDF(Abstract)

EP06.05. Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC - PDF(Abstract)

EP06.05. Immunohistochemical Features in Tissue Microarray in Pleomorphic Carcinoma of the Lungs - PDF(Abstract)

EP06.05. Histopathologic Changes of the Perioperative Pirfenidone Therapy in Lung Cancer with Idiopathic Pulmonary Fibrosis - PDF(Abstract)

EP06.05. Validation of the IASLC Grading System of Invasive Adenocarcinoma of the Lung in Small Volume Center - PDF(Abstract)

EP06.05. Twelve Cell Death Patterns-Related Classification of the Immune Microenvironment and Prognosis Prediction of LUSC - PDF(Abstract)

EP06.05. STAS and Expression of EMT-markers in Surgically Resected Lung Pleomorphic Carcinomas - PDF(Abstract)

EP06.06. Insulin Like Growth Factor 2 mRNA Binding Protein3 is a Novel Post-Transcriptional Regulator of Lung Adenocarcinoma Malignancy - PDF(Abstract)

EP06.06. Correlation between Vitamin C and CRP Serum Levels in Non Small Cell Lung Cancer Patient Among Sumatera Utara Population - PDF(Abstract)

EP06.06. The Expression of MIR-320B in Extracellular Vesicles as a Prognostic factor for Non-small Cell Lung Carcinoma - PDF(Abstract)

EP06.06. The Expression of MIR-320B in Extracellular Vesicles as a Prognostic Factor for Non-small Cell Lung Carcinoma (2) - PDF(Abstract)

EP06.06. Circular RNA hsa_circ_0067705 Expression as a Potential Diagnostic Biomarker for Malignant Pleural Effusion - PDF(Abstract)

EP06.06. Plasma Extracellular Vesicle miR-10b-5p as a Biomarker for Progressivity, Survivorship and Treatment Response in NSCLC Patients - PDF(Abstract)

EP06.06. Surveying for Lung Cancer after Idiopathic Pulmonary Fibrosis at Pham Ngoc Thach Hospital - Viet Nam in 5 year (2017 - 2021) - PDF(Abstract)

EP06.06. Comparison of RICTOR FISH and Rictor Immunohistochemistry in Lung Squamous Cell Carcinoma - PDF(Abstract)

EP06.06. Clinical Significance of the Presence of MECA-79-Positive Tumor Cells in Pathological Stage IA Invasive Adenocarcinoma of the Lung - PDF(Abstract)

EP06.06. Cancer-Associated Fibroblasts and Estrogen Receptor Beta in Lung Cancer with Idiopathic Pulmonary Fibrosis - PDF(Abstract)

EP06.06. Expression of miR-30a-5p in Expression of Mir-30A-5P in Extracellular Vesicle as a Prognostic Biomarker for Non Small Cell Lung Cancer Therapy - PDF(Abstract)

EP06.06. EBUS as a Novel Procedure for Microbiome Collection and Analysis in NSCLC - PDF(Abstract)

EP06.06. Fibronectin Promotes Tumor Angiogenesis and Progression of Non-small-Cell Lung Cancer - PDF(Abstract)

EP06.06. High Circulating Activin a Plasma Level Is Associated with Advanced Tumor Stage and Poor Prognosis in Lung Squamous Cell Cancer Patients - PDF(Abstract)

EP06.06. Epigenetic Silencing of MYO1E in a US Veterans Cohort with Lung Adenocarcinoma and the Effect on Overall Survival - PDF(Abstract)

EP07.01. Nomogram for Predictingprognosis andAdjuvant Chemotherapy BenefitsinEarly-stageInvasive Mucinous Lung Adenocarcinoma - PDF(Abstract)

EP07.01. Perioperative Outcomes & Strategies for Pleomorphic Carcinoma in Lung - PDF(Abstract)

EP07.01. A Study of the Characteristics of Lung Cancer Surgery Cases in the Elderly and the Usefulness of the Japanese NCD risk calculator - PDF(Abstract)

EP07.01. Lead-Time Bias in Surgically Resected Non-Small Cell Lung Cancer (NSCLC) Diagnosed Through Different Pathways of Care - PDF(Abstract)

EP07.01. Comparison of Surveillance with Contrast Chest CT and Non-contrast Chest CT among who Survived 2 Years after Curative Resection for Lung Cancer - PDF(Abstract)

EP07.01. Development of a Shared Decision-Making Tool for Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer. - PDF(Abstract)

EP07.01. Can the Use of New Haemostatic Agent Improve Short Term Outcomes of Surgically Treated Non-small Cell Lung Cancer Patients? - PDF(Abstract)

EP07.01. Ablation of Early-Stage Non-Small Cell Lung Cancer in Patients With Interstitial Lung Disease: A Multicenter Retrospective Cohort Study - PDF(Abstract)

EP07.01. A Retrospective Study on the Methods of Covering Bronchial Stump/Anastomotic Site to Avoid the Bronchopleural Fistula after Lung Cancer Surgery - PDF(Abstract)

EP07.01. Definitive Chemoradiation versus Radiation Alone for Stage II Non-Small Cell Lung Cancer. A National Cancer Database Analysis - PDF(Abstract)

EP07.01. Assessing Morphometric Complexity in Lung Parenchyma of NSCLC Patients with IPF Undergoing Radiotherapy - PDF(Abstract)

EP07.01. Utility of Bronchus-First Right Upper Lobectomy as a Routine Technique - PDF(Abstract)

EP07.01. The Relationship of FDG PET-SUVm and Glucose Metabolism and Contribution to Early-Stage Non-Small Cell Lung Cancer Survival - PDF(Abstract)

EP07.01. Adjuvant Chemotherapy is Less Effective in Non Small Cell Lung Cancer Patients Rated Undernourished by CONUT Score - PDF(Abstract)

EP07.01. Factors Affecting Postoperative Nausea and Vomiting in Surgical Patients with Non-Small Cell Lung Cancer - PDF(Abstract)

EP07.01. A 22 to 23G Intraoperative Needle Biopsy Does Not Affect Recurrence of Preoperatively Undiagnosed Stage 1 Lung Cancer - PDF(Abstract)

EP07.01. Identifying the Optimal Number of Lymph Node Stations for Improving Survival in Resections for Non-small Cell Lung Cancer - PDF(Abstract)

EP07.01. Stereotactic Body Radiation Therapy for Patients with Early-Stage Non-small Cell Lung Cancer Inoperable - PDF(Abstract)

EP07.01. Surgical Treatment of Lung Cancer in Patients Over the Age of 75 Years: Single Cancer Centre Experience - PDF(Abstract)

EP07.01. Implementation and Safety of a Same-day Discharge Program for Minimally-invasive Pulmonary Resection - PDF(Abstract)

EP07.01. Is Chemical Venous Thromboembolism Prophylaxis Necessary After Lung Cancer Resection? A 10-year T-ERAS Experience - PDF(Abstract)

EP07.01. The Impact of Comorbidities on Exercise Level after Treatment for Early-Stage Lung Cancer Patients - PDF(Abstract)

EP07.01. Local Control & Toxicity Results of Stereotactic Body Radiotherapy in Central Lung Tumors - PDF(Abstract)

EP07.01. What Is a Risk Factor for Postoperative Home Oxygen Therapy in Primary Lung Cancer Patients? - PDF(Abstract)

EP07.01. Predictors of Poor Quality of Life Following Lung Cancer Surgery - PDF(Abstract)

EP07.01. Preoperative Respiratory Assessment Predicts Post-Operative Survival in Stage IA Non-small Cell Lung Cancer - PDF(Abstract)

EP07.01. Long Term Outcomes beyond Five Years after Pulmonary Resection for Non Small Cell Lung Cancer - PDF(Abstract)

EP07.01. Recurrence Patterns and Prognostic Factors for Relapse in Operated Lung Cancers - PDF(Abstract)

EP07.02. Evaluation of the Efficacy of Oral Bacterial Lysates in Patients with High-risk Lung Nodules Detected by CT Screening - PDF(Abstract)

EP07.02. Impact of Neoadjuvant Immunotherapy on Surgical Management for Non-small Cell Lung Cancer:A Multi-center Survey of Current Practice from China - PDF(Abstract)

EP07.02. The Prediction of Pathological Pleural Invasion of Lung Cancer by Artificial Intelligence Image Analysis - PDF(Abstract)

EP07.02. A Three-Dimensional Computed Tomography Analysis of Residual Lung Volume Changes after Segmentectomy for Non-small-Cell Lung Cancer - PDF(Abstract)

EP07.02. MIDRIXNEO-LUNG: Safety and Immunogenicity of a Neoantigen-Presenting Autologous Dendritic Cell Therapy in Resected NSCLC Patients - PDF(Abstract)

EP07.02. Prospective Study of Hypofractionated Proton Therapy for Inoperable Early Stage Non-small Cell Lung Cancer - PDF(Abstract)

EP07.02. Comparison of ICG and Methylene Blue in Preoperative Dye Marking Localization of Pulmonary Nodules Under the Guidance of ENB - PDF(Abstract)

EP07.02. Hypofractionated Radiation Therapy vs Stereotactic Body Radiation Therapy for Ultra-Central Lung Tumors - PDF(Abstract)

EP07.02. Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer - PDF(Abstract)

EP07.02. Navigational Bronchoscopy: Driving to the Nodule Drives Your Patients to Earlier Stage - PDF(Abstract)

EP07.02. The Role of Online MR-guided Multi-Fraction Stereotactic Ablative Radiotherapy in Lung Tumors - PDF(Abstract)

EP07.02. Utilization of Real-time MRI-guided Stereotactic Ablative Body Radiotherapy in NSCLC, One Step forward Precise Targeting in Radiotherapy - PDF(Abstract)

EP07.02. Image-Guided Thermal Ablation of Early-Stage Non-small Cell Lung Cancer; Five-Year Outcome - PDF(Abstract)

EP07.02. Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers - PDF(Abstract)

EP07.02. Localization of Lung Nodules by Electromagnetic Navigation Bronchoscopy-Guided Dye Marking: Procedural Outcomes and Learning Curve - PDF(Abstract)

EP07.02. The Utility of Postoperative ctDNA Detection in Guiding Adjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer - PDF(Abstract)

EP07.03. Meeting the Quality Metric for Minimum Lymph Node Harvest for Robotic Lobectomy for Lung Cancer - PDF(Abstract)

EP07.03. Pulmonary Ligament Approach for Robot-Assisted S9 or S9 and 10 Segmentectomy - PDF(Abstract)

EP07.03. Uniportal Video-Assisted Thoracoscopic Surgery Simple Segmentectomy versus Complex Segmentectomy in Lung Cancer Patients - PDF(Abstract)

EP07.03. Non-Small Cell Lung Cancer in Obese Patients: Comparison of Open, Robotic and Videothoracoscopic Surgery. A Multicenter Retrospective Series - PDF(Abstract)

EP07.03. Oncological Outcomes After Uniportal Versus Multiportal Thoracoscopic Lobectomy for Lung Cancer Patients - PDF(Abstract)

EP07.03. Challenges in Robotic Lobectomy of the Lung through the Anterior Approach - PDF(Abstract)

EP07.03. Negative Impacts of Mediastinal Lymph Node Dissection Forstage I Ground Glass Opacity Pulmonary Lesions - PDF(Abstract)

EP07.03. Impact of Tumor Location on Surgical Margin in Segmentectomy and Wedge Resection - PDF(Abstract)

EP07.03. A Minimally Invasive Open Surgery Approach Is Superior to VATS with Respect to Intraoperative Outcomes during Lung Cancer Surgery - PDF(Abstract)

EP07.03. Effects of Preoperative Diabetes Mellitus on Postoperative Outcomes after Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy - PDF(Abstract)

EP07.03. Effects of Intraoperative Trainees on Outcomes after Robotic-Assisted Pulmonary Lobectomy - PDF(Abstract)

EP07.03. Effect of Lymph Node Dissection on Recurrence and Survival Following Thoracoscopic Segmentectomy for Early-Stage Non-small Cell Lung Cancer - PDF(Abstract)

EP07.03. Nodal Upstaging in Uniportal VATS Lobectomy for Early-Stage Lung Cancer: Is It Fair? - PDF(Abstract)

EP07.03. Early PROs after Thoracoscopic Segmentectomy versus Wedge Resection for Small-sized Peripheral NSCLC - PDF(Abstract)

EP07.03. Robotic Lung Cancer Program: Initial Experience and Results - PDF(Abstract)

EP07.04. Free Circulating and Extracellular Vesicles-Derived microRNA as Prognostic Biomarkers in Resected Early-Stage NSCLC: RESTING Study Results - PDF(Abstract)

EP07.04. Real-World Data Based on EGFR Mutation Status in Early-Stage NSCLC - PDF(Abstract)

EP07.04. Analyze Gene Changes Characteristics of MSLAs in Genomic Study - PDF(Abstract)

EP07.04. High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma - PDF(Abstract)

EP07.04. Spread through Air Spaces in Non-small Cell Lung Cancer. Clinical and Pathological Associations - PDF(Abstract)

EP07.04. ALK Rearrangement Is Associated with Early Lymphatic Spread in Resected LUAD with Negative Preoperative Mediastinal Staging - PDF(Abstract)

EP07.04. Early-Stage Low Malignant Potential Adenocarcinomas: A Histological Category With A Significantly Better Prognosis - PDF(Abstract)

EP07.04. Immune Cell States as Predictors of Survival in Surgically Treated Stage I Non-small Cell Lung Cancer (NSCLC) - PDF(Abstract)

EP07.04. Pleural CEA and SUVmax as Predictors of Visceral Pleural Invasion in Clinical T1N0M0 Lung Adenocarcinoma - PDF(Abstract)

EP07.04. Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center - PDF(Abstract)

EP07.04. Clinicopathological Features and Postoperative Prognosis of Bubble-like Appearance Type Lung Adenocarcinoma - PDF(Abstract)

EP07.04. Comparison of Pathologic Outcomes Following Neoadjuvant Regimens in Resectable Locally Advanced Non-Small Cell Lung Cancer - PDF(Abstract)

EP07.04. Pathologic Risk Factors for Recurrence in Early Stage Invasive Lung Adenocarcinoma with Tumor Spread through Air Spaces - PDF(Abstract)

EP07.04. Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in China - PDF(Abstract)

EP07.04. Occult Lymph Node Metastasis Is Not a Favorable Factor for Resected NSCLC Patients - PDF(Abstract)

EP07.04. Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma - PDF(Abstract)

EP07.04. Factors Associated with Postoperative Recurrence in Early NSCLC with EGFR Mutation: Analysis of Korean National Population Data - PDF(Abstract)

EP07.04. Clinical and Molecular Profile and Risk Factors of Stage IA NSCLC Relapsing after Radical Resection - PDF(Abstract)

EP07.04. Identification of Tumor Microenvironment and Prognosis Risk Prediction through Proteomics Analysis in Stage I Lung Adenocarcinoma - PDF(Abstract)

EP07.04. Lymphatic Vascular Invasion: Diagnostic Variability and Overall Survival Impact on Patients Undergoing Surgical Resection of NSCLC - PDF(Abstract)

EP07.04. Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US - PDF(Abstract)

EP07.04. Telomerase-Based Circulating Tumor Cell Detection for the Treatment Response Prediction in Patients with Non-small-Cell Lung Cancer - PDF(Abstract)

EP07.04. Histopathologic Fate of Resected Pulmonary Pure Ground Glass Nodule: A Systematic Review and Meta-Analysis - PDF(Abstract)

EP07.04. Construction of Genome Atlas for lung Nodule and Molecular Insight into Lung Adenocarcinoma Development in Chinese Population - PDF(Abstract)

EP07.04. Real-World Biomarker Testing and Treatment Patterns Identified Using Machine Learning in Early Non-small Cell Lung Cancer - PDF(Abstract)

EP07.04. Analysis of Radiologic-Pathologic Correlation for Subsolid Lung Adenocarcinoma Using the Whole-Mount Section Technique: A Prospective Study - PDF(Abstract)

EP07.05. Postoperative Recurrence Pattern and the Role of Adjuvant Therapy in Radiological Solid-Predominant Part-Solid Lung Adenocarcinoma - PDF(Abstract)

EP07.05. NEOEAST: A Phase II Study of Ensartinib as Neoadjuvant Therapy for Stage II-IIIB ALK-rearranged Non-small Cell Lung Cancer - PDF(Abstract)

EP07.05. Neoadjuvant Chemotherapy or Chemo-IO in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience - PDF(Abstract)

EP07.05. CDDP/TS1 Followed by Maintenance TS1 as Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer - PDF(Abstract)

EP07.05. Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions - PDF(Abstract)

EP07.05. Minimal Residual Lesion Might Predict Adequate Cycles for Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer - PDF(Abstract)

EP07.05. Real-World Outcomes of Adjuvant Cisplatin/Vinorelbine vs Cisplatin/Pemetrexed in Resected Non-Squamous NSCLC - PDF(Abstract)

EP07.05. Application of Neoadjuvant Chemoimmunotherapy in A Specific Group of Stage IB NSCLC - PDF(Abstract)

EP07.05. Oncologic Outcomes of Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease - PDF(Abstract)

EP07.05. Efficacy and Safety of Osimertinib Therapy in High-Risk Stage I EGFRm NSCLC after R0 Resection(OSTAR): A Prospective, Single-Arm Study - PDF(Abstract)

EP07.05. The Impact of COVID-19 on Both the Diagnosis and Surgical Outcomes of Lung Cancer in Korea - PDF(Abstract)

EP07.05. The Efficacy of Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemotherapy in Resectable NSCLC, a Comparison Research from Real World - PDF(Abstract)

EP07.05. Prognostic Factors in Non-Small-Cell Lung Cancer Treated with Chemoimmunotherapy or Chemotherapy: A Real-World Data Study - PDF(Abstract)

EP07.05. MPR and pCR Rates after Neoadjuvant Chemo-immunotherapy for Stage III Non small Cell Lung Cancer. - PDF(Abstract)

EP07.05. Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial - PDF(Abstract)

EP07.05. Spontaneous Ventilation Video-assisted Thoracoscopic Surgery for Super-elderly NSCLC Patients: a Noninferiority Study. - PDF(Abstract)

EP08.01. Subtyping EGFR-mutated NSCLC Patients with Adjuvant TKIs or Chemotherapy Using Deep Radiomic Signatures - PDF(Abstract)

EP08.01. Single-Cell RNA Sequencing Reveals Unique Immune Landscape in Rare-Mutant Non-Small Cell Lung Cancer Undergoing Chemo-Immunotherapy - PDF(Abstract)

EP08.01. Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy - PDF(Abstract)

EP08.02. Parameters of FDG PET/CT Predicting Pathological Response to Neoadjuvant Immunotherapy in Stage II/III Non-small Cell Lung Cancer Patients - PDF(Abstract)

EP08.02. Real World Chemoradiotherapy Outcomes for Frail Older Adults with Unresectable Stage III Non Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

EP08.02. Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

EP08.02. Real-World Disease-Free Survival (DFS) in Non-metastatic Non-small Cell Lung Cancer (NSCLC): A German I-O Optimise Analysis - PDF(Abstract)

EP08.02. Neoadjuvant Immunochemotherapy Combined with Probiotic Supplements in Stage IIB-IIIB NSCLC: A Real-World Prospective Study - PDF(Abstract)

EP08.02. Neoadjuvant Therapy, Still a Contraindication to VATS Lobectomy or is it a New Indication? - PDF(Abstract)

EP08.02. FDG PET Scan Based Response Assesment in Non-Small Cell Lung Cancer Treated With Chemoradiotherapy And Neoadjuvant Chemotherapy - PDF(Abstract)

EP08.02. Lymphovascular Invasion Prediction with CT images in Patients with Non-Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

EP08.02. Comprehensive Assessment of Pulmonary Function in Patients Receiving Radical (Chemo)Radiotherapy for Carcinoma Lung - PDF(Abstract)

EP08.02. Clinicopathological Analyses for Predicting Survival After Salvage Surgery for Initially Unresectable Lung Cancer - PDF(Abstract)

EP08.02. Dosimetric Contribution of LAD Sparing Radiotherapy Plan in Patients with Postoperative Lung Cancer - PDF(Abstract)

EP08.02. Dosimetric Contribution of LAD Artery Sparing RT Plan in Lung Cancer Patients Who Received Definitive RT - PDF(Abstract)

EP08.02. Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer - PDF(Abstract)

EP08.02. Prognostic Role of Baseline PET/CT Parameters in Frail Patients with Inoperable Node-Positive Stage IIB-IIIC/Recurrent NSCLC - PDF(Abstract)

EP08.02. Moderately Hypofractionated PET/CT-Based Thoracic Radiotherapy in Elderly and Multimorbid Patients with Stage II/III NSCLC - PDF(Abstract)

EP08.02. Higher Radiation Dose to Immune Cells is a Negative Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) - PDF(Abstract)

EP08.02. Comparison of Long-term Survival of Patients With Locally Advanced Lung Cancer After Video-Assisted Thoracoscopic Surgery Versus Thoracotomy - PDF(Abstract)

EP08.02. The Value of Combined Immunotherapy in Neoadjuvant Regimen for Patients with Resectable Non-small Cell Lung Cancer - PDF(Abstract)

EP08.02. Correlation of Quantified Metabolic Activity with Gross Tumor Volume in Patients with Non Small Cell Lung Cancer - PDF(Abstract)

EP08.02. A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC - PDF(Abstract)

EP08.02. Robot-Assisted Thoracic Surgery for Locally Advanced Non-small Cell Lung Cancer in a Japanese Single Institution - PDF(Abstract)

EP08.02. Survival Outcome Comparison of Stage III and IV NSCLC Patients in Latvia and Israel: An Analysis of Treatment Approaches - PDF(Abstract)

EP08.02. Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC? - PDF(Abstract)

EP08.02. Neoadjuvant Immune Checkpoint Inhibitor plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World - PDF(Abstract)

EP08.02. A Case of Persistent Complete Response To Personalized Osimertinib and Concurrent Chemoradiation for Stage IIIC EGFRm NSCLC - PDF(Abstract)

EP08.02. Trimodality Treatment of Superior Sulcus non-Small Cell Lung Cancer. An Institutional Series of 47 Consecutive Patients. - PDF(Abstract)

EP08.02. Is Moderate-intensity Stereotactic Body Radiation Therapy for Ultra-central Lung Tumor a Feasible Option? - PDF(Abstract)

EP08.02. Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120) - PDF(Abstract)

EP08.02. Long-Term Efficacy and Safety of Tislelizumab Plus Chemotherapy as Neoadjuvant/Adjuvant Therapy for IIB-III NSCLC: A Retrospective Study - PDF(Abstract)

EP08.02. Optimal Planning Target Volume Margins for Spirometer-Based DIBH Radiotherapy for Lung Cancer - PDF(Abstract)

EP08.02. Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-small Cell Lung Cancer - PDF(Abstract)

EP08.02. Evaluation of Treatment Strategies for Patients with Stage IIIA Non-Small Cell Lung Cancer in the Immunotherapy Era - PDF(Abstract)

EP08.02. Prognostic Impacts of Lymphovascular Invasion of Resected Lung Adenocarcinoma after Induction Chemoradiotherapy - PDF(Abstract)

EP08.02. Definitive Hypofractionated Radiation Therapy with or without Immunotherapy for Stage IIb-III NSCLC: An Institutional Experience - PDF(Abstract)

EP08.02. Dosimetric Comparison of Free- Breathing versus Respiratory Motion-managed Radiotherapy with 4D-CT Based VMAT in Lung Cancer - PDF(Abstract)

EP08.02. Management of Inoperable Locally Advanced Stage III ALK fusion Positive NSCLC: A Retrospective Multi-institutional Analysis - PDF(Abstract)

EP08.03. Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials - PDF(Abstract)

EP08.03. Nivolumab Plus Ipilimumab in Relapsed Stage III Non-small Cell Lung Cancer after Durvalumab Following Chemoradiotherapy - PDF(Abstract)

EP08.03. S-1 and CDDP with Concurrent TRT Followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI - PDF(Abstract)

EP08.03. MicroDurva: A Prospective Study to Investigate the Role of Microbiome in Predicting the AEs from Durvalumab in Post-CCRT NSCLC Patients - PDF(Abstract)

EP08.03. Role of DCE MRI in Predicting Treatment Response to Induction Immunochemotherapy in Locally Advanced NSCLC Patients - PDF(Abstract)

EP08.04. Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab - PDF(Abstract)

EP08.04. Evaluating Safety Profiles of Radiation-Related Toxicities in Thoracic Re-Irradiation - PDF(Abstract)

EP08.04. Acute Postoperative Pain is the Most Severe at the Site of Chest Tube Insertion in Multiportal Video-assisted Thoracoscopic Surgery - PDF(Abstract)

EP08.04. Development of a Risk Score to Predict Postoperative Complications in Patients with Non-small Cell Lung Cancer - PDF(Abstract)

EP09.01. Feasibility and Survival Outcomes of “Salvage Surgery” for Initially Clinical Stage IV Non-small Cell Lung Cancer - PDF(Abstract)

EP09.01. Clinical Outcome of Palliative Thoracic Radiotherapy in Advanced Lung Cancer in the Modern Era - A Single Institution Experience - PDF(Abstract)

EP09.01. Hypofractionated Radiotherapy for Elderly Lung Cancer Patients - PDF(Abstract)

EP09.01. Surgical Treatment in Non-small Cell Lung Cancer with Pulmonary Oligometastasis; 26 Years of Experience in a Single Center - PDF(Abstract)

EP09.01. Is Palliative Thoracic Radiation Beneficial in Stage IV Non-small Cell Lung Cancer (NSCLC) In the Era of Modern Systemic Therapy? - PDF(Abstract)

EP09.01. Outcomes of Surgical Treatment for Stage IV Non-Small Cell Lung Cancer (NSCLC) in a Population-Based Cohort - PDF(Abstract)

EP09.01. Reverse Endobronchial Y-stent Implantation in Selected Cases of the Malignant Central Airway Obtruction - PDF(Abstract)

EP09.02. Combination Of EGFR-TKIs And Radiotherapy In Stage IV LUAD - PDF(Abstract)

EP09.02. Stereotactic Body Radiotherapy Synergizes Immunotherapy in Advanced or Recurrent NSCLC: A Single-center Experience - PDF(Abstract)

EP09.02. A Phase II Study on Aggressive Local Consolidative Therapy in Combination With Chemotherapy for Oligometastic NSCLC: TORG1529 - PDF(Abstract)

EP09.02. Operative and Mid-Term Oncologic Outcomes of the Surgery as a Form of Local Consolidation for Oncogenic-Driven Advanced NSCLC - PDF(Abstract)

EP09.02. Fibrates Enhances Radiotherapy Efficacy by Elevating HDL Levels to Induce Tumor Cell Ferroptosis in NSCLC with Brain Metastasis - PDF(Abstract)

EP09.02. Long-term Efficacy of Tumor Treating Fields (TTFields 150 kHz) in metastatic NSCLC: A Case Report - PDF(Abstract)

EP09.03. Outcomes of Extracranial SBRT for Induced Oligopersistant and Oligoprogressive NSCLC Combined with Novel Systemic Therapies - PDF(Abstract)

EP09.03. Local Ablation Induces Abscopal Effects and Improves the Efficacy of Continuous ICIs in Advanced NSCLC Patients with Oligo-progression - PDF(Abstract)

EP09.04. Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases - PDF(Abstract)

EP09.04. Preoperative Circulating Tumor DNA Status Predicts Pathological Response in Advanced Non-small Cell Lung Cancer - PDF(Abstract)

EP09.04. Survival of Non-small Cell Lung Cancer with and without Brain Metastasis - Shifting to a Merging Survival Curves Era - PDF(Abstract)

EP09.05. Ionizing Radiation Induces Vascular Smooth Muscle Cell Senescence through Activating NF-κB/CTCF/p16 Pathway - PDF(Abstract)

EP09.05. Changes in Pulmonary Function Following Single and Multi-Fraction Stereotactic Body Radiotherapy for Pulmonary Oligometastatic Disease - PDF(Abstract)

EP10.01. DDR1 Mediated Glycolysis Regulates the Synergistic Effect of Anlotinib and Docetaxel in Lung Cancer - PDF(Abstract)

EP10.01. Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes - PDF(Abstract)

EP10.01. A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC - PDF(Abstract)

EP10.01. First-Line Treatment for Driver-Gene Negative Metastatic Lung Adenocarcinoma with MPE: A Multicenter Retrospectively Study - PDF(Abstract)

EP10.01. Retrospective Analysis of Real-World Treatment Patterns and Survival Outcomes for Non-small Cell Lung Cancer Patients in Thailand - PDF(Abstract)

EP10.01. Predictors of Survival for Docetaxel as a Subsequent Line after Progression to Platinum-Based Chemotherapy and Immunotherapy - PDF(Abstract)

EP10.01. Clinical Features and Outcome Evaluation of Patients with Non-small-Cell Lung Cancer: A Single Center Study - PDF(Abstract)

EP10.01. Relationship Between Age and Chemotherapy Regimen for Elderly Patients with Advanced Lung Cancer - PDF(Abstract)

EP10.01. Added Serum Albumin to Lung-mol GPA Score Improves Prediction of Overall Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis - PDF(Abstract)

EP10.01. Retrospective Study on Outcomes and Treatment Options for Patients with NSCLC Progression after Treatment with Durvalumab - PDF(Abstract)

EP10.01. Efficacy of Intraventricular Chemotherapy with Pemetrexed for Leptomeningeal Metastasis from Lung Adenocarcinoma: A Retrospective Study - PDF(Abstract)

EP10.01. Patterns of Systemic Anti-Cancer Therapy & Overall Survival of Stage IV NSCLC at Tertiary General Hospital - PDF(Abstract)

EP10.01. Evaluating Osimertinib Induced Pneumonitis in EGFR Advanced Lung Cancer in a Real World Clinical Practice. - PDF(Abstract)

EP10.01. Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis - PDF(Abstract)

EP10.01. Sarcopenia as a Predictive Factor of Carboplatin Toxicity in Patients with Advanced Non-small Cell Lung Cancer - PDF(Abstract)

EP10.01. Relationship between Impaired Fasting Glucose and Prognosis of the Disease in Patients with Advanced Stage Non-small Cell Lung Cancer. - PDF(Abstract)

EP10.01. Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China - PDF(Abstract)

EP11.01. Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study - PDF(Abstract)

EP11.01. A Multicenter Study of the Association between TTF-1 and Immunochemotherapy in Lung Adenocarcinoma - PDF(Abstract)

EP11.01. Neutrophil to Lymphocite Ratio in Patients Treated with Immunotherapy after Progression on Chemotherapy - PDF(Abstract)

EP11.01. Does Tumor Microvessel Density Predict Response to Immune Checkpoint Inhibitors in Metastatic Non Small Cell Lung Cancer? - PDF(Abstract)

EP11.01. ICTIS: A Novel Scoring System to Assess the Inclusivity of Metastatic Non-Small-Cell Lung Cancer Immunotherapy Trials - PDF(Abstract)

EP11.01. SPD-CD40L Prevents Tumor Growth via Recruitment of Immune Cells to the Tumor Microenvironment - PDF(Abstract)

EP11.01. Low NLR Predicted Overall Survival Benefit of Pembrolizumab and Chemotherapy Combination in Patients with NSCLC and Low PD-L1 Expression - PDF(Abstract)

EP11.01. GSDME-dependent Pyroptosis Affects the Prognosis and Response to Immunotherapy in Lung Adenocarcinoma - PDF(Abstract)

EP11.01. Study on Biomarkers for Predictive the Clinical Efficacy of Non-small Cell Lung Cancer Immunotherapy - PDF(Abstract)

EP11.01. Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Does Histology Matter? - PDF(Abstract)

EP11.01. Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors - PDF(Abstract)

EP11.01. Prediction of NSCLC Immunotherapy Outcomes Across Multiple Clinical Indicators - PDF(Abstract)

EP11.01. The Value of PD-L1 in Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Receiving Immunotherapy - PDF(Abstract)

EP11.02. Nivolumab as Maintenance Therapy Following Platinum-Based Chemotherapy in EGFR-mutant Lung Cancer Patients After TKI Failure - PDF(Abstract)

EP11.02. Phase I Study of Epacadostat in Combination with Sirolimus in Solid Tumors and PK Data. - PDF(Abstract)

EP11.02. First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis - PDF(Abstract)

EP11.02. Efficacy and Safety of Camrelizumab plus Famitinib in Previously Treated Patients with Advanced Non Small Cell Lung Cancer - PDF(Abstract)

EP11.02. Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS - PDF(Abstract)

EP11.02. Dostarlimab + CT vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial - PDF(Abstract)

EP11.02. Predictive Toxicity and Response to Immunotherapy in Patients with Metastatic Non Small Cell Lung Cancer (IMMUNOPREDICT) - PDF(Abstract)

EP11.02. Rh-endostatin Combined With PD-1 inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC - PDF(Abstract)

EP11.02. Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC : A Multi-Center Prospective Study (Endouble) - PDF(Abstract)

EP11.03. Characterizing Neurologic Immune-related Adverse Events Using Consensus Disease Definitions - PDF(Abstract)

EP11.03. Patient-Reported Fatigue in Lung Cancer Patients Undergoing Immunotherapy: A Real-Life Study - PDF(Abstract)

EP11.03. Multi-Institutional Retrospective Study for the Efficacy of ICIs plus Platinum-Based Chemotherapy for EGFR Mutated NSCLC - PDF(Abstract)

EP11.03. Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer - PDF(Abstract)

EP11.03. Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastases - PDF(Abstract)

EP11.03. Long-term Outcomes and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Immunotherapy Containing Regimens - PDF(Abstract)

EP11.03. Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years - PDF(Abstract)

EP11.03. Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study - PDF(Abstract)

EP11.03. ​Similar Efficacy Observed for Frontline Immunotherapy in Ethnic-Minority Patients with Metastatic NSCLC - PDF(Abstract)

EP11.03. Site-Specific Response Patterns in Patients with Advanced NSCLC Treated with First-Line Systemic Therapy - PDF(Abstract)

EP11.03. Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study - PDF(Abstract)

EP11.03. The Economic Burden of Lung Cancer (NSCLC) In the County of Gävleborg - Sweden - PDF(Abstract)

EP11.03. Sarcopenia Is a Poor Predictive Prognostic Factor for Non Small Cell Lung Cancer Patients Who Were Treated with Immune Check Point Inhibitors - PDF(Abstract)

EP11.03. Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody - PDF(Abstract)

EP11.03. Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials - PDF(Abstract)

EP11.03. Optimal Duration of Immune Checkpoint Inhbitors in Non-small Cell Lung Cancer: Less Is More? - PDF(Abstract)

EP11.03. Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations - PDF(Abstract)

EP11.03. Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre - PDF(Abstract)

EP11.03. Incidence of Cardiotoxicity in Patients Treated for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors - PDF(Abstract)

EP11.03. Proton Pump Inhibitors’ Impact on the Effectiveness of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer - PDF(Abstract)

EP11.03. Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis - PDF(Abstract)

EP11.03. The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC) - PDF(Abstract)

EP11.03. A Novel Approach for Personalized Strategy of Cancer Immunotherapy with Pattern Identification: From the Results of the HARMONY Study - PDF(Abstract)

EP11.03. Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression - PDF(Abstract)

EP11.03. Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China - PDF(Abstract)

EP11.03. Real World Outcomes after Chemotherapy and Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer in Europe - PDF(Abstract)

EP11.03. Immunotherapy and Overall Survival in Advanced NSCLC: A Systematic Review of Randomised Trials - PDF(Abstract)

EP11.03. What Are Favorable Clinicopathological Factors and Types of Therapy for Postoperatively Recurrent NSCLC Patients? - PDF(Abstract)

EP11.03. Quantification of Interstitial Lung Abnormality Using Deep Learning in Cancer Patients Who Underwent Immune Checkpoint Inhibitors - PDF(Abstract)

EP11.03. Dose the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy? - PDF(Abstract)

EP11.03. Prognostic Value of Body Mass Index and Serum Lipid for First-line Immunotherapy in Patients with Advanced NSCLC: A Retrospective Study - PDF(Abstract)

EP11.03. Clinical Impact of Immune Checkpoint Inhibitors Following Platinum Chemotherapy in Advanced or Metastatic Non-small Cell Lung Cancer Patients - PDF(Abstract)

EP11.03. Impact of KRAS Mutation Subtype and Comutations across PD-L1 Levels in aNSCLC Patients Treated with (Chemo)Immunotherapy - PDF(Abstract)

EP11.03. Clinical Outcomes of Immunotherapy with or without Radiation in Advanced Lung Cancer: a Real-World, Retrospective Study - PDF(Abstract)

EP11.03. Efficacy and Safety of Chemotherapy Plus Immunotherapy and Recombinant Human Endostatin in Advanced Non-small-Cell Lung Cancer - PDF(Abstract)

EP11.03. Comparison of Real-World Outcomes in aNSCLC Patients Receiving 1L Immunotherapy Alone or in Combination with Chemotherapy - PDF(Abstract)

EP11.03. Platinum/Taxane versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1 - PDF(Abstract)

EP11.03. An Observational Study to Identify Selection Criteria for Initiation of Different First Line Treatment Options in NSCLC Patients - PDF(Abstract)

EP11.03. Successful Treatment with Pembrolizumab Alone for SMARCA4-deficient Lung Sarcomatoid with a High-TMB and PD-L1(+) A Case Report - PDF(Abstract)

EP11.03. Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy vs Bevacizumab Plus Chemotherapy for NSCLC with Brain Metastases - PDF(Abstract)

EP11.04. Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer - PDF(Abstract)

EP11.04. Increasing Liquid Biopsy Sensitivity to the Next Level: Usability of Minimal Residual Disease Detection of Genomic Fusions by ddPCR - PDF(Abstract)

EP12.01. The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study - PDF(Abstract)

EP12.01. NGS Reveals Convergent Acquired Resistance and Newly Emerging Driver Involving MET Alterations in NSCLC: A Case Report - PDF(Abstract)

EP12.01. Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study - PDF(Abstract)

EP12.01. Clinical Features and Progression Free Survival of Lung Adenocarcinoma Patients with EGFR sensitizing mutations with Dose Reduction of Afatinib - PDF(Abstract)

EP12.01. Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR+) Metastatic Non-Small-Cell Lung Cancer (NSCLC) Real-World Patients - PDF(Abstract)

EP12.01. Metastatic NSCLC with G719X/S781I EGFR-mutations with acquired BRAF V600E mutation - response to Osimertinib, Dabrafenib and Trametinib - PDF(Abstract)

EP12.01. Brigatinib Restores Disease Control at Second Progression on Osimertinib in Metastatic EGFR ex19del Mutated NSCLC with Acquired EML4-ALK Fusion - PDF(Abstract)

EP12.01. Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation - PDF(Abstract)

EP12.01. Predictive and Prognostic Value of Early Skeletal Muscle Loss during First-Line EGFR-TKIs for Advanced Lung Adenocarcinoma - PDF(Abstract)

EP12.01. Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer - PDF(Abstract)

EP12.01. Efficacy of Amivantamab in a Patient with EGFR ex20ins Lung Adenocarcinoma with Symptomatic Pleural Effusion after Platinum Doublet Failure - PDF(Abstract)

EP12.01. Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study - PDF(Abstract)

EP12.01. Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC - PDF(Abstract)

EP12.01. First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases - PDF(Abstract)

EP12.01. Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report - PDF(Abstract)

EP12.01. The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment - PDF(Abstract)

EP12.01. Association of CYP450 and Drug Efflux Transporters Polymorphism Influence Outcomes of Thai Non-small Cell Lung Cancer Treated with Osimertinib - PDF(Abstract)

EP12.01. Validation of the ALK-Brain Prognostic Index (ALK-BPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases - PDF(Abstract)

EP12.01. Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib - PDF(Abstract)

EP12.01. Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins) - PDF(Abstract)

EP12.01. A Case of Brain Metastases from Lung Cancer with Epilepsy and ECOG Score of 4 Successfully Treated with Aumolertinib - PDF(Abstract)

EP12.01. Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC - PDF(Abstract)

EP12.01. Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report - PDF(Abstract)

EP12.01. High-Dose Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC with Meningeal Symptoms as the First Symptom - PDF(Abstract)

EP12.01. Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results - PDF(Abstract)

EP12.01. Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations - PDF(Abstract)

EP12.01. Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer - PDF(Abstract)

EP12.01. A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis - PDF(Abstract)

EP12.01. Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib - PDF(Abstract)

EP12.01. Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis - PDF(Abstract)

EP12.01. Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer - PDF(Abstract)

EP12.01. Liquid Biopsy Reduce Time to Treatment for Patients with EGFR mutated Advanced Nonsquamous Non-small Cell Lung Cancer : A Mexican Unit Experience - PDF(Abstract)

EP12.01. Autopsy and Next Generation Sequencing Report of First-Line Treatment with Osimertinib for EGFR-Mutated Squamous Cell Carcinoma of the Lung - PDF(Abstract)

EP12.01. Skin Toxicity Associated with Targeted and Immune Therapies in Stage IV Lung Cancer Patients: A 14-year Cohort - PDF(Abstract)

EP12.01. Heart Failure Incidence and Mortality With EGFR TKIs in Patients with NSCLC: Targeted Literature Review - PDF(Abstract)

EP12.01. Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations - PDF(Abstract)

EP12.01. Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype - PDF(Abstract)

EP12.01. Therapeutic or Prophylactic Targeting C797S in EGFR Mutant Lung Adenocarcinoma - PDF(Abstract)

EP12.01. The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastasess - PDF(Abstract)

EP12.01. Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort - PDF(Abstract)

EP12.01. Case Report of Short-Term Gefitinib Induced IgA Nephropathy and Tubulointerstitial Nephritis in a Patient with Non-small Cell Lung Cancer - PDF(Abstract)

EP12.01. A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib - PDF(Abstract)

EP12.01. L858R Exon 21 Mutation Is Associated with a Higher Risk of Brain Metastases in Patients with NSCLC Treated with TKI - PDF(Abstract)

EP12.01. Lazertinib in Pretreated Epidermal Growth Factor Receptor T790M-Mutated Advanced Non-small Cell Lung Cancer: A Real-World Multicenter Study - PDF(Abstract)

EP12.01. A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases - PDF(Abstract)

EP12.01. Molecular Characteristics and Response to TKIs in NSCLC Patients with EGFR Exon 19 Insertions - PDF(Abstract)

EP12.01. Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration - PDF(Abstract)

EP12.01. A Multi-Center Observational Study of Effectiveness and Safety of First Line Afatinib in Major Uncommon EGFR mutated NSCLC - PDF(Abstract)

EP12.01. The Contribution of Compound EGFR Mutations and Other Co-mutations to Efficacy of EGFR TKI in Lung Adenocarcinoma - PDF(Abstract)

EP12.01. Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam - PDF(Abstract)

EP12.01. Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE) - PDF(Abstract)

EP12.01. Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases - PDF(Abstract)

EP12.01. Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report - PDF(Abstract)

EP12.01. Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment - PDF(Abstract)

EP12.01. Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC) - PDF(Abstract)

EP12.01. An Observational Study Analyzing Progression Free Survival of Patients With EGFR Mutant NSCLC Treated with Osimertinib in South Carolina - PDF(Abstract)

EP12.01. Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer - PDF(Abstract)

EP12.01. Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib - PDF(Abstract)

EP12.01. Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study - PDF(Abstract)

EP12.01. Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review - PDF(Abstract)

EP12.01. Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC - PDF(Abstract)

EP12.01. Long Survival in LM NSCLC Treated with Aumolertinib and Metronomic Intrathecal Pemetrexed under Dynamic Detection of CSF ctDNA - PDF(Abstract)

EP12.01. A Real World Cohort Study of First Line Afatinib in Patients with EGFR mutant Advanced Non Small Cell Lung Cancer in Vietnam - PDF(Abstract)

EP12.01. Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases - PDF(Abstract)

EP12.01. Response Evaluation of Newly Diagnosed EGFR Mutated NSCLC in Tertiary Referral Cancer Center in Jakarta-Indonesia - PDF(Abstract)

EP12.01. Anlotinib Combined with Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c-MET/MYC/AXL Axis - PDF(Abstract)

EP12.01. Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure - PDF(Abstract)

EP12.01. Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results - PDF(Abstract)

EP12.01. Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy - PDF(Abstract)

EP12.01. Increased Progression Free Survival of Patients with EGFR positive mutation NSCLC Treated with Afatinib in Regard to Toxicity - PDF(Abstract)

EP12.01. Good Results of Osimertinib in a Patient with EGFR (L861Q) and MET Amplification NSCLC: A Case Report - PDF(Abstract)

EP12.01. Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC - PDF(Abstract)

EP12.01. Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area - PDF(Abstract)

EP12.02. Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs - PDF(Abstract)

EP12.02. Judith Tam ALK Lung Cancer Research Initiative - PDF(Abstract)

EP12.02. The Response to First-line Therapies in Stage IV RET Fusion-Positive Non-small Cell Lung Cancer: a Multi-center Retrospective Study in China - PDF(Abstract)

EP12.02. PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer - PDF(Abstract)

EP12.02. Comparative Efficacy and Safety of Lorlatinib vs Alectinib and Brigatinib Using Matching Adjusted Indirect Comparisons (MAIC) - PDF(Abstract)

EP12.02. The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan - PDF(Abstract)

EP12.02. Frequency and Outcomes of Leptomeningeal Metastases in Patients with Fusion-Positive Lung Cancers - PDF(Abstract)

EP12.02. Prevalence and Treatment of Advanced NSCLC patients with REarranged During Transfection [RET]-fusion at a South Korean Centre - PDF(Abstract)

EP12.02. Personalizing Care for Patients with Advanced ALK+ NSCLC through a Blended Continuing Education and Quality Improvement Initiative - PDF(Abstract)

EP12.02. Sequencing Patterns and Treatment Effectiveness in ALK-positive aNSCLC Following First-Line Alectinib or Brigatinib - PDF(Abstract)

EP12.02. Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC - PDF(Abstract)

EP12.03. Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy - PDF(Abstract)

EP12.03. Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA) - PDF(Abstract)

EP12.03. Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib. - PDF(Abstract)

EP12.03. A Retrospective Analysis on the Lung Cancer Specimens for Multi-CDx System in Keio University Hospital - PDF(Abstract)

EP12.03. A Case Report of Sustained Survival of NSCLC Treated with Combination of Cell Therapy and Immunotherapy - PDF(Abstract)

EP13.01. pN Stage Predicts Survival Benefits of Postoperative Radiotherapy in Combined Small Cell Lung Cancer Patients after Surgery - PDF(Abstract)

EP13.01. Patient-Specific Factors as Prognostic Biomarkers in Extensive Disease SCLC - PDF(Abstract)

EP13.01. Does Oligometastases state exist in patients of Small Cell Lung Cancer? - A Small Retrospective Analysis from a Tertiary Cancer Centre - PDF(Abstract)

EP13.01. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer with an Emphasis on Oligo-Progressive Disease - PDF(Abstract)

EP13.01. Prognostic Impact of Neutrophil-to-Lymphocyte Ratio (NLR) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PDF(Abstract)

EP13.01. Immunohistochemical Classification of Patients with Small Cell Lung Cancer - A Single Center Study - PDF(Abstract)

EP13.01. Stratified Control Study Of Neuroendocrine Differentiation and Potential Clinicopathologic Markers - PDF(Abstract)

EP13.01. Single-Cell RNA Sequencing Reveals Immune Microenvironment of Small Cell Lung Cancer-associated Malignant Pleural Effusion - PDF(Abstract)

EP13.01. Mitotic Counts and Phospho-Histone H3 Index in Grading Pulmonary Neuroendocrine Tumors: Assessment of Interobserver Variability and Utility - PDF(Abstract)

EP13.01. Study of NLI Use in the First Line of Atezolizumab Plus Chemotherapy - PDF(Abstract)

EP13.01. Validation of LIPI index in SCLC - PDF(Abstract)

EP13.01. Prognostic Nutritional Index-Based immune Risk System for Prognosis and Immunotherapy Response Prediction in Small Cell Lung Cancer - PDF(Abstract)

EP13.02. Minimally Invasive Surgery for Endobronchial Small Cell Lung Carcinoma following Neoadjuvant Chemotherapy - PDF(Abstract)

EP13.02. Dynamic Transition of Molecular Subtypes in Relapsed Small Cell Lung Cancer Treated with Multimodal Therapy - PDF(Abstract)

EP13.02. Entrectinib Amazing Efficacy in a Case of Lung Atypical Carcinoid with NTRK Gene Fusion - PDF(Abstract)

EP13.03. Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study - PDF(Abstract)

EP13.03. Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era - PDF(Abstract)

EP13.03. RWD of Atezolizumab Plus Chemotherapy in First Line SCLC - PDF(Abstract)

EP13.03. A Single Arm Phase II Study of Tislelizumab Plus Anlotinib as Maintenance Therapy in Patients with Extensive-stage Small Cell Lung Cancer - PDF(Abstract)

EP13.03. Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study - PDF(Abstract)

EP13.03. Small Cell Lung Cancer Immune Related Adverse Events, Survival Impacts - PDF(Abstract)

EP13.03. Real-World Analysis of ICI Efficacy in ES-SCLC Patients with and without Brain Metastases: A Call for Inclusion in Clinical Trials - PDF(Abstract)

EP13.03. Developing Strategies for Delivery of Patient-Centered Care for Small Cell Lung Cancer - PDF(Abstract)

EP13.03. Outcomes of ES-SCLC Patients Treated with Platinum Doublet and Immunotherapy: A Western Australia Retrospective Review - PDF(Abstract)

EP13.03. Clinical Effectiveness of First-Line Immunotherapy in Small Cell Lung Cancer - PDF(Abstract)

EP13.03. Prophylactic Cranial and Consolidation Thoracic Radiation in Extensive Stage Small Cell (ES-SCLC) Lung Cancer in the Chemo-immunotherapy Era - PDF(Abstract)

EP13.03. A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients - PDF(Abstract)

EP13.03. Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC - PDF(Abstract)

EP13.04. Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer - PDF(Abstract)

EP13.04. Characterization of Limited-Stage Small Cell Lung Cancer: Molecular Subtypes, Tumor Microenvironment and Clinical Follow-up - PDF(Abstract)

EP13.04. The Impact of PCI on the Prognosis of Limited-stage SCLC Patients in the Era of MRI Surveillance - PDF(Abstract)

EP13.04. Preliminary Results of a Prospective Trial of Hypofractionated Radiotherapy Versus Hyperfractionated Radiotherapy for Limited-stage SCLC - PDF(Abstract)

EP13.04. Outcomes of Limited-Stage Extrapulmonary Small Cell Carcinoma and Small Cell Lung Cancer - PDF(Abstract)

EP13.05. Early ctDNA Changes and Clinical Outcomes in Extensive Stage Small Cell Lung Cancer Patients on Nivolumab and Temozolomide - PDF(Abstract)

EP13.05. Temozolomide-associated Hypermutation and Response to Immunotherapy in Advanced Pulmonary Neuroendocrine Tumors. - PDF(Abstract)

EP13.05. A Comparison of the Outcomes of Pulmonary versus Extrapulmonary Extensive Stage Small Cell Carcinoma - PDF(Abstract)

EP13.05. Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma - PDF(Abstract)

EP13.05. Comparative Study of LCNEC and LCLC of the Lung Pathologically Diagnosed by Surgical Resection Specimens - PDF(Abstract)

EP13.05. Effects and Outcomes Analysis of Immunotherapy for Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma - PDF(Abstract)

EP13.06. hSSB1 is Elevated and a Potential Target for Therapy in SCLC - PDF(Abstract)

EP13.06. Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer - PDF(Abstract)

EP13.06. Radiotheranostics targeting Delta-Like Ligand 3 Expressing Small-Cell Lung Cancers. - PDF(Abstract)

EP13.06. Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer - PDF(Abstract)

EP13.06. Exploratory Clinical Study of Anlotinib Combined with Concurrent Chemoradiotherapy in the Treatment of Small Cell Lung Cancer(SCLC) - PDF(Abstract)

EP13.07. Understanding Real-Life Response to Lurbinectedin as Second Line Therapy in Patients with Extensive Stage Small-Cell Lung Cancer - PDF(Abstract)

EP13.07. Is Concept of Continuous Immunotherapy Beyond Progression Effective in Small Cell Lung Cancer? - PDF(Abstract)

EP13.07. Treatment Patterns and Outcomes in Recent US Clinical Practice for SCLC Patients After Two Prior Lines of Therapy - PDF(Abstract)

EP13.07. Immune Activation Effect of Different Irradiated Sites and Survival in ES-SCLC Patients Treated with Radioimmunotherapy: A Real-World Analysis - PDF(Abstract)

EP13.07. RYZ101 (Ac-225 DOTATATE) Opportunity Beyond GEP-NETs: Preclinical Efficacy in Small Cell Lung Cancer - PDF(Abstract)

EP13.07. Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients - PDF(Abstract)

EP13.07. Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others - PDF(Abstract)

EP13.07. Canadian Consensus Recommendations: Use of Radiation Therapy among Patients with ES-SCLC receiving Immunotherapy - PDF(Abstract)

EP13.07. A Study of Sintilimab Combined with Anlotinib and chemotherapy as Second-Line or Later Therapy in Extensive-Disease Small Cell Lung Cancer - PDF(Abstract)

EP13.07. Efficacy and Safety of Antiangiogenic Therapy plus Immunotherapy as Later-line Treatment for Small Cell Lung Cancer - PDF(Abstract)

EP14.01. Does Delaying Surgery Following Induction Chemotherapy Compromise Survival in Patients with Malignant Pleural Mesothelioma? - PDF(Abstract)

EP14.01. Treatment Response in Malignant Pleural Mesothelioma Patients Can Be Predicted by Exhaled Breath Analysis - PDF(Abstract)

EP14.01. Cytologic Predictors and Novel Markers of Malignant Mesothelial Proliferation (mesothelioma) in Pleural Effusion - PDF(Abstract)

EP14.01. Risk Factors Influencing Postoperative Pleural Empyema in Patients with Pleural Mesothelioma after Multimodal Therapy - PDF(Abstract)

EP14.01. Neo-Adjuvant Immunotherapy in Malignant Pleural Mesothelioma: Report on Three Cases Treated in a Single Institution - PDF(Abstract)

EP14.01. Patients Who Undergo Surgery Survive Longer than Those Who Refuse Surgery - PDF(Abstract)

EP14.01. Low Ki-67 Positive Index is a Prognostic Factor for Better Survival Outcomes of Patients treated with Intracavitary Cisplatin-Fibrin - PDF(Abstract)

EP14.01. Clinical Significance of BAP1 Expression in Malignant Mesothelioma Treated with Ipilimumab and Nivolumab. - PDF(Abstract)

EP14.01. Feasibility of Near-Infrared Fluorescence-Guided Robotic-Assisted Minimally Invasive Esophagectomy with Indocyanine Green Dye - PDF(Abstract)

EP14.01. Three-port Robot-assisted Thoracoscopic Surgery for Mediastinal Tumor with “Confronting View” at Our Hospital - PDF(Abstract)

EP14.01. Forced Vital Capacity Is a Strong Predictor for Postoperative Survival of Patients with Malignant Pleural Mesothelioma - PDF(Abstract)

EP14.02. Neoadjuvant Immune Checkpoint Inhibitor-Based Therapy Followed by Resection for Locally Advanced Thymic Malignancies - PDF(Abstract)

EP14.02. Preoperative Steroid Pulse Therapy for Invasive Thymoma - PDF(Abstract)

EP14.02. Open Versus Video-Assisted and Robotic-Assisted Thymectomy for the Treatment of Thymic Neoplasms - PDF(Abstract)

EP14.02. Identification of Risk Factors for Postoperative Acute Exacerbation of Myasthenia Gravis after Total Thymectomy - PDF(Abstract)

EP14.02. Mixed Feelings about Mixed Thymomas - PDF(Abstract)

EP14.02. Atypical Response to Metronomic Chemotherapy in a Patient with Advanced Thymoma - PDF(Abstract)

EP14.02. The Significance and Risk Factors of Lymph Node metastasis in Thymic Malignancies: A Large Population-based Database Analysis - PDF(Abstract)

EP14.03. Is Subxiphoid Uniportal Video-Assisted Thoracoscopic Mediastinal Surgery Safe, Minimally Invasive, and Radical? - PDF(Abstract)

EP14.03. The Impact of Expanded Indication of Robot-Assisted Thoracic Surgery for Mediastinal Tumors - PDF(Abstract)

EP14.03. Pulmonary Blastoma is Successfully Treated with Immunotherapy and Targeted Therapy - PDF(Abstract)

EP14.03. Rare but Aggressive: A Case of Primary Pulmonary Synovial Sarcoma - PDF(Abstract)

EP14.03. Implant Associated Squamous Cell Carcinoma: An Emerging Chest Wall Malignancy - PDF(Abstract)

EP14.03. PULS - An International Collaboration for Collection and Assessment of Data from Patients with PUL Monary Artery Sarcoma - PDF(Abstract)

EP14.03. Three Cases of Mediastinal Teratoma Resulting in Thoracic Perforation - PDF(Abstract)

EP14.03. Pulmonary Metastastasis of Dermatofibrosarcoma Protuberans of the Scalp : A Challenging Mesenchymal Tumor - PDF(Abstract)

EP14.03. Expression of Fibroblast Activation Protein in Intrathoracic Solitary Fibrous Tumor - PDF(Abstract)

EP14.03. Ebstein-Barr Virus-Associated Pulmonary Lymphomatoid Granulomatosis with Trigeminal Nerve Involvement - PDF(Abstract)

EP14.03. Lung Epithelioid Hemangioendothelioma with Paraneoplastic Nail Clubbing and Hypertrophic Osteoarthropathy - PDF(Abstract)

EP14.03. Anastomosing Hemangioma of Mediastinum and Pleura Mimicking Chest Malignancy - PDF(Abstract)

EP14.04. BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma - PDF(Abstract)

EP14.04. Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients (p) - PDF(Abstract)

EP15.01. Can Nurses Successfully Do Patient Advocacy : Need in Resource Poor Settings - PDF(Abstract)

EP15.02. Improving the Lives of Patients Diagnosed with Lung Carcinoma: The Holistic Power of Palliative Care - PDF(Abstract)

EP15.02. Starting Early Palliative Care for Lung Cancer as Soon as Possible: lesson learned from Resource-limited Setting in Indonesia - PDF(Abstract)

EP15.03. Implementation of an Interdisciplinary Distress Assessment and Response Program for Family Caregivers - PDF(Abstract)

EP15.03. Assessment of the Multidisciplinary Onco-thoracic Consultation Meeting of the University Hospital Center of Tangier - PDF(Abstract)

EP15.03. Unscheduled Hospitalizations in Patients with Lung Cancer as a Frailty Event - PDF(Abstract)

EP16.01. Virtual Educational Patient Meetings Empower, Unite Small Cell Lung Cancer Patients - PDF(Abstract)

EP16.01. A Brief History of Lung Cancer in Canada: Care, Contributions and Challenges - PDF(Abstract)

EP16.01. Optimizing Treatment Outcomes for L858R EGFR+ NSCLC - PDF(Abstract)

EP16.01. Creation of Mental Health Support Materials for People with Lung Cancer and Healthcare Providers (HCPs) - PDF(Abstract)

EP17.01. The Lung Cancer Clinical Quality Data Platform (LUCAP): Results from a Western Australia Pilot Study - PDF(Abstract)

EP17.01. Data Mining to Build Metrics. A Feasible Assessment of Quality of Care for Stage III Non-small Cell Lung Cancer (NSCLC). - PDF(Abstract)

EP17.01. Proposing Relevant Diagnosis Associated with Lung Cancer Based on Prior Diagnosis: Implementing Apriori Algorithm - PDF(Abstract)

EP17.01. Lung Cancer Information System: Enabling Precision Oncology through Informatics - PDF(Abstract)

EP17.01. Lung Cancer (Internet-Based) Delphi (LuCiD): a Delphi Consensus to Develop Australasian Thoracic Oncology Quality Indicators - PDF(Abstract)

EP17.02. Concordance on Treatment Recommendations from Multidisciplinary Tumor Boards -Data from Driver-Mutated Lung Cancer in Focus - PDF(Abstract)

EP17.03. Quantitative Findings from a Survey of Health Insurance in Patients Diagnosed as Advanced Lung Cancer in Japan - PDF(Abstract)

EP17.03. Utilities Used in HTAs in mNSCLC Following Progression on or After Platinum-Based Chemotherapy - PDF(Abstract)

EP17.03. Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer - PDF(Abstract)

EP17.03. The Economic Evaluation of The protein-Based Lung Cancer Biomarker Panel (LCBP):Evidencebased Onamulticenter Clinicaltrialin China - PDF(Abstract)

EP17.04. The Impact of the Emergency Presentation of Patients Diagnosed with Lung Cancer on Treatment Outcomes in Wales. - PDF(Abstract)

EP17.04. Global, Regional, National Burden of Lung Cancer Attributable to High Fasting Plasma Glucose - PDF(Abstract)

EP17.04. Lung Cancer Care in Singapore: A review of the Healthcare Registry, 2013-2020 - PDF(Abstract)

EP17.04. Survival Rate of Untreated Lung Cancer Patients at Dr. (H.C) Ir. Soekarno Hospital Bangka - PDF(Abstract)

EP17.04. Research and Analysis on the Situation of Prevention and Treatment Capability of Cancer in County of China - PDF(Abstract)

EP17.04. Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small Cell Lung Cancer (NSCLC) Treated with Durvalumab - PDF(Abstract)

EP17.04. Lung Stereotactic Body Radiation Therapy in a Developing Country: Patterns of Safety and Treatment Toxicities - PDF(Abstract)

EP17.04. Changing Lung Cancer Incidence Trends and Risk Patterns Among Asian Americans in Los Angeles County, California, USA - PDF(Abstract)

EP17.06. COVID-19 Long-Lasting Effect on Lung Cancer Diagnoses in Italy: Update of the Real-World Multicenter COVID-DELAY Study - PDF(Abstract)

P1.01. Frequency of Germline Mutations in Patients with Non-small Cell Lung Cancer (NSCLC) Harboring Actionable DRIVER Alterations (G-DRIVER) - PDF(Abstract)

P1.01. Diabetes as Prognostic and Predictive Factors in Resected Non-small Cell Lung Cancer, from a Large Chinese Cohort - PDF(Abstract)

P1.01. Novel Anoikis-Related Prognostic Signatures of NSCLC Based on mRNA‑lncRNA Analysis and Primary Validation in CRISPR Screening - PDF(Abstract)

P1.01. Clinical and Genetic Characteristics in Younger vs Older Lung Cancer Patients - PDF(Abstract)

P1.01. A Phase IB Trial Of Nivolumab For Immunoprevention Of Bronchial Dysplasia Progression In High-risk Current And Former Smokers - PDF(Abstract)

P1.01. Asbestos Exposure and Small Cell Lung Cancer. Systematic Review and Meta-Analysis - PDF(Abstract)

P1.01. A Content Analysis E-cigarette Retailer Websites and Nicotine Addiction among E-cigarette Users- Mixed Methods Study from Malaysia - PDF(Abstract)

P1.01. Assessing the Relationship Between Frailty and Lung Cancer Survival: A Systematic Review and Meta-Analysis - PDF(Abstract)

P1.01. Peptic Ulcer and Long-Term Risk of Lung Cancer: A Prospective Cohort Study from UK Biobank - PDF(Abstract)

P1.01. Lung Cancer Risk Prediction Model Incorporating Liver Function Markers: a Prospective Cohort Study from the UK Biobank - PDF(Abstract)

P1.01. “A Core Part of the Whole Thing...”: Stakeholder Views on Offering Smoking Cessation Support in Lung Cancer Screening - PDF(Abstract)

P1.01. Amelioration of the Toll of Air Pollution on Lung Cancer - PDF(Abstract)

P1.02. HRA00129-C004, a Novel c-Met ADC with Promising Preclinical Anti-tumor Activity and Expanded Therapeutic Window - PDF(Abstract)

P1.02. Co-inhibition of MEK/RTKs Pathways via Trametinib Plus Anlotinib forKRAS-Mutant NSCLC - PDF(Abstract)

P1.02. Identifying Biomarkers of Response to Ensartinib, Lorlatinib, and Alectinib in an ALK+ Non-Small Cell Lung Cancer Preclinical Model (ResCu) - PDF(Abstract)

P1.02. Targeting ATP7A by Elesclomol-Copper Derived Endoplasmic Reticulum Stress to Mediate Cuproptosis in KRAS-G12 Mutant LUAD - PDF(Abstract)

P1.02. Glucose Deprivation Promotes Pseudo-Hypoxia and De-differentiation in Lung Adenocarcinoma - PDF(Abstract)

P1.03. Dynamic Transcriptomic Characterization Changes of Early Stage Lung Adenocarcinoma as per the Incrassation of Consolidation Tumor Ratio - PDF(Abstract)

P1.03. Combinationof Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment - PDF(Abstract)

P1.04. CDK4/6 Inhibitor Improves Radioimmunotherapy Efficacy via Inducing PD-L1 Transcription through Increased c-Jun Activation in NSCLC - PDF(Abstract)

P1.04. Ablative Radiation Induces Distinct Sequential Waves of Mitotic and Innate Immune Death Regulated through DNA Repair Pathways - PDF(Abstract)

P1.05. Research on Specific DNA Methylation Regulatory Mechanism Based on Pan-Cancer Analysis - PDF(Abstract)

P1.06. NIR-II Mediates Non-small Cell Lung Cancer Nanovaccines for Targeted Lymph Node Delivery and Anti-tumor Immune Activation - PDF(Abstract)

P1.06. Trametinib Plus ANTI-PD-1 Immunotherapy Impairs Tumor Growth and Increases Survival of Lung Cancer through ID1 Downregulation - PDF(Abstract)

P1.06. Effect and Mechanism of ASNS Remodeling the Metastatic Lymph Node Immune Microenvironment in Lung Cancer - PDF(Abstract)

P1.06. Phenotype Mapping of Patient-Derived Small Cell Lung Cancer Organoids Illuminate Subtype-Specific Therapeutic Vulnerability - PDF(Abstract)

P1.07. Collective Lung Cancer Migration Using a 3D Model - PDF(Abstract)

P1.07. Patient-Derived Xenografts from Thoracic Malignancies as Promising Preclinical Models - PDF(Abstract)

P1.08. CoxMoE: A Deep Learning Model Predicts Survival and Response in T790M Positive NSCLC Patients Treated with Third-Generation EGFR-TKI - PDF(Abstract)

P1.08. Exploring Autophagy Flux-Related Molecules for Overcoming EGFR TKI Resistance - PDF(Abstract)

P1.08. Hyper-Interferon Sensitive Influenza Virus Induces Immune Activation and Overcomes Resistance to Anti-PD-1 in Murine NSCLC - PDF(Abstract)

P1.08. Delivery of ATRA and Gefitinib by Polyphenylalanine Nanosystem to Overcome EGFR-TKI Resistance in Lung Adenocarcinoma - PDF(Abstract)

P1.08. On-Target Acquired Resistance to Mobocertinib and Strategy to Overcome It - In Vitro Study Using EGFR Ex20 Insertion Models - PDF(Abstract)

P1.08. Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes - PDF(Abstract)

P1.09. Anti-Cancer Immune Activation Post Bronchoscopic Thermal Ablation in Non-Small Cell Lung Cancer - PDF(Abstract)

P1.09. Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR Mutant NSCLC - PDF(Abstract)

P1.09. SFRP2+ CAFs Hinder Abscopal Effect from Combined Radiotherapy and Immunotherapy by Forming a Hostile Perivascular Niche - PDF(Abstract)

P1.09. Characterization of the Expression of BTN1A1 Exclusive to PD-L1/PD-1 Axis in Small Cell Lung Cancer Using Spatial Biology Approach - PDF(Abstract)

P1.09. DCBLD2 Impacts Tumor Immune-Vascular Microenvironment of Lung Cancer by Inducing Pro-angiogenic Macrophages - PDF(Abstract)

P1.10. Enrichment of FA/HR Aberrations inATM/ATR-mutated NSCLC Was Accompanied by Distinct Molecular Features and Poor Prognosis - PDF(Abstract)

P1.11. Utility of ctDNA Monitoring during Surveillance in Surgically Resected NSCLC Patients - PDF(Abstract)

P1.11. DYNAMALK: Dynamic ctDNA Profiling in ALK+ NSCLC. A Study of the Australian Registry and Biobank of Thoracic Cancers AURORA - PDF(Abstract)

P1.11. Clinical Implication of Multi-Genomic Analysis about Compound and Uncommon EGFR Mutations in the Non-small Cell Lung Cancer - PDF(Abstract)

P1.11. Application of the CRISPR/Cas9-based Gene Editing Technology for the Treatment of NUT Carcinoma - PDF(Abstract)

P1.12. CD66c Activates EGFR Signalling Pathway and Promotes EMT in Lung Adenocarcinoma - PDF(Abstract)

P1.12. Mechanism of Osteopontin Mediating Targeted Therapy Induced Interstitial Lung Disease Through Integrin αVβ3/Prostaglandin E2 - PDF(Abstract)

P1.12. LP-184, a Tumor Site Activated Small Molecule Acylfulvene, Is Effective Preclinically in Subsets of Lung Cancer - PDF(Abstract)

P1.12. In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a Broad Panel of NSCLC Patient-Derived Xenograft Models - PDF(Abstract)

P1.12. Combining Anti-HER3 Antibody, HMBD-001, with EGFR Inhibition and Chemotherapy may Improve Treatment Outcomes in SqNSCLC - PDF(Abstract)

P1.12. BiFeO3@PANI Sensitizes LKB1-Deficient LUAD to Radiotherapy via Induction of Tumoral Lipid Oxidation and Ferroptosis - PDF(Abstract)

P1.12. Ferroptosis-induction Therapy Combined with Super-enhancers Inhibitors Selectively Target NRF2-activated Lung Cancer - PDF(Abstract)

P1.12. Characterization of MET Exon 14 Skipping Analog (Y1003) in Non-Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

P1.12. APC-1, A Novel Aptamer-Cisplatin Conjugate, Exhibits Promising Anti-tumor Effect in Lung Cancer - PDF(Abstract)

P1.12. Sensitization of Cancer Cells to Tumor Treating Fields (TTFields) via Inhibition of the PI3K/AKT Signaling Pathway - PDF(Abstract)

P1.13. Deep Multi-omic Blood-Based Biomarker Discovery in People with Smoking History Demonstrates High Early Detection of Nsclc - PDF(Abstract)

P1.13. Proof-of-mechanism for a Diagnostic Probe Generating D5-Ethanol Asan On-Breath Reporter Molecule for Lung Cancer - Evolution Phase 1. - PDF(Abstract)

P1.13. The LuCID Study: Detection of Lung Cancer Breath Biomarkers via Breath Biopsy in a Multi-Centre Trial - PDF(Abstract)

P1.13. Targeting SGLT2 for Early Diagnosis of Lung Adenocarcinoma - PDF(Abstract)

P1.13. Plasma Cell-free RNA Sequencing Enables Sensitive Detection of Lung Cancer - PDF(Abstract)

P1.13. A Novel Blood-Based DNAMethylation Panel for Detection of Lung Cancer at Very Early Stage - PDF(Abstract)

P1.13. Detection of Lung Cancer in People Without a Smoking History Using Exhaled Breath as an Exogenous Probe - PDF(Abstract)

P1.13. A Multi-Stage Imaging-Based Deep Learning Classifier for EGFR-TKI Response Prediction in EGFR mutant Non-small Cell Lung Cancer - PDF(Abstract)

P1.14. Strengthening the Screening of Lung Cancer in Europe (SOLACE) Project - PDF(Abstract)

P1.14. Validation of Lung Cancer Risk Prediction Models in an Asbestos Exposed Population - PDF(Abstract)

P1.14. How Do Patients with Screening-Detected Pulmonary Nodules, Experience and React to Being under Surveillance? - PDF(Abstract)

P1.14. European Lung Cancer Screening Implementation: 4-IN-THE-LUNG-RUN trial - PDF(Abstract)

P1.15. Optimised Lung Cancer Screening to Prevent Cardiovascular and Pulmonary Diseases Coupled with Primary Prevention: Results of the Baseline Round - PDF(Abstract)

P1.15. Cardiovascular implications of Lung Cancer Screening Program: The Smokers health Multiple Actions (SMAC) study - PDF(Abstract)

P1.15. Dedicated Cardiovascular Screening in Lung Cancer Screening: Preliminary Results from the European 4-IN-THE-LUNG-RUN Trial - PDF(Abstract)

P1.15. Awareness, Understanding, and Follow Up of Women with Dense Breasts Identified on Low-Dose CT Screening for Lung Cancer - PDF(Abstract)

P1.16. Artificial Intelligence-Assisted Quantitative CT parameters in Predicting the Degree of Risk of Solitary Pulmonary Nodules - PDF(Abstract)

P1.16. Three Dimensional Volumetric Analysis Is Useful to Improve Diagnostic Accuracy in Early-Stage Lung Adenocarcinoma. - PDF(Abstract)

P1.16. Transbronchial Cryobiopsy Using 1.1 mm-Diameter Cryoprobe for the Diagnosis of Early Stage Lung Cancer - PDF(Abstract)

P1.16. Differences in Incidentally Detected Versus Screening Detected Stage I Lung Cancer Surgery Patients - PDF(Abstract)

P1.16. Quality Initiative to Improve Timeliness of Care in a Rapid Assessment Lung Cancer Clinic - PDF(Abstract)

P1.17. Lung Cancer Screening in Low- and Middle-income Countries - Report on Status, Challenges and Perspectives from WCLC2022 and LALCA2023 - PDF(Abstract)

P1.17. Interval of Computed Tomography after Lung Cancer Surgery Follow-Ups Did Not Affect Survival - PDF(Abstract)

P1.17. Cost-effectiveness of Low-dose Computerized Tomography Lung Cancer Screening in High-risk Non-smokers and Smokers in Hong Kong - PDF(Abstract)

P1.17. Lung-Cancer Screening: Is It Worth Investing? Evidence from a Population-Based Markov Study in Italy - PDF(Abstract)

P1.17. Cost-Effectiveness of LDCT Screening in Never Smokers at High Lung-Cancer Risk - PDF(Abstract)

P1.17. Integrated TB and Lung Cancer Screening in Viet Nam - PDF(Abstract)

P1.17. Impact of Lung Cancer Screening with Low-Dose Chest Computed Tomography Scan in an Elderly Population: A Retrospective Cohort Study - PDF(Abstract)

P1.17. Program Factors Associated with the Psychosocial Outcomes of Lung Cancer Screening: A Systematic Review - PDF(Abstract)

P1.18. Association between Cognitive Impairment & Lung Cancer Screening Use among People with Significant Smoking History: Population-Based Study - PDF(Abstract)

P1.18. Coordinating Lung Cancer Screening with Screening Mammography: The CALM Study - PDF(Abstract)

P1.18. First Annual Lung Cancer Screening Day in the United States Saturday November 12 2022 - PDF(Abstract)

P1.18. Te Oranga Pūkahukahu: Developing an Indigenous Māori Led Approach to Lung Cancer Screening - PDF(Abstract)

P1.18. Barriers to Completing Low Dose CT Scan for Lung Cancer Screening - PDF(Abstract)

P1.18. Systematic Enrolment Ensures High Participation Rate in Lung Cancer Screening - Results of Regional Pilot Study in Estonia - PDF(Abstract)

P1.19. Pleural Invasion of Primary Lung Cancer Withinterstitial Lung Disease Treated by Surgical Resection. - PDF(Abstract)

P1.20. Computed Tomography-based Deep Learning Model for Spread Through Air Spaces Prediction in Ground-Glass Predominant Lung Adenocarcinoma - PDF(Abstract)

P1.20. Improved Diagnosis of Lung Neuroendocrine Tumors: Role of Proliferative Activity and Deep Learning - PDF(Abstract)

P1.20. Predictability of Actionable Mutations in NSCLC using Attention-Based Multiple-Instance Learning on H&E Images - PDF(Abstract)

P1.20. Leveraging NLP to Identify Biomarker-Eligible Patients - PDF(Abstract)

P1.20. Mapping the Histopathological Landscape of Lung Adenocarcinoma using Self-Supervised Learning Artificial Intelligence - PDF(Abstract)

P1.21. Major Pathologic Response after Neoadjuvant Therapy in NSCLC: Predicting Better Outcomes with High Interobserver Agreement - PDF(Abstract)

P1.21. Genetic Susceptibility to Immune Checkpoints Blockade Resistance - PDF(Abstract)

P1.21. Upregulation of HLA-I/II and Pro-inflammatory Cells in PBMCs Indicated Efficacy of Neoadjuvant Chemo-immunotherapy in Locally Advanced NSCLC - PDF(Abstract)

P1.21. The Upregulated Expression of IGF2BP2 Predicts Poor Prognosis in Lung Adenocarcinoma and Affects Immune Microenvironment and Drug Sensitivity - PDF(Abstract)

P1.21. Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer - PDF(Abstract)

P1.21. Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer - PDF(Abstract)

P1.21. Eosinophil to Neutrophil Ratio Predicts Efficacy in Patients Receiving Immunotherapy in Metastatic Non-small Cell Lung Cancer (mNSCLC) - PDF(Abstract)

P1.21. Radiomic Signature of Identifies Outcome and Prognosis to Immune Checkpoint Inhibitors (ICI) in PD-L1 Low Non-small Cell Lung Cancer (NSCLC) - PDF(Abstract)

P1.21. PD-1 and Interleukin-10-Receptor Expression by T Lymphocytes in Malignant and Benign Pleural Effusions - PDF(Abstract)

P1.21. Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50% - PDF(Abstract)

P1.21. Microsatellite Instability Defines a Subset of Lung Cancers with Smoking Exposure, High Tumor Mutational Burden and MLH1 Inactivation. - PDF(Abstract)

P1.21. LIPI-based Score Predicting OS Benefit for the Addition of Chemotherapy to Pembrolizumab in aNSCLC with PD-L1 TPS≥50% - PDF(Abstract)

P1.21. Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab - PDF(Abstract)

P1.21. NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy - PDF(Abstract)

P1.21. DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer - PDF(Abstract)

P1.21. Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy - PDF(Abstract)

P1.21. Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI - PDF(Abstract)

P1.21. Tertiary Lymphoid Structures Assessed by an AI-powered Analysis of H&E Images is Correlated with Favorable Outcomes of Immunotherapy in NSCLC - PDF(Abstract)

P1.21. PD-L1 Expression in Surgically Resected Lung Pleomorphic Carcinoma - One-centre Study of 107 Patients - PDF(Abstract)

P1.22. Clinical Characteristics and Biomarkers in Lung Cancer: A Comparison Between Screened and Non-Screened Cohorts - PDF(Abstract)

P1.22. Whole Genome Sequencing Analysis of ALK-rearranged Non-small Cell Lung Cancer - PDF(Abstract)

P1.22. Ventana ALK (D5F3) Immunohistochemistry Improves the Accuracy of Pathologic Assessment after Neoadjuvant ALK-TKIs for ALK-Positive NSCLC - PDF(Abstract)

P1.22. Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study - PDF(Abstract)

P1.22. Prevalence of KRAS Subtype Alterations in Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases - PDF(Abstract)

P1.22. Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey - PDF(Abstract)

P1.22. Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer - PDF(Abstract)

P1.22. Biomarker Testing Trends from a Global Patient-Reported Outcomes Registry - PDF(Abstract)

P1.22. Molecular Profiling Reveals Distinct Clinical and Genomic Features as Potential Therapeutic Targets in Pulmonary Spindle Cell Carcinoma - PDF(Abstract)

P1.22. RET Fusion (RETfus+) Driven Non-Small Cell Lung Cancer (NSCLC): AComprehensive Genomic Profiling (CGP) Study with Histologic Correlation - PDF(Abstract)

P1.22. Comparison of NGS and FISH Platforms to Test MET Amplification in Chinese Lung Cancer Patients: A Prospective Study - PDF(Abstract)

P1.22. Nomogram Prediction for the Detection of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma Patients in Indonesia - PDF(Abstract)

P1.22. Predominant Solid Patterns in Advanced EGFR Mutated Lung Adenocarcinoma Treated with TKI Is Associated with Worse Outcomes - PDF(Abstract)

P1.22. A Phase 3 Multicenter Study to Evaluate the Feasibility of a New NGS Panel Using Cytological Specimens for NSCLC - PDF(Abstract)

P1.22. Identification of MIF as a Multiple Primary Lung Cancer Related Gene Based on RNA Sequencing Technology and Study of Its Function - PDF(Abstract)

P1.22. ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments - PDF(Abstract)

P1.22. Addressing Lung Cancer Biomarker Testing Through the ECHO Model - Results from a 3-State Pilot in the United States - PDF(Abstract)

P1.22. Immediate Biomarkers Profiling of Actionable NSCLC Panel from a Digitized H&E Biopsy Image - PDF(Abstract)

P1.22. Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions. - PDF(Abstract)

P1.22. High Incidence of Ischemic Stroke in Patients with Non-small cell lung cancer and RET fusions - PDF(Abstract)

P1.22. Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations - PDF(Abstract)

P1.23. ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+ NSCLC - PDF(Abstract)

P1.23. Circulating Tumour DNA as a Predictive Biomarker for Tumour Response and Prolonged Clinical Benefit with Nivolumab in NSCLC - PDF(Abstract)

P1.23. Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer - PDF(Abstract)

P1.23. Extracellular Small Vesicle Phosphorylated PD-L1 Liquid Biopsy Levels Correlate with Tumour Proportion Score (TPS) in NSCLC - PDF(Abstract)

P1.23. Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer - PDF(Abstract)

P1.23. Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study - PDF(Abstract)

P1.23. Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer - PDF(Abstract)

P1.23. Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study - PDF(Abstract)

P1.24. Mortality Benefit of a 4-Protein Blood-Based Biomarker Panel for Lung Cancer - PDF(Abstract)

P1.24. TAT3 Predicts Favourable Prognosis in Advanced Non Small Cell Lung Cancer - PDF(Abstract)

P1.24. A Comparative Analysis of Secreted MiRNAs Reveals Candidate Biomarkers for Pleural Mesothelioma Detection - PDF(Abstract)

P1.24. The Association of Acinar Pattern with Clinicopathological, Molecular Features, and Prognosis in Lung Adenocarcinoma Patients - PDF(Abstract)

P1.24. Prognostic Value of DNA Ploidy and Nucleotyping in Early-stage Non-small Cell Lung Cancer - PDF(Abstract)

P1.24. Association between Whole Blood ACTB methylation and Lung Cancer: A Case- Control Study - PDF(Abstract)

P1.24. Effect of Gut Microbiome on Metastasis of Non-small Cell Lung Cancer - PDF(Abstract)

P1.24. Spatially Defined Immune Response Signatures in 5µm Tumor Section of Resected T1-2N0M0 Lung Cancer Predict Clinical Outcome - PDF(Abstract)

P1.24. Clinical Implication of Karyopherin a 2, Which Is a Nuclear Export Protein in Lung Adenocarcinoma - PDF(Abstract)

P1.24. Single-Cell Profiling Reveals the Trajectory of FOLR2+TAMs to Tregs in the Progression of Lung Adenocarcinoma - PDF(Abstract)

P1.24. Exploring the Stability of Gut Microbiome and Its Association with the Prognosis of NSCLC Treated with Chemoraditherapy - PDF(Abstract)

P1.24. Clinicopathological Characteristics of Pulmonary Squamous Cell Carcinoma with KDM5D Copy Number Loss - PDF(Abstract)

P1.24. Prognostic Molecular and Genetic Factors in Early Stage Non Small Cell Lung Cancer - PDF(Abstract)

P1.24. Discovery of Novel Biomarkers of Small Cell Lung Cancer Using Highly Sensitive Quantitative Proteomic Analysis - PDF(Abstract)

P1.24. The Paradoxical Behavior of Kappa When Quantifying Agreement in Histological Subtype Classification among Thoracic Pathologists - PDF(Abstract)

P1.25. Real-World Data of Completely Resected Lung Adenocarcinoma Harboring Common EGFR Mutation in Japan (CReGYT-01 EGFR study) - PDF(Abstract)

P1.25. Complete Pathologic Response (pCR) as a Surrogate Endpoint in Neoadjuvant Immunotherapy Clinical Trials for NSCLC: A Meta-analysis - PDF(Abstract)

P1.25. Comparing Timeliness of Treatment for Surgery vs Radiation for Early-Stage Lung Cancer - PDF(Abstract)

P1.25. Days Alive and Out of Hospital After Thoracoscopic Surgery and Exploratory Study the Correlation on the PRO of First Discharge Day - PDF(Slides)

P1.25. Real-World Outcomes in Non-metastatic Non-small Cell Lung Cancer (NSCLC): An I-O Optimise Multi-Country Analysis - PDF(Abstract)

P1.25. Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR - PDF(Abstract)

P1.25. Surgical Outcomes in Patients with Resected Node-negative Lung Adenocarcinoma of 2 cm or Smaller - PDF(Abstract)

P1.25. TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC - PDF(Abstract)

P1.25. Delays to Early-Stage Lung Cancer Surgery: Patient and Surgeon Perspectives - PDF(Abstract)

P1.25. Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC - PDF(Abstract)

P1.25. Adequacy of Mediastinal Lymph Node Dissection in the Setting of New NCCN Guidelines: Simplified Method From A Rural Hospital - PDF(Abstract)

P1.25. Enhanced Assessment Of Recurrence Risk Of Stage I NSCLC By Combined Adenocarcinoma Grading System And Serum Proteomic Testing - PDF(Abstract)

P1.25. Delayed Recovery Time of Percutaneous Oxygen Saturation After Stair-climbing as a Predictor of Postoperative Complications - PDF(Abstract)

P1.25. Trends and Disparities in Curative-Intent Treatment for Early-Stage Non-Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT - PDF(Abstract)

P1.25. Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study - PDF(Abstract)

P1.25. Stereotactic Ablative Body Radiotherapy for Early NSCLC: Changes in Pulmonary Function, Dyspnoea and Quality of Life - PDF(Abstract)

P1.25. Prognostic Impact of Exon20 Insertion in Surgically Resected Lung Adenocarcinoma Harboring Atypical EGFR Single Mutation - PDF(Abstract)

P1.25. Patient-Reported Outcomes and Exercise Capacity in a Real-Life Setting in Non-small Cell Lung Cancer Patients Undergoing Radiotherapy - PDF(Abstract)

P1.26. A Real World Study of Perioperative Outcomes after Minimally Invasive Segmentectomy versus Lobectomy for Early-Stage Lung Cancer - PDF(Abstract)

P1.26. Random Matrix Based Multiple Scattering Component Extraction Can Significantly Shorten the Time of Lung Segmentectomy - PDF(Abstract)

P1.26. Retrospective Comparison of Robotic- and Video-assisted Thoracic Surgery after Neoadjuvant Therapy for Non-small Cell Lung Cancer - PDF(Abstract)

P1.26. Increased Risk of Death from Other Causes After Lobectomy Compared with Sublober Resection in Lung Cancer Patients - PDF(Abstract)

P1.26. Sublobar Resection is Equivalent to Lobectomy for Stage IA Adenocarcinoma Presenting as Subsolid Nodule - PDF(Abstract)

P1.26. Harmonized Maximum Standardized Uptake Value as an Indicator for Sublobar Resection: A Multicenter Retrospective Study - PDF(Abstract)

P1.26. Trisegmentectomy is Indicated for Non-Small Cell Lung Cancer in the Left Upper Division - PDF(Abstract)

P1.26. Usefulness and Safety of Chest Tube Removal Regardless of Drainage Volume of Pleural Effusion in Patients Who Underwent Pulmonary Resection - PDF(Abstract)

P1.26. Wedge Resection vs. Segmentectomy for NSCLC Size ≤2 CM, Consolidation Tumor Ratio >0.25, cN0: A Multicenter Propensity-Score Matching Analysis - PDF(Abstract)

P1.26. Is Mediastinal Lymph Node Dissection Necessary in Segmentectomy for Peripheral Stage IA (≤2 CM) Non-small-Cell Lung Cancer? - PDF(Abstract)

P1.27. Comparison of Physical and Mental Load Between VATS and RATS Based on NASA-Task Load Index: A Prospective Cohort Study - PDF(Abstract)

P1.27. Artificial Intelligence Analysis Predicts Highly Malignant Potential in Small-Sized Lung Adenocarcinoma - PDF(Abstract)

P1.27. Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis - PDF(Abstract)

P1.27. Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung - PDF(Abstract)

P1.27. Two- and Three-dimensional Radiomic Measurements for Clinical Stage IA Lung Adenocarcinoma: Less is More - PDF(Abstract)

P1.27. Construction of Postoperative Prediction Model Based on the New IASLC Grading System for Early Stage Lung Adenocarcinoma - PDF(Abstract)

P1.27. BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy - PDF(Abstract)

P1.27. Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials - PDF(Abstract)

P1.27. Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT) - PDF(Abstract)

P1.27. NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma - PDF(Abstract)

P1.28. Adherence to Post-treatment Surveillance Guidelines in Non-small Cell Lung Cancer - A Veteran’s Health Administration Cohort - PDF(Abstract)

P1.28. EVs-miRNAs-Based Models in Predicting Radiosensitive Patients with Local Advanced-NSCLC Who Can Benefit from Adaptive Radiotherapy - PDF(Abstract)

P1.28. Adjuvant CCRT Does Not Improve Survival Outcomes in Patients with ECE Positive Pathologic Stage III-N2 NSCLC After Upfront Surgery - PDF(Abstract)

P1.28. Should Older Patients with Stage Iii Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy? - PDF(Abstract)

P1.28. Cessation of Marrow Proliferation on FLT-PET with Low RT Doses During ChemoRT for NSCLC Correlates with Lymphocyte Decline - PDF(Abstract)

P1.28. Treatment Strategies for Locally-advanced NSCLC with Invasive T4 Tumors: A SEER Analysis in the Era of Precision Medicine - PDF(Abstract)

P1.28. Dose-Response Relationship Between Radiotherapy and Loss in Lung Perfusion Determined From DECT and PET/CT in NSCLC - PDF(Abstract)

P1.28. Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group - PDF(Abstract)

P1.28. Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel - PDF(Abstract)

P1.28. Differential Kinetics of Blood and Immune Subpopulations for Cisplatin vs. Sensitizing Paclitaxel Radiotherapy in Locally Advanced Lung Cancer - PDF(Abstract)

P1.28. Recurrence Dynamics for Pathological N2 Non-small Cell Lung Cancer depending on the IASLC Residual Tumor Descriptor - PDF(Abstract)

P1.28. Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy - PDF(Abstract)

P2.01. Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT - PDF(Abstract)

P2.01. Efficiency and Survival Data of Neoadjuvant PD-1 Inhibitor Combined With Chemotherapy in Potentially Resectable IIIA or IIIB NSCLC - PDF(Abstract)

P2.01. An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC - PDF(Abstract)

P2.01. The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC - PDF(Abstract)

P2.01. NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC - PDF(Abstract)

P2.01. Restoring Lymphocytes Using NKTR-255 after Chemoradiotherapy in Solid Tumors (RESCUE) - PDF(Abstract)

P2.02. PROphylactic Pirfenidonefor Prevention of Radiation Induced Pneumonitis in Patients with Lung Cancer(PROPeR study) - PDF(Abstract)

P2.02. Pneumonitis Rates Before Versus After Adoption of Immunotherapy Consolidation for Locally Advanced Non-Small Cell Lung Cancer - PDF(Abstract)

P2.02. Neoadjuvant Immunotherapy Related Pneumonitis in Non-Small Cell Lung Cancer Patients: Incidence, Risk Factors, and Management - PDF(Abstract)

P2.02. Comprehensive Pneumonitis Assessment Among Inoperable Stage III NSCLC Patients Treated with Chemoradiotherapy-Immunotherapy Regimen - PDF(Abstract)

P2.03. Effectiveness and Safety of Combining Bevacizumab and Fractionated Stereotactic Radiotherapy for Brain Metastases in NSCLC Patients - PDF(Abstract)

P2.03. Hybrid Immuno-RT (EclipseRT) for Bulky Tumors: Low-Dose Radiotherapy with Partial Tumor SBRT in Mice and Patients - PDF(Abstract)

P2.03. Upfront or Delayed Cranial RT in Oncogene Mutated NSCLC with Asymptomatic Brain Metastases: A Phase III Randomized Controlled Trial - PDF(Abstract)

P2.03. Predicting Risk of Distant Brain Failure with Radiosurgery and Systemic Therapy in a Diverse NSCLC Brain Metastasis Population - PDF(Abstract)

P2.03. Clinical Impact of Genomic Characterization in Induced Oligometastatic Non-small Cell Lung Cancer - PDF(Abstract)

P2.03. Treatment-related Pneumonitis in Non-small Cell Lung Cancer Treated with Thoracic RT plus TKI: A Systematic Review and Meta-Analysis - PDF(Abstract)

P2.04. AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC - PDF(Abstract)

P2.04. EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours - PDF(Abstract)

P2.05. Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study - PDF(Abstract)

P2.05. MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial - PDF(Abstract)

P2.05. Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort - PDF(Abstract)

P2.05. Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

P2.05. Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC - PDF(Abstract)

P2.05. An Artificial Neural Network System to Predict the Immune-related Adverse Events Based on the RNA Data of ORIENT-3 Study - PDF(Abstract)

P2.05. Immunotherapy Prognostication with Thoracic CT Contrastive Self-Supervised Learning in Patients with Non-Small Cell Lung Cancer - PDF(Abstract)

P2.05. SIPS as a Prognostic Biomarker within Performance Status in Advanced Lung Cancer Patients Treated with Pembrolizumab - PDF(Abstract)

P2.05. The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome - PDF(Abstract)

P2.05. Serum Metabolomics to Determine Survival of Immunotherapy for Advanced Non-small Cell Lung Cancer: Metabolomic Analysis Based on Two Cohorts - PDF(Abstract)

P2.05. Full Spectrum Flow Cytometry-powered Analysis of PBMC as Biomarkers for Immunotherapy in NSCLC with EGFR-TKI Resistance - PDF(Abstract)

P2.05. Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1 - PDF(Abstract)

P2.05. Understanding Genomic and Social Determinants of Cancer Immunotherapy Outcome across Ancestry - PDF(Abstract)

P2.05. Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials - PDF(Abstract)

P2.05. Immune Suppressive Microenvironment in Liver Metastases Contributes to Organ-Specific Response of Immunotherapy - PDF(Abstract)

P2.05. A Novel Autoantibodies Panel Predicted the Prognosis of Advanced Non-Small Cell Lung Cancer Receiving Anti-PD1 Combined With Chemotherapy - PDF(Abstract)

P2.05. A Seven-Lnc RNA Signature for Prognosis Prediction of Patients with Lung Squamous Cell Carcinoma through Tumor Immune Escape - PDF(Abstract)

P2.05. Prediction of Durable Response to Immunotherapy by Early Dynamic in ctDNA and Peripheral Immune Features in NSCLC - PDF(Abstract)

P2.06. Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3 - PDF(Abstract)

P2.06. DEnosumab plus PD-1 Inhibitor for MAINtenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN) - PDF(Abstract)

P2.06. Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients - PDF(Abstract)

P2.06. First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN - PDF(Abstract)

P2.06. Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON - PDF(Abstract)

P2.06. Study Design to Assess Anti-TIGIT Mab Combination with Dostarlimab vs Pembrolizumab or Dostarlimab Monotherapy in NSCLC - PDF(Abstract)

P2.06. PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901) - PDF(Abstract)

P2.06. Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab - PDF(Abstract)

P2.06. Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227 - PDF(Abstract)

P2.06. Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1 - PDF(Abstract)

P2.06. Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small-Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial - PDF(Abstract)

P2.06. The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2 - PDF(Abstract)

P2.07. Development of Postoperative Bronchopleural Fistula after Neoadjuvant Immunochemotherapy in Non-small Cell Lung Cancer: Case Reports - PDF(Abstract)

P2.07. Association between OS and Subsequent ICI in Control Arm Patients of First Line ICI-based RCTs of Advanced/Metastatic NSCLC: FDA Analysis - PDF(Abstract)

P2.07. Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer - PDF(Abstract)

P2.07. Genomic Subtypes of EGFR-Mutant NSCLC and Real-World Progression-Free Survival (rwPFS) with Immunotherapy (IO) - PDF(Abstract)

P2.07. Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry - PDF(Abstract)

P2.07. Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics - PDF(Abstract)

P2.07. Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors - PDF(Abstract)

P2.07. Checkpoint Inhibitor Pneumonitis Model for NSCLC based onPreexistingLung Ground Glass Opacities: Development and Validation - PDF(Abstract)

P2.07. Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO? - PDF(Abstract)

P2.08. TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) - PDF(Abstract)

P2.08. STAR-121: Phase 3 Study of DOM and ZIM plus Chemo vs Pembro plus Chemo in 1L mNSCLC with No Actionable Gene Alterations - PDF(Abstract)

P2.08. A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab - PDF(Abstract)

P2.08. A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab - PDF(Abstract)

P2.08. IMRPrinter: A Phase 1/1b Trial of IMU‑201 (PD1-Vaxx) as Monotherapy or in Combination with Atezolizumab +/- Chemotherapy in NSCLC - PDF(Abstract)

P2.08. A Phase II Study of Subcutaneous (SC) Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model - PDF(Abstract)

P2.08. EDGE-Lung: A Phase 2 Open-Label Platform Study to Evaluate Immunotherapy-Based Combinations in Patients with Metastatic NSCLC - PDF(Abstract)

P2.09. A Large Asian Real-World EGFR exon 20Insertion Mutated NSCLC Dataset with Deep Genomic Characterization - PDF(Abstract)

P2.09. Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis - PDF(Abstract)

P2.09. Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC - PDF(Abstract)

P2.09. Identification of Co-existing Genetic Alterations in Advanced Stage EGFR mutated NSCLC at Baseline and Disease Progression - PDF(Abstract)

P2.09. Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer - PDF(Abstract)

P2.09. Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated - PDF(Abstract)

P2.09. Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial - PDF(Abstract)

P2.09. A Phase 1, 2 Study to Evaluate the Safety and Anti-tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced NSCLC - PDF(Abstract)

P2.09. JIN-A04, Highly Effective and Brain-penetrant Tyrosine Kinase Inhibitor Targeting HER2 Exon20 Insertion Mutations in NSCLC - PDF(Abstract)

P2.09. Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations - PDF(Abstract)

P2.09. QT-interval Prolongation and Torsades de Pointes With EGFR TKIs in NSCLC: Targeted Literature Review - PDF(Abstract)

P2.09. Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations - PDF(Abstract)

P2.09. Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer - PDF(Abstract)

P2.09. Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles - PDF(Abstract)

P2.09. OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small Cell Lung Cancer - PDF(Abstract)

P2.09. FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions - PDF(Abstract)

P2.09. Increased Dose of Aumolertinib Rechallenge in Advanced NSCLC with Gradual Progression - PDF(Abstract)

P2.09. VRN110755, A New Therapeutic Option for EGFR Mutation-Driven NSCLC with Brain Metastasis or 1st-line Osimertinib-Resistant EGFR Mutations - PDF(Abstract)

P2.09. A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study) - PDF(Abstract)

P2.09. Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD - PDF(Abstract)

P2.09. Inhibition of AXL and Mcl-1 Contributes to Eradicating Tolerance to EGFR-TKI Lazertinib in Lung Cancer Cells Expressing Mutant EGFR - PDF(Abstract)

P2.09. Trials in Progress: Phase 1a/b study of ELVN-002, in Solid Tumors with HER2 Mutations, Amplification or Overexpression - PDF(Abstract)

P2.09. Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC) - PDF(Abstract)

P2.09. Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY) - PDF(Abstract)

P2.09. Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR ex20ins+ NSCLC PDX Models - PDF(Abstract)

P2.09. A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs - PDF(Abstract)

P2.09. Design, Synthesis and Assessment of Novel Molecule against Drug-Resistant Dual Mutant EGFR (T790M/L858R) to Treat NSCLC - PDF(Abstract)

P2.09. Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China - PDF(Abstract)

P2.09. Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases - PDF(Abstract)

P2.09. Combined Multi-omics Explore the Resistance Mechanism of Third-generation EGFR-TKI BPI-7711 - PDF(Abstract)

P2.09. MRI Radiomics Approach to Predict the Intracranial Efficacy of the Third Generation EGFR-TKI Osimertinib in NSCLC Patients with Brain Metastases - PDF(Abstract)

P2.09. Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers - PDF(Abstract)

P2.09. Efficacy of Anlotinib in T790M-positive NSCLC Patients with Osimertinib Resistance: A Retrospective and Exploratory Study - PDF(Abstract)

P2.09. Phase I/II Study Exploring Safety and Efficacy of Apl-101 Plus Frontline Osimertinib in EGFR-mutated Metastatic Non-small Cell Lung Cancer - PDF(Abstract)

P2.09. Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy - PDF(Abstract)

P2.10. ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK+ NSCLC and ALK-inhibitor Resistance - PDF(Abstract)

P2.10. Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma ALK-positive Cohort (A-Liquid) - PDF(Abstract)

P2.10. Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study - PDF(Abstract)

P2.10. Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors - PDF(Abstract)

P2.10. Cost of Managing Brain Metastases in Patients with ALK+ aNSCLC with First-Line Tyrosine Kinase Inhibitors (TKIs) in the UK - PDF(Abstract)

P2.10. Brain Metastases in Patients with Fusion-Positive Lung Cancers - PDF(Abstract)

P2.10. ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases - PDF(Abstract)

P2.10. Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study - PDF(Abstract)

P2.10. Co-occurring Loss of CDKN2A/2B Associated with Worse Survival and Increase Risk of Brain Metastasis in ALK-Rearranged Non-small Cell Lung Cancer - PDF(Abstract)

P2.10. Comparative Effectiveness Analysis of Selpercatinib versus Standard Therapy in Patients with Non-small Cell Lung Cancer - PDF(Abstract)

P2.10. Loss of EPHA2 Induces Primary Lorlatinib Resistance Through Sustained MAPK Activation - PDF(Abstract)

P2.10. Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice - PDF(Abstract)

P2.10. First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs - PDF(Abstract)

P2.10. Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK+ NSCLC in ALTA-1L - PDF(Abstract)

P2.11. A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer - PDF(Abstract)

P2.11. Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION - PDF(Abstract)

P2.11. Synergistic Co-Targeting Of MYC And KRAS In Lung Cancer By Novel Ligand-Directed Inverted Chimeric RNAi Molecules - PDF(Abstract)

P2.11. A Phase 1B Trial of Tarloxotinib and Sotorasib in Lung Cancer Patients with KRAS G12C Mutations - PDF(Abstract)

P2.11. SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation - PDF(Abstract)

P2.12. Tumor Microenvironment Remodeling Contributes to the Resistance to EGFR-TKI in EGFR-mutated Non-small Cell Lung Cancer - PDF(Abstract)

P2.12. Beware: Tyrosine Kinase Inhibitors for Lung Cancers that Inhibit MATE-1 can Lead to "False” Decreases in Renal Function - PDF(Abstract)

P2.12. Cerebrospinal Fluid is an Alternative Medium of Liquid Biopsy for Patients with Brain Parenchymal Metastases from Non-Small Cell Lung Cancer - PDF(Abstract)

P2.12. Real-World Data of Biomarker Diagnostics, Treatment Strategy, and Survival Outcome with Advanced or Recurrent NSCLC in Japan - PDF(Abstract)

P2.12. Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib - PDF(Abstract)

P2.12. Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression - PDF(Abstract)

P2.12. Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon Mutations - PDF(Abstract)

P2.12. Targeted and Immunotherapy Associated Cardiotoxicity in Stage IV Lung Cancer Patients with and without Cardiac Comorbidities - PDF(Abstract)

P2.13. Spatially Resolved Transcriptomics deciphers Inter- and Intra-Tumor Heterogeneity of Small Cell Lung Cancer - PDF(Abstract)

P2.13. Molecular Subtyping of Small Cell Lung Carcinoma: An Attempt at Unravelling Its Biological Heterogeneity - PDF(Abstract)

P2.13. Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients - PDF(Abstract)

P2.13. Pathological Images Machine Learning Predicts Long Term Effects for Immunotherapy in Small-Cell Lung Cancer - PDF(Abstract)

P2.13. Spatiotemporal Heterogeneity of Transcription Factor-Based Subtype Assignment in Small Cell Lung Carcinoma - PDF(Abstract)

P2.13. A Novel Clinical Scoring System (EAST score) for the Prediction of Treatment Response in Limited-Stage Small-Cell Lung Cancer - PDF(Abstract)

P2.13. Biomarkers for Predicting the Efficacy of PD-L1 Inhibitors Combined with Chemotherapy in ES-SCLC - PDF(Abstract)

P2.13. Integrated Clinical and Radiomics Approach to Assess the Treatment Outcome of Combined Chemoimmunotherapy in Extensive-Stage SCLC - PDF(Abstract)

P2.14. Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC - PDF(Abstract)

P2.14. First-Line Envafolimab plus Carboplatin-etoposide in Extensive-Stage Small-Cell Lung Cancer: a Single-Arm Phase II Study - PDF(Abstract)

P2.14. Outcomes of Chemoimmunotherapy in Patients with ES-SCLC According to Liver Metastasis: A Multicenter Prospective Cohort Study - PDF(Abstract)

P2.14. Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study - PDF(Abstract)

P2.14. A Phase II Study of Sintilimab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small Cell Lung Cancer:SINCE-01 Trial - PDF(Abstract)

P2.14. Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial - PDF(Abstract)

P2.15. Priming SCLC Vasculature to Facilitate NK Cell Attack - PDF(Abstract)

P2.15. Distinct Tumor Microenvironment in SCLC as compared with NSCLC by Single Cell Analysis - PDF(Abstract)

P2.16. Sintilimab in Combination With Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC - PDF(Abstract)

P2.16. Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial - PDF(Abstract)

P2.16. RYZ101 + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer - PDF(Abstract)

P2.16. Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated ES-SCLC in Brazil - PDF(Abstract)

P2.16. Durvalumab+EP in Advanced Large-Cell Neuroendocrine Carcinoma of Lung (aLCNEC): a Pilot Phase II study - PDF(Abstract)

P2.16. A Phase 2 Study of Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC - PDF(Abstract)

P2.17. Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer - PDF(Abstract)

P2.17. EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study - PDF(Abstract)

P2.17. CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer - PDF(Abstract)

P2.17. Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC - PDF(Abstract)

P2.17. Characterizing Mechanisms of Treatment Resistance in SCLC - PDF(Abstract)

P2.17. Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial - PDF(Abstract)

P2.17. Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis - PDF(Abstract)

P2.18. Successful Generation of Tumor-Infiltrating Lymphocytes (TIL) for Adoptive Cell Therapy from Mesothelioma - PDF(Abstract)

P2.18. Impact of Inclusion of Immunotherapy in National Treatment Guidelines on Survival Outcomes in Malignant Pleural Mesothelioma - PDF(Abstract)

P2.18. Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso) - PDF(Abstract)

P2.18. Impact of Evolving Treatment Paradigms on Survival Outcomes in Advanced Pleural Mesothelioma: A Real-World Analysis - PDF(Abstract)

P2.18. Co-designing an Experience of Care and Quality of Life Survey for an Australian Mesothelioma Clinical Outcomes Registry - PDF(Abstract)

P2.19. First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced Mesothelioma - PDF(Abstract)

P2.19. [DREAM] Double Lung Transplant Registry Aimed for Lung-Limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers - PDF(Abstract)

P2.20. A Precision Medicine Approach by Performing Comprehensive Cancer Genome Profiling of Thymomas and Recurrent Thymomas - PDF(Abstract)

P2.20. Thymomatous Myasthenia Gravis after Total Thymectomy at a Tertiary-Care Surgical Centre: a 20-Year Retrospective Review - PDF(Abstract)

P2.20. Clinical Outcome of Patients with Thymic Carcinoma Treated with Preoperative Induction Therapy Followed by Surgical Resection - PDF(Abstract)

P2.20. Differential Expression of Genes in Type A and B3 Thymomas and Thymic Carcinomas - PDF(Abstract)

P2.20. The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors - PDF(Abstract)

P2.20. Does Radical Thymectomy Influence the Neurological Outcome in Patients Aged over 65 with Thymoma and Myasthenia Gravis? - PDF(Abstract)

P2.21. Inflammatory Biomarkers as Prognostic Factors for Malignant Pleural Mesothelioma - PDF(Abstract)

P2.21. A Combination of PD-1 and TIGIT Checkpoint Blockade Elicits a Strong Antitumor Response in the Patient and Mouse Pleural Mesothelioma Model - PDF(Abstract)

P2.21. Novel microRNAs are Associated with Presence of Pleural Mesothelioma and Response to Chemotherapy - PDF(Abstract)

P2.21. The Significance of BAP1 and MTAP/CDKN2A Expression in Well-Differentiated Papillary Mesothelial TUmour: A Series of 21 Cases - PDF(Abstract)

P2.21. CD47 as Biomarker of Prognosis in Patients with Malignant Pleural Mesothelioma - PDF(Abstract)

P2.21. Characterization of the Genomic and Immune Landscape of Malignant Pleural Mesothelioma - PDF(Abstract)

P2.21. A Novel Proteomic Technique Uncovers New Diagnostic Biomarkers for Malignant Pleural Mesothelioma - PDF(Abstract)

P2.21. Mutant NF2-Driven De Novo Pyrimidine Synthesis is a Metabolic Vulnerability in Malignant Pleural Mesothelioma - PDF(Abstract)

P2.21. Single-Cell Dissection Reveals Mesothelial Heterogeneity and Dysfunctional Immunity in Malignant Pleural Mesothelioma - PDF(Abstract)

P2.22. Single-nuclei RNA Sequencing Reveals Heterogeneity and Malignancy in Pulmonary Sarcomatoid Carcinoma - PDF(Abstract)

P2.22. Long-term Survival in Patients with Primitive Neuroectodermal Tumors of Thorax: Does Size Matter? - PDF(Abstract)

P2.22. NUT Midline Carcinoma (NC) Deciphering the Standard of Care in an Ultra-rare Cancer - PDF(Abstract)

P2.22. Is the Modified Frailty Index (mFI) a Reliable Predictor of Complications after Transthoracic Esophagectomy? - PDF(Abstract)

P2.23. An Untold Story About Living with Low Muscle Mass and its Impact Throughout Curative Radiotherapy Treatment for Lung Cancer - PDF(Abstract)

P2.23. Prospective Observational Study of Cachexia and Its Effect on Systemic Therapy in Patients with Previously-Untreated Advanced NSCLC (NEJ050A) - PDF(Abstract)

P2.23. The Role of The Mesothelioma UK Nurse Increases the Number of Patients Accessing Legal Representation, Financial Entitlement. - PDF(Abstract)

P2.23. Changes in Physical Activity, Fatigue, and Six-Minute Walk Distance Among Lung Cancer Patients Before and After Chemotherapy - PDF(Abstract)

P2.23. Counseling & Rehabilitation of Lung-Cancer Sufferers by Nursing Personnel - PDF(Abstract)

P2.23. Evaluation/Analysis of Opinions of Oncology Nurses , What We Need to Do ? - PDF(Abstract)

P2.23. Determination of the Best Cut-off Point To Establish the Performance of a Mexican Cohort with Non-small Cell Lung Cancer in the 6-Minute Walk Test - PDF(Abstract)

P2.25. Geriatric Assessment in Lung Cancer Surgery Patients and Caregivers - PDF(Abstract)

P2.25. Resiliency among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Novel Pilot Supportive Care Intervention Study - PDF(Abstract)

P2.25. Functional Independence of Older Adults after Lung Cancer Surgery: Final Analysis of a Prospective Observational Study - PDF(Abstract)

P2.25. Unmet Social Needs and Spiritual Well-Being of Lung Cancer Surgery Patients and Family Caregivers from the United States - PDF(Abstract)

P2.26. Managing Pain Lung Cancer Patients -- Contribution of Oncology Nurses - PDF(Abstract)

P2.26. Patient-Reported Symptom Monitoring Improves 1-Year Quality of Life in Lung Cancer Patients; the SYMPRO-Lung Trial - PDF(Abstract)

P2.27. Does Patient Experience with Robotic Thoracic Surgery Influence Their Willingness to Pay for It? - PDF(Abstract)

P2.27. Stigma-Reducing Interventions for Lung Cancer and Other Smoking-Related Respiratory Diseases: A Systematic Review - PDF(Abstract)

P2.27. Perception of Benefits and Risks of Treatments in Patients with Metastatic NSCLC with EGFRex20ins - PDF(Abstract)

P2.27. Advocates Unite to Increase Lung Cancer Research Funding - PDF

P2.27. Everywhere Is Local: Applying Lessons from the Community to Areas across the Globe - PDF(Abstract)

P2.28. Lung Cancer Mortality in Brazil: Temporal Trends, Regional Disparities and the Impact of the COVID-19 Pandemic - PDF(Abstract)

P2.28. Impact of the Covid-19 Pandemic on Lung Cancer Diagnosis in a German Comprehensive Cancer Center. Are we still paying the debt? - PDF(Abstract)

P2.28. Symptomatic vs. Asymptomatic SARS-CoV-2 Infection Rates in Lung Cancer: Longitudinal Nucleocapsid Antibody Analysis - PDF(Abstract)

P2.29. Harnessing Artificial Intelligence to Expand Lung Cancer Clinical Trial Opportunities in Spain - PDF(Abstract)

P2.29. The LungTrust Methodology - PDF(Abstract)

P2.30. Cost Estimation of Radiotherapy for Local Control and Overall Survival Benefit of Lung Cancer in the Australian Population - PDF(Abstract)

P2.30. Assessing the Impact of Using Disease-Specific Novel Value Elements on Cost-Effectiveness Results in Lung Cancer - PDF(Abstract)

P2.31. Characterization of Survival Disparities among Asian Pacific Islander (API) Subgroups in Stage IV NSCLC in California - PDF(Abstract)

P2.31. Real-World Survival Outcomes in NSCLC in Adults Ages 50 and Younger at a Large Academic Institution - PDF(Abstract)

P2.31. Lambert-Eaton Myasthenic Syndrome is Underrecognized in Small Cell Lung Cancer: An Analysis of Real-World Data - PDF(Abstract)

P2.31. Implementation of a Novel Chart Rounds Application to Facilitate Lung Radiotherapy Plan Peer-Review in a Virtual Environment - PDF(Abstract)

P2.31. Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data - PDF(Abstract)

P2.31. Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy - PDF(Abstract)

P2.31. Incidence and Survival Outcomes of Lung Cancer Post-Double Lung Transplant and its Association with Graft Rejection - PDF(Abstract)

P2.31. Disparities in Representation of Older Adults, Women, Racial/Ethnic Minorities in Lung Cancer Clinical Trials: Meta-analysis - PDF(Abstract)

P2.31. Missed Opportunities for Lung Cancer Personalized Medicine in a Brazilian Public Healthcare Service - PDF(Abstract)

P2.31. Clinical Outcomes of Real-World Treatment for Metastatic EGFRm NSCLC after Osimertinib and Platinum-Based Chemotherapy - PDF(Abstract)

P2.31. Impact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia - PDF(Abstract)

P2.31. Sexual Dysfunction on Patients with Lung Cancer: Results from the CLARIFY Project. - PDF(Abstract)

EP01.01. Adenocarcinoma and Small Cell Lung Cancer Risk Associated with Occupation in Women - PDF(Slides)

EP01.01. Prognostic Analysis and Nomogram Establishment of Synchronous Dual Primary Lung Cancer: Based on Multicenter Data - PDF(Slides)

EP01.01. Postoperative Course of Surgically Resected Lung Cancer Patients in Preserved Ratio Impaired Spirometry - PDF(Slides)

EP01.01. Poor Sleep Quality in Lung Cancer Patients - PDF(Slides)

EP01.01. Casual Effects of Some Chronic Respiratory Diseases on Squamous Cell Lung Cancer: A Mendelian Randomization Study - PDF(Slides)

EP01.01. Sex Difference Indicate Survival Disparity in Resected NSCLC, from a Large Chinese Cohort - PDF(Slides)

EP01.01. Histopathological Risk Factors Correlation in Patients with Non-Small Cell Lung Cancer - PDF(Slides)

EP01.01. Radiation Exposure in Intraoperative Navigation for Peripheral Small Pulmonary Nodule - PDF(Slides)

EP01.01. Long-term Survivals Associated with High Levels of Na+ and Ca2+ in the Blood of Patients with Stage IV Lung Cancer - PDF(Slides)

EP01.01. Familial Aggregation in Non-small Cell Lung Cancer - PDF(Slides)

EP01.01. Binge-Watching Frequency and Tobacco Use in Adolescents: Data from “Blaam Smoke-Free Movie” Program - PDF(Slides)

EP01.01. Awareness and Perceptions of Compliance with the Nigerian Tobacco Control Law Among Young Adults in Lagos, Nigeria - PDF(Slides)

EP01.01. Gender Differences in Clinical Course and Patient-Reported Outcomes among Patient with Early-Stage Non-Small Cell Lung Cancer - PDF(Slides)

EP01.01. Osteoporotic Vertebral Fractures in Non-small Cell Lung Cancer : A Cracking Connection - PDF(Slides)

EP01.01. Genomic Alterations of Lung Cancer: Experience in Peru - PDF(Slides)

EP01.01. Impact of Smoking on Survival in NSCLC Patients Treated with Chemoimmunoimmunotherapy or Chemotherapy: A Real-world Data Study - PDF(Slides)

EP01.01. Evaluation of Perioperative Nintedanib for Lung Cancer with Idiopathic Pulmonary Fibrosis - PDF(Slides)

EP01.01. Respirable Crystalline Silica Exposure and Lung Cancer Risk: A Review of Cut-off Points - PDF(Slides)

EP01.01. Risk Factors of Intraoperative Air Leakage in Anatomical Pulmonary Resection - PDF(Slides)

EP01.01. Provider Perspectives on a Navigational Pilot Study for Cancer Patients within a Tobacco Treatment Program - PDF(Slides)

EP01.01. Median Age at Lung Cancer Diagnosis in 60 Countries: An International Comparative Study - PDF(Slides)

EP01.01. Occupational Exposure and Lung Cancer Risk in Women: A Pooling Study - PDF(Slides)

EP01.01. Association between ACEI-Induced Cough and the Risk of Lung Cancer: A Mendelian Randomization Study - PDF(Slides)

EP01.01. Gender and Lung Cancer (LC): Preliminary Data from a Prospective, Woman-Centered Local Registry - PDF(Slides)

EP02.01. Differing Cell Cycle Responses for Alectinib and SHP099 in Variant 1 and Variant 3 ALK+ Non-Small Cell Lung Cancer Cell Lines - PDF(Slides)

EP02.01. Novel Therapeutic Vulnerabilities in SOX2-dependent Squamous Cell Lung Cancer - PDF(Slides)

EP02.01. Suppression of Telomerase RNA Component Induces Autophagy and Ferroptosis in Lung Cancer via Regulation of AMP-actived Protein Kinase - PDF(Slides)

EP02.01. Androgen Receptor Suppresses Lung Cancer Invasion and Cisplatin Resistance via Decreasing TPD52 Expression - PDF(Slides)

EP02.01. Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases - PDF(Slides)

EP02.01. TP53 Mutation Has Significant Impact on Other Driver Genes in Lung Cancer - PDF(Slides)

EP02.01. DEPDC1 Expression and Mechanisms in Lung Adenocarcinoma : Insights into Proliferation and KIF2C Regulation - PDF(Slides)

EP02.01. SOX2 Deregulated Squamous Carcinomas Are Vulnerable to AKT3 Inhibition - PDF(Slides)

EP02.01. Synergism of KRAS G12C Inhibitor and mTOR Inhibitor in Lung Adenocarcinoma and Squamous Cell Carcinoma - PDF(Slides)

EP02.01. Dysfunction of FBXL5-mediated Ferrous Iron Homeostasis Suppresses Lung Cancer Growth - PDF(Slides)

EP02.01. CSNK1D and CSNK1E Inhibition Regulates Autophagy by Promoting Autophagic Flux in Lung Cancer - PDF(Slides)

EP02.01. PEG2000-PLA-Based Nanoscale Polymeric Micellar Reduces Paclitaxel-Related Toxicity in Beagles - PDF(Slides)

EP02.02. Genomic Correlates with Ancestry in Lung Squamous Cell Carcinoma - PDF(Slides)

EP02.02. Transcriptomic Response to Tumor Treating Fields (TTFields) Across Tumor Types - PDF(Slides)

EP02.02. Combination of Radiotherapy and PD-L1 Blockade Induces Abscopal Responses in EGFR-mutated Lung Cancer - PDF(Slides)

EP02.02. Microbiome in Lung Cancer: Culture-Based Analysis Using Transthoracic Needle Biopsy (TTNB) - PDF(Slides)

EP02.02. Radiation-induced SERPINE2 Expression Inhibit Abscopal Effect in Non-small Cell Lung Cancer via Exosomes - PDF(Slides)

EP02.02. Machine Learning for Multi-Omics Data Identifies Vulnerabilities in a Subset of Squamous Cell Lung Cancers - PDF(Slides)

EP02.02. Identification of COL5A2+ Cancer-Associated Fibroblast in Solid Subtype of LUAD by Integrated Analysis of WGCNA and Single Cell RNA-seq - PDF(Slides)

EP02.03. ADAR1 Knockout Results in Loss of Tumorigenicity in a Syngeneic Murine Model of Non-small Cell Lung Cancer. - PDF(Slides)

EP02.03. Defining Genetic Instability at Tetranucleotide Repeats (EMAST) In a Non-small Cell Lung Cancer - PDF(Slides)

EP02.03. The Functional and Mechanistic Role of PA28α in Lung Cancer - PDF(Slides)

EP02.03. Silencing of Long Non-coding RNA LINC00265 Triggers Autophagy in Lung Canerby Reducing Protein Stability ofSIN3A Oncogene - PDF(Slides)

EP02.03. Circular RNA-mediated ceRNA Network was Indentified in Human Lung Adenocarcinoma by High-throughput Sequencing - PDF(Slides)

EP02.03. Suppression of the Long Non-coding RNA LINC01279 Triggers Autophagy in Lung Cancer by Regulating SIN3A - PDF(Slides)

EP02.03. LINC00629 Regulates Cell Proliferation, Migration, Invasion and Apoptosis of Lung Adenocarcinoma - PDF(Slides)

EP02.04. The Suppressed Peritumoral Immune Microenvironment Enhances the Progression of Primary Lung Cancer And Metastatic Liver Tumor - PDF(Slides)

EP02.04. A Nanoplatform Based on an in Situ Tumor Vaccine and Activation of STING and TLR7/8 Pathways for Enhanced NSCLC Immunotherapy - PDF(Slides)

EP02.04. Frequency of the Number of Myeloid Derived Suppressor Cells in Patients with Lung Cancer According to Tumor Pathohistological Type - PDF(Slides)

EP02.04. PHLPP2 Enhances Anti-tumor Immunity by Promoting M1 Polarization of Macrophages via STAT3-related Pathway in NSCLC - PDF(Slides)

EP02.04. Xenotransplanted Lung Tumors Display Variable Pleomorphic Patterns in Immunosuppressed BALB/c Mice - PDF(Slides)

EP02.04. Integrative Single Cell RNA Sequencing Reveals New Insight in Lung Cancer Microenvironment - PDF(Slides)

EP03.01. Genetic Alterations as Independent Prognostic Factors to Predict Organ-Specific Metastases of Lung Cancer - PDF(Slides)

EP03.01. Molecular Characterization of Non-small Cell Lung Cancer in People Living with HIV or Solid Organ Transplants - PDF(Slides)

EP03.01. Differences in Glucose and Energy Metabolism between Lung Squamous Cell Carcinoma and Lung Adenocarcinoma - PDF(Slides)

EP03.01. The Role of Microenvironmental Biomechanics in Lung Cancer Development and Metastasis - PDF(Slides)

EP03.02. EGFR T790M Detection Differences by Original Mutation Types and Detection Samples - PDF(Slides)

EP03.02. miR-4487 Enhances Gefitinib-Mediated Ubiquitination and Autophagic Degradation of EGFR in NSCLC cells by targeting USP37 - PDF(Slides)

EP03.02. High-Throughput Screening Reveals Ceritinib as a Sensitizer for Cafs-Induced Osimertinib Resistance in Non-small Cell Lung Cancer - PDF(Slides)

EP03.03. IS1160 Transposon Mycobacterium Tuberculosis Detection in Lung Cancer - A Preliminary Study - PDF(Slides)

EP03.03. Multi-omics Analysis of Immune Determinants of STK11 in Non-Small Cell Lung Cancer - PDF(Slides)

EP03.03. Comprehensive Analysis of Primary Immunotherapy-resistant Genes with Regard Immune Infiltration and Prognosis in Lung Adenocarcinoma - PDF(Slides)

EP03.03. Decoding the Immune Dysfunction of Cancer Cachexia in Lung Cancer Patients - PDF(Slides)

EP03.03. Immunological Profiling of PD-1-Treated Murine Model Reveals Meyloid-Enriched Phenotypes - PDF(Slides)

EP03.03. The Involvement of Tumor Endothelial Cells in the Regulation of PD-L1 and Tregs in the Immune Microenvironment of Early-stage Lung Adenocarcinoma - PDF(Slides)

EP03.03. T-Cell Receptor Repertoire Profiling as a Predictive Biomarker for Immunotherapy in Unresectable Stage III Non-small Cell Lung (NSCLC) - PDF(Slides)

EP03.03. Single-nucleus RNA Sequencing Dissecting the Tumor Microenvironment of Liver Metastasis of Non-small Cell Lung Cancer - PDF(Slides)

EP03.03. Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS CoV2 Vaccination in Patients with Non Small Cell Lung Cancer - PDF(Slides)

EP03.04. Detection of Possible Targets in Aggressive Lung Cancer Using Molecular Abundances and Catalytic Action of Serine Hydrolases - PDF(Slides)

EP03.05. Aberrant Methylation of ZNF577 As a Potential Prognostic Biomarker for Lung Adenocarcinoma - PDF(Slides)

EP03.05. Genomic Landscape Features of Minimally Invasive Adenocarcinoma and Invasive Lung Adenocarcinoma - PDF(Slides)

EP03.05. Hollow-MnO2 Nanofabricated Platform Equipped with Carbon Monoxide Gas Combined with SDT Enhanced ROS Generator for Lung Cancer Treatment - PDF(Slides)

EP03.05. RNA Sequencing to Characterize Pathways in Patients with EGFR-mutated Non-Small Cell Lung Cancer - PDF(Slides)

EP03.05. Non-Small Cell Lung Cancer: Artificial Intelligence, Complex System Analysis and Computer Simulation for Best Management. - PDF(Slides)

EP03.05. Identification of Oncogenic Non-coding Regions Inducing the ANKZF1 Expression in Lung Cancer by a Multi-omics Website Omics3D - PDF(Slides)

EP03.06. Differential Anticancer Compound Response of Filipino Patient-derived Lung Adenocarcinoma Cells (GL01) Against A549 Cell Line - PDF(Slides)

EP03.06. The Landscape of NF1 Alteration in Chinese Non-Small-Cell Lung Cancer Patients - PDF(Slides)

EP03.06. Development of an Inhibitor for the Treatment of Lung Cancer - PDF(Slides)

EP03.06. Synthetic Lethality Targeting Programmed Cell Death Reverses the Osimertinib Resistance Induced by ARID1A Deficiency in LUAD - PDF(Slides)

EP03.06. KRAS-B: Molecular Epidemiology and Clinical Outcomes of KRAS-Mutant Non-small Cell Lung Cancer (NSCLC) in Brazil - PDF(Slides)

EP04.01. The PneuVision Test Detects Both Lung Squamous Cell Carcinoma and Adenocarcinoma from Cells in Sputum - PDF(Slides)

EP04.01. Volatile Organic Compounds in Exhaled Breath as Biomarkers for Lung Cancer. A Screening-Based Study in High-Risk Participants - PDF(Slides)

EP04.01. Advancing Malignancy Risk Stratification for Early-Stage Cancers in Lung Nodules by Combined Imaging and Electrical Impedance Analysis - PDF(Slides)

EP04.01. Detecting KRAS Mutations in Peripheral Blood Extracellular Vesicles in Non-Small Cell Lung Cancer Using Digital Droplet PCR - PDF(Slides)

EP04.01. True Abnormal Cells in Normal Cases Detected by the PneuVision Test for Early-Stage Lung Cancer - PDF(Slides)

EP04.01. Double Blind Evaluation of Circulating Cancer Associated Macrophage Like (CAML) Cells for Detection of Cancer in Pulmonary Nodules - PDF(Slides)

EP04.01. Optimal Predictors for Lung Cancer Using High-Resolution CT - PDF(Slides)

EP04.01. The Combination of a Seven-Autoantibody Panel with Computed Tomography Scanning Can Enhance the Diagnostic Efficiency of Lung Cancer - PDF(Slides)

EP04.01. AI-based Detection on Low-Dose CT: A Focus on Augmenting Model Performance - PDF(Slides)

EP04.01. METTL7A Inhibits Cell Proliferation and M2-Like Polarisation of Tumor-Associated Macrophage in Lung Adenocarcinoma - PDF(Slides)

EP04.02. Impact of an Urban Based Lung Cancer Screening Program: Seven Year Follow-up - PDF(Slides)

EP04.02. Implementation of an Integrated Lung Cancer Screening Program at a Large Academic Community Health System in the U.S. - PDF(Slides)

EP04.02. Cost-Consequence Analysis of Artificial Intelligence Assisted Image Reading in Lung Cancer Screening - PDF(Slides)

EP04.02. Screening Success: A Review of Outcomes from Lehigh Valley Health Network’s Multi-Disciplinary Lung Cancer Screening Program. - PDF(Slides)

EP04.04. Delay in Lung Cancer Diagnosis as a result of being Diagnosed as Pulmonary Tuberculosis in Riau Province - PDF(Slides)

EP04.04. Incidental Lung Nodule Identification and Subsequent Diagnosis of Lung Cancer in a University Hospital in Hong Kong - PDF(Slides)

EP04.04. Impact of a Lung Nodule Program in a Tertiary Care Academic Center in the United States - PDF(Slides)

EP04.04. Relevance of AI (qCT ) In Automated Progression Monitoring of Pulmonary Nodules in Follow-up Lung CT Scans - PDF(Slides)

EP04.04. Ten-year CTNB Data Indicate Its Usefulness and Safety, Especially Salvage Situation after Bronchoscopy without Diagnosis - PDF(Slides)

EP04.04. Low-Dose CT Iterative Reconstructions can Impact Lung Nodule Measurements and Type Classification - PDF(Slides)

EP04.04. The Frequency of Incidental Lung Cancer Detected in Thorax CT During the COVID-19 Pandemic Process in Turkey - PDF(Slides)

EP04.05. Comparison of Two Enrolment Criteria in Lung Cancer Screening Pilot Project in Estonia - PDF(Slides)

EP04.05. Incidentally-Detected Lung Cancer in Persons Too Young or Too Old for Lung Cancer Screening. - PDF(Slides)

EP04.05. Perspectives of Potentially Eligible Indigenous Māori on a Lung Cancer Screening Programme - A Qualitative Study - PDF(Slides)

EP04.05. Impact of Magnitude of Lung Cancer Screening Benefit on Uptake - PDF(Slides)

EP04.05. Singapore Lung Cancer Screening through Integrating CT with Other Biomarkers (SOLSTICE), A Single Arm Lung Cancer Screening Study - PDF(Slides)

EP04.05. Centralized Shared Decision Making in Lung Cancer Screening: Unexpected Consequences - PDF(Slides)

EP04.05. Improved Efficiency with Lungflag vs Opportunistic Selection in a Theoretical East Asian Lung Cancer Screening Program - PDF(Slides)

EP04.06. Compliance with Lung Cancer Screening Guidelines Among At-Risk Patients at a Rural Teaching Hospital in West Texas - PDF(Slides)

EP04.06. Multimodal Intervention Strategies to Improve Lung Cancer Screening for Women Undergoing Breast Screening - PDF(Slides)

EP04.06. Qualitative Study Using Focus-Group Interviews on Cognition of Lung Cancer Screening and Symptom - PDF(Slides)

EP04.06. Impact of a Navigational Program on Lung Cancer Screening at a Community Health Center Serving an Urban Diverse Population - PDF(Slides)

EP04.07. Message from the Patients: What If I Wasn’t COVID 19 - PDF(Slides)

EP05.01. An Analysis of Lymph Node Metastasis Patterns in Surgical Cases of Non-small-Cell Lung Cancer - PDF(Slides)

EP05.01. Cryobiopsy for Peripheral Pulmonary Lesions Using a 1.1 mm Cryoprobe and Guide Sheath without Fluoroscopy: The Initial 400 Cases - PDF(Slides)

EP05.01. A Retrospective Study on the Efficacy and Safety of Flexible Bronchoscopy in Elderly Patients with Suspected Primary Lung Cancer - PDF(Slides)

EP05.01. Predictive Factors for Hemoptysis Following CT-guided PCNB : The Role of Post-procedure CT Findings and Cough after Biopsy - PDF(Slides)

EP05.01. Propective Study: Usefulness of D-Dimer Determination for Thromboembolic Disease Screening in Patients with Metastatic Lung Cancer. - PDF(Slides)

EP05.01. Observation of Peripheral Airways Using Ultra-Thin Fiberscope - PDF(Slides)

EP05.01. Lung Cancer in Combined Pulmonary Fibrosis and Emphysema Syndrome Patients. A Complication or a Comorbidity? - PDF(Slides)

EP05.01. Multi-scale Generator with Channel-wise Mask Attention to Generate Synthetic Contrast-enhanced Chest Computed Tomography - PDF(Slides)

EP05.01. Lung Cancers Diagnosed in a Retrospective Cohort of Lung Nodule Patients in Singapore - PDF(Slides)

EP05.01. A Retrospective Audit of Lung Nodules with Validation of the Brock Tool in a Singaporean Cohort - PDF(Slides)

EP05.01. Time to Lung Cancer Diagnosis and Treatment in the Era of the COVID-19 Pandemic - PDF(Slides)

EP05.01. Survival in Patients with Malignant Pleural Effusion Treated with a Tunneled Pleural Catheter Compared to the Lent Prognostic Score Scale - PDF(Slides)

EP05.01. Prognosis in Terms of Invasive Non-mucinous Adenocarcinoma Grading System - PDF(Slides)

EP05.01. Re Evaluation of a Larger Sample: Anatomical Variation Analysis of Left Upper Pulmonary Based on 3Dreconstruction of Chest CT - PDF(Slides)

EP06.01. Concordance Between Generative AI GPT-4 and NCCN Guidelines: Biomarker-Driven Treatment Strategies in NSCLC - PDF(Slides)

EP06.01. A Circulating Tumor Cell-based Artificial Neural Network of Patients with Advanced Non-Small Cell Lung Cancer - PDF(Slides)

EP06.01. Evaluation of Unstained Cytology Slides for Artificial Intelligence Rapid On-Site Evaluation - PDF(Slides)

EP06.01. Deep Learning Based Quality Assessment of DAPI Stained Nuclei Images Obtained from Routine FISH Test for Lung Cancer - PDF(Slides)

EP06.02. Prevalence of PD-L1 Expression in Non-Small Cell Lung Cancer: a Real-World Australian Perspective - PDF(Slides)

EP06.02. Enrichment for PD-L1 High Tumors in AXL-Expressing Advanced Non-small Cell Lung Cancer (NSCLC) - PDF(Slides)

EP06.02. PD-L1 Expressions in Non-small Cell Lung Cancer and its Correlation with Imaging Findings - PDF(Slides)

EP06.02. The Relationship between Pathologic and Molecular Characteristics and PD-L1 Expression in Surgically Resected Non-small Cell Lung Cancer - PDF(Slides)

EP06.02. Agreement among Programmed Cell Death Ligand-1 Immunohistochemistry Results Using 73-10, 22C3 and 28-8 Antibodies for Lung Cancer. - PDF(Slides)

EP06.02. Pan-cancer Analyses Reveal Immune Infiltration and Clinical Outcomes of IL7R - PDF(Slides)

EP06.02. Tertiary Lymphoid Structures Predict Clinical Outcomes of Neoadjuvant Chemoimmunotherapy in Resectable NSCLC - PDF(Slides)

EP06.03. Genetic Characterization of Driving Metastasis in TP53-Mutant Non-small Cell Lung Cancer Patients - PDF(Slides)

EP06.03. Elucidating Tumor Heterogeneity from Spatially Resolved Transcriptomics in ALK-Rearranged Non-small Cell Lung Cancer - PDF(Slides)

EP06.03. Molecular Alterations in Non-Small Cell Lung Cancer Arising in Emphysematous and Fibrotic Lungs - PDF(Slides)

EP06.03. EGFR Exon 20 Insertion Mutations in NSCLC: The Need for Accurate Naming Conventions and Implications for Personalized Therapy - PDF(Slides)

EP06.03. Clinical Impact of EGFR vs KRAS Mutations in Multifocal Lung Adenocarcinoma - PDF(Slides)

EP06.03. Clinical Impact of Next-Generation Sequencing in KRAS-Mutated Non-Small Cell Lung Cancer Patients: a Single-Center Experience - PDF(Slides)

EP06.03. Clinical Study to Molecularly Profile Filipino Lung Adenocarcinoma - PDF(Slides)

EP06.03. Characteristics of Insufficient Samples for EGFR Mutation Testing at the Lung Center of the Philippines - PDF(Slides)

EP06.03. HER3 Expression in Archived Tissue Samples from Patients with NSCLC Across Various Genomic Subtypes and Characteristics - PDF(Slides)

EP06.03. Characterization of KRAS Mutations in Black Patients with NSCLC at an Urban Academic Medical Center - PDF(Slides)

EP06.03. Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2) - PDF(Slides)

EP06.03. HRR Gene Mutations- A New Biomarker for Precision Genomics Based Testing in Metastatic Lung Cancer - PDF(Slides)

EP06.03. Genomic Alterations in Advanced Lung Cancer Patients Compared via CGP and Hotspot Panel Test in a Bangladeshi Tertiary Hospital - PDF(Slides)

EP06.03. Predicting ROS1 Fusions and Targetable Mutations in Non-small Cell Lung Cancer through H-score Pathological Analysis - PDF(Slides)

EP06.03. Demographic and Genomic Characteristics of Non-Small Cell Lung Cancer Patients with ARID1A Alterations - PDF(Slides)

EP06.03. The Prognostic Impact of Postoperative EGFR Mutation Status in Lung Cancer Patients with Stage II - III - PDF(Slides)

EP06.03. Atlas: Italian Knowledge Based Database for Biomarkers Analysis In NSCLC Patients - PDF(Slides)

EP06.03. Genomic Landscape of Non-Small Cell Lung Cancer in the Republic of Ireland - PDF(Slides)

EP06.03. Molecular Testing of Pulmonary Adenosquamous Cell Carcinoma for EGFR Mutation and ALK Gene Rearrangement - PDF(Slides)

EP06.03. Usefulness of Immunohistochemistry for the Detection of BRAFV600E in Lung Cancer: A Multicenter Retrospective Study in China - PDF(Slides)

EP06.03. Implementing Next Generation Sequencing for Lung Cancer Patients in Mexico: A Real-World Study from Puebla - PDF(Slides)

EP06.04. Challenge to Detect CTC-derived EGFR Mutation of Non-small Cell Lung Carcinoma by Unique Blood-Filtration Device - PDF(Slides)

EP06.04. FLUIDIndia:Liquid "First" Approach is a "Solid" Solution in NSCLC - PDF(Slides)

EP06.05. Molecular, Clinicopathological Characteristics of Thoracic SMARCA4‑defcientUndifferentiated Malignant Tumor -5 Cases Review- - PDF(Slides)

EP06.05. Accuracy of Postoperative Thoracic Malignancy Diagnosis in National Respiratory Center Persahabatan Hospital - PDF(Slides)

EP06.05. Subpleural Cystic Mesenchymal Neoplasm with Endometrial-type Stromal Proliferation: A Report of 3 Cases - PDF(Slides)

EP06.05. SMARCA4/BRG1 Deficient Thoracic Neoplasms: Spectrum Encompassing Carcinomas to Undifferentiated Tumors - PDF(Slides)

EP06.05. Molecular Characteristics of Lung Signet Ring Cell Carcinoma in the Chinese Population - PDF(Slides)

EP06.05. Distant Metastasis Pattern and Baseline Clinicopathological Features from a Real-World KRAS G12C Mutant Cohort of Advanced NSCLC Patients - PDF(Slides)

EP06.05. Non Small Cell Lung Cancer Associated to Dipnech: A Clinico-Pathological Analysis of 32 Cases - PDF(Slides)

EP06.05. Efficacy of Preoperative Biopsy in Predicting the Newly Proposed Histologic Grade of Resected Lung Adenocarcinoma - PDF(Slides)

EP06.05. Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC - PDF(Slides)

EP06.05. Immunohistochemical Features in Tissue Microarray in Pleomorphic Carcinoma of the Lungs - PDF(Slides)

EP06.05. Histopathologic Changes of the Perioperative Pirfenidone Therapy in Lung Cancer with Idiopathic Pulmonary Fibrosis - PDF(Slides)

EP06.05. Validation of the IASLC Grading System of Invasive Adenocarcinoma of the Lung in Small Volume Center - PDF(Slides)

EP06.05. Twelve Cell Death Patterns-Related Classification of the Immune Microenvironment and Prognosis Prediction of LUSC - PDF(Slides)

EP06.05. STAS and Expression of EMT-markers in Surgically Resected Lung Pleomorphic Carcinomas - PDF(Slides)

EP06.06. Insulin Like Growth Factor 2 mRNA Binding Protein3 is a Novel Post-Transcriptional Regulator of Lung Adenocarcinoma Malignancy - PDF(Slides)

EP06.06. Correlation between Vitamin C and CRP Serum Levels in Non Small Cell Lung Cancer Patient Among Sumatera Utara Population - PDF(Slides)

EP06.06. The Expression of MIR-320B in Extracellular Vesicles as a Prognostic factor for Non-small Cell Lung Carcinoma - PDF(Slides)

EP06.06. The Expression of MIR-320B in Extracellular Vesicles as a Prognostic Factor for Non-small Cell Lung Carcinoma (2) - PDF(Slides)

EP06.06. Circular RNA hsa_circ_0067705 Expression as a Potential Diagnostic Biomarker for Malignant Pleural Effusion - PDF(Slides)

EP06.06. Plasma Extracellular Vesicle miR-10b-5p as a Biomarker for Progressivity, Survivorship and Treatment Response in NSCLC Patients - PDF(Slides)

EP06.06. Surveying for Lung Cancer after Idiopathic Pulmonary Fibrosis at Pham Ngoc Thach Hospital - Viet Nam in 5 year (2017 - 2021) - PDF(Slides)

EP06.06. Comparison of RICTOR FISH and Rictor Immunohistochemistry in Lung Squamous Cell Carcinoma - PDF(Slides)

EP06.06. Clinical Significance of the Presence of MECA-79-Positive Tumor Cells in Pathological Stage IA Invasive Adenocarcinoma of the Lung - PDF(Slides)

EP06.06. Cancer-Associated Fibroblasts and Estrogen Receptor Beta in Lung Cancer with Idiopathic Pulmonary Fibrosis - PDF(Slides)

EP06.06. Expression of miR-30a-5p in Expression of Mir-30A-5P in Extracellular Vesicle as a Prognostic Biomarker for Non Small Cell Lung Cancer Therapy - PDF(Slides)

EP06.06. EBUS as a Novel Procedure for Microbiome Collection and Analysis in NSCLC - PDF(Slides)

EP06.06. Fibronectin Promotes Tumor Angiogenesis and Progression of Non-small-Cell Lung Cancer - PDF(Slides)

EP06.06. High Circulating Activin a Plasma Level Is Associated with Advanced Tumor Stage and Poor Prognosis in Lung Squamous Cell Cancer Patients - PDF(Slides)

EP06.06. Epigenetic Silencing of MYO1E in a US Veterans Cohort with Lung Adenocarcinoma and the Effect on Overall Survival - PDF(Slides)

EP07.01. Nomogram for Predictingprognosis andAdjuvant Chemotherapy BenefitsinEarly-stageInvasive Mucinous Lung Adenocarcinoma - PDF(Slides)

EP07.01. Perioperative Outcomes & Strategies for Pleomorphic Carcinoma in Lung - PDF(Slides)

EP07.01. A Study of the Characteristics of Lung Cancer Surgery Cases in the Elderly and the Usefulness of the Japanese NCD risk calculator - PDF(Slides)

EP07.01. Lead-Time Bias in Surgically Resected Non-Small Cell Lung Cancer (NSCLC) Diagnosed Through Different Pathways of Care - PDF(Slides)

EP07.01. Comparison of Surveillance with Contrast Chest CT and Non-contrast Chest CT among who Survived 2 Years after Curative Resection for Lung Cancer - PDF(Slides)

EP07.01. Development of a Shared Decision-Making Tool for Adjuvant Treatment for Patients with Resected Non-Small Cell Lung Cancer. - PDF(Slides)

EP07.01. Can the Use of New Haemostatic Agent Improve Short Term Outcomes of Surgically Treated Non-small Cell Lung Cancer Patients? - PDF(Slides)

EP07.01. Ablation of Early-Stage Non-Small Cell Lung Cancer in Patients With Interstitial Lung Disease: A Multicenter Retrospective Cohort Study - PDF(Slides)

EP07.01. A Retrospective Study on the Methods of Covering Bronchial Stump/Anastomotic Site to Avoid the Bronchopleural Fistula after Lung Cancer Surgery - PDF(Slides)

EP07.01. Definitive Chemoradiation versus Radiation Alone for Stage II Non-Small Cell Lung Cancer. A National Cancer Database Analysis - PDF(Slides)

EP07.01. Assessing Morphometric Complexity in Lung Parenchyma of NSCLC Patients with IPF Undergoing Radiotherapy - PDF(Slides)

EP07.01. Utility of Bronchus-First Right Upper Lobectomy as a Routine Technique - PDF(Slides)

EP07.01. The Relationship of FDG PET-SUVm and Glucose Metabolism and Contribution to Early-Stage Non-Small Cell Lung Cancer Survival - PDF(Slides)

EP07.01. Adjuvant Chemotherapy is Less Effective in Non Small Cell Lung Cancer Patients Rated Undernourished by CONUT Score - PDF(Slides)

EP07.01. Factors Affecting Postoperative Nausea and Vomiting in Surgical Patients with Non-Small Cell Lung Cancer - PDF(Slides)

EP07.01. A 22 to 23G Intraoperative Needle Biopsy Does Not Affect Recurrence of Preoperatively Undiagnosed Stage 1 Lung Cancer - PDF(Slides)

EP07.01. Identifying the Optimal Number of Lymph Node Stations for Improving Survival in Resections for Non-small Cell Lung Cancer - PDF(Slides)

EP07.01. Stereotactic Body Radiation Therapy for Patients with Early-Stage Non-small Cell Lung Cancer Inoperable - PDF(Slides)

EP07.01. Surgical Treatment of Lung Cancer in Patients Over the Age of 75 Years: Single Cancer Centre Experience - PDF(Slides)

EP07.01. Implementation and Safety of a Same-day Discharge Program for Minimally-invasive Pulmonary Resection - PDF(Slides)

EP07.01. Is Chemical Venous Thromboembolism Prophylaxis Necessary After Lung Cancer Resection? A 10-year T-ERAS Experience - PDF(Slides)

EP07.01. The Impact of Comorbidities on Exercise Level after Treatment for Early-Stage Lung Cancer Patients - PDF(Slides)

EP07.01. Local Control & Toxicity Results of Stereotactic Body Radiotherapy in Central Lung Tumors - PDF(Slides)

EP07.01. What Is a Risk Factor for Postoperative Home Oxygen Therapy in Primary Lung Cancer Patients? - PDF(Slides)

EP07.01. Predictors of Poor Quality of Life Following Lung Cancer Surgery - PDF(Slides)

EP07.01. Preoperative Respiratory Assessment Predicts Post-Operative Survival in Stage IA Non-small Cell Lung Cancer - PDF(Slides)

EP07.01. Long Term Outcomes beyond Five Years after Pulmonary Resection for Non Small Cell Lung Cancer - PDF(Slides)

EP07.01. Recurrence Patterns and Prognostic Factors for Relapse in Operated Lung Cancers - PDF(Slides)

EP07.02. Evaluation of the Efficacy of Oral Bacterial Lysates in Patients with High-risk Lung Nodules Detected by CT Screening - PDF(Slides)

EP07.02. Impact of Neoadjuvant Immunotherapy on Surgical Management for Non-small Cell Lung Cancer:A Multi-center Survey of Current Practice from China - PDF(Slides)

EP07.02. The Prediction of Pathological Pleural Invasion of Lung Cancer by Artificial Intelligence Image Analysis - PDF(Slides)

EP07.02. A Three-Dimensional Computed Tomography Analysis of Residual Lung Volume Changes after Segmentectomy for Non-small-Cell Lung Cancer - PDF(Slides)

EP07.02. MIDRIXNEO-LUNG: Safety and Immunogenicity of a Neoantigen-Presenting Autologous Dendritic Cell Therapy in Resected NSCLC Patients - PDF(Slides)

EP07.02. Prospective Study of Hypofractionated Proton Therapy for Inoperable Early Stage Non-small Cell Lung Cancer - PDF(Slides)

EP07.02. Comparison of ICG and Methylene Blue in Preoperative Dye Marking Localization of Pulmonary Nodules Under the Guidance of ENB - PDF(Slides)

EP07.02. Hypofractionated Radiation Therapy vs Stereotactic Body Radiation Therapy for Ultra-Central Lung Tumors - PDF(Slides)

EP07.02. Adjuvant Chemotherapy with Nanoparticle Albumin-Bound Paclitaxel and Carboplatin for Stage IB Non-small Cell Lung Cancer - PDF(Slides)

EP07.02. Navigational Bronchoscopy: Driving to the Nodule Drives Your Patients to Earlier Stage - PDF(Slides)

EP07.02. The Role of Online MR-guided Multi-Fraction Stereotactic Ablative Radiotherapy in Lung Tumors - PDF(Slides)

EP07.02. Utilization of Real-time MRI-guided Stereotactic Ablative Body Radiotherapy in NSCLC, One Step forward Precise Targeting in Radiotherapy - PDF(Slides)

EP07.02. Image-Guided Thermal Ablation of Early-Stage Non-small Cell Lung Cancer; Five-Year Outcome - PDF(Slides)

EP07.02. Longitudinal ctDNA Testing in Resected, Early Stage Non-small Cell Lung Cancers - PDF(Slides)

EP07.02. Localization of Lung Nodules by Electromagnetic Navigation Bronchoscopy-Guided Dye Marking: Procedural Outcomes and Learning Curve - PDF(Slides)

EP07.02. The Utility of Postoperative ctDNA Detection in Guiding Adjuvant Therapy for Resectable Stage III Non-small Cell Lung Cancer - PDF(Slides)

EP07.03. Meeting the Quality Metric for Minimum Lymph Node Harvest for Robotic Lobectomy for Lung Cancer - PDF(Slides)

EP07.03. Pulmonary Ligament Approach for Robot-Assisted S9 or S9 and 10 Segmentectomy - PDF(Slides)

EP07.03. Uniportal Video-Assisted Thoracoscopic Surgery Simple Segmentectomy versus Complex Segmentectomy in Lung Cancer Patients - PDF(Slides)

EP07.03. Non-Small Cell Lung Cancer in Obese Patients: Comparison of Open, Robotic and Videothoracoscopic Surgery. A Multicenter Retrospective Series - PDF(Slides)

EP07.03. Oncological Outcomes After Uniportal Versus Multiportal Thoracoscopic Lobectomy for Lung Cancer Patients - PDF(Slides)

EP07.03. Challenges in Robotic Lobectomy of the Lung through the Anterior Approach - PDF(Slides)

EP07.03. Negative Impacts of Mediastinal Lymph Node Dissection Forstage I Ground Glass Opacity Pulmonary Lesions - PDF(Slides)

EP07.03. Impact of Tumor Location on Surgical Margin in Segmentectomy and Wedge Resection - PDF(Slides)

EP07.03. A Minimally Invasive Open Surgery Approach Is Superior to VATS with Respect to Intraoperative Outcomes during Lung Cancer Surgery - PDF(Slides)

EP07.03. Effects of Preoperative Diabetes Mellitus on Postoperative Outcomes after Robotic-Assisted Video-Thoracoscopic Pulmonary Lobectomy - PDF(Slides)

EP07.03. Effects of Intraoperative Trainees on Outcomes after Robotic-Assisted Pulmonary Lobectomy - PDF(Slides)

EP07.03. Effect of Lymph Node Dissection on Recurrence and Survival Following Thoracoscopic Segmentectomy for Early-Stage Non-small Cell Lung Cancer - PDF(Slides)

EP07.03. Nodal Upstaging in Uniportal VATS Lobectomy for Early-Stage Lung Cancer: Is It Fair? - PDF(Slides)

EP07.03. Early PROs after Thoracoscopic Segmentectomy versus Wedge Resection for Small-sized Peripheral NSCLC - PDF(Slides)

EP07.03. Robotic Lung Cancer Program: Initial Experience and Results - PDF(Slides)

EP07.04. Free Circulating and Extracellular Vesicles-Derived microRNA as Prognostic Biomarkers in Resected Early-Stage NSCLC: RESTING Study Results - PDF(Slides)

EP07.04. Real-World Data Based on EGFR Mutation Status in Early-Stage NSCLC - PDF(Slides)

EP07.04. Analyze Gene Changes Characteristics of MSLAs in Genomic Study - PDF(Slides)

EP07.04. High-Risk Clinicopathologic and Genomic Features of Recurrence in Stage I Lung Adenocarcinoma - PDF(Slides)

EP07.04. Spread through Air Spaces in Non-small Cell Lung Cancer. Clinical and Pathological Associations - PDF(Slides)

EP07.04. ALK Rearrangement Is Associated with Early Lymphatic Spread in Resected LUAD with Negative Preoperative Mediastinal Staging - PDF(Slides)

EP07.04. Early-Stage Low Malignant Potential Adenocarcinomas: A Histological Category With A Significantly Better Prognosis - PDF(Slides)

EP07.04. Immune Cell States as Predictors of Survival in Surgically Treated Stage I Non-small Cell Lung Cancer (NSCLC) - PDF(Slides)

EP07.04. Pleural CEA and SUVmax as Predictors of Visceral Pleural Invasion in Clinical T1N0M0 Lung Adenocarcinoma - PDF(Slides)

EP07.04. Early-Stage EGFR Mutated NSCLC: Outcomes After Surgical Resection at a Large Academic Medical Center - PDF(Slides)

EP07.04. Clinicopathological Features and Postoperative Prognosis of Bubble-like Appearance Type Lung Adenocarcinoma - PDF(Slides)

EP07.04. Comparison of Pathologic Outcomes Following Neoadjuvant Regimens in Resectable Locally Advanced Non-Small Cell Lung Cancer - PDF(Slides)

EP07.04. Pathologic Risk Factors for Recurrence in Early Stage Invasive Lung Adenocarcinoma with Tumor Spread through Air Spaces - PDF(Slides)

EP07.04. Diagnosis, Treatment Patterns and Outcomes in Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in China - PDF(Slides)

EP07.04. Occult Lymph Node Metastasis Is Not a Favorable Factor for Resected NSCLC Patients - PDF(Slides)

EP07.04. Study on the Regulatory Mechanism of OM-85 BV on the Immune Microenvironment of Clinical Early-stage Lung Adenocarcinoma - PDF(Slides)

EP07.04. Factors Associated with Postoperative Recurrence in Early NSCLC with EGFR Mutation: Analysis of Korean National Population Data - PDF(Slides)

EP07.04. Clinical and Molecular Profile and Risk Factors of Stage IA NSCLC Relapsing after Radical Resection - PDF(Slides)

EP07.04. Identification of Tumor Microenvironment and Prognosis Risk Prediction through Proteomics Analysis in Stage I Lung Adenocarcinoma - PDF(Slides)

EP07.04. Lymphatic Vascular Invasion: Diagnostic Variability and Overall Survival Impact on Patients Undergoing Surgical Resection of NSCLC - PDF(Slides)

EP07.04. Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US - PDF(Slides)

EP07.04. Telomerase-Based Circulating Tumor Cell Detection for the Treatment Response Prediction in Patients with Non-small-Cell Lung Cancer - PDF(Slides)

EP07.04. Histopathologic Fate of Resected Pulmonary Pure Ground Glass Nodule: A Systematic Review and Meta-Analysis - PDF(Slides)

EP07.04. Construction of Genome Atlas for lung Nodule and Molecular Insight into Lung Adenocarcinoma Development in Chinese Population - PDF(Slides)

EP07.04. Real-World Biomarker Testing and Treatment Patterns Identified Using Machine Learning in Early Non-small Cell Lung Cancer - PDF(Slides)

EP07.04. Analysis of Radiologic-Pathologic Correlation for Subsolid Lung Adenocarcinoma Using the Whole-Mount Section Technique: A Prospective Study - PDF(Slides)

EP07.05. Postoperative Recurrence Pattern and the Role of Adjuvant Therapy in Radiological Solid-Predominant Part-Solid Lung Adenocarcinoma - PDF(Slides)

EP07.05. NEOEAST: A Phase II Study of Ensartinib as Neoadjuvant Therapy for Stage II-IIIB ALK-rearranged Non-small Cell Lung Cancer - PDF(Slides)

EP07.05. Neoadjuvant Chemotherapy or Chemo-IO in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience - PDF(Slides)

EP07.05. CDDP/TS1 Followed by Maintenance TS1 as Adjuvant Chemotherapy in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer - PDF(Slides)

EP07.05. Adjuvant Aumolertinib in Resected EGFR-Mutated Non-Small Cell Lung Cancer: Impact on Residual GGO Lesions - PDF(Slides)

EP07.05. Minimal Residual Lesion Might Predict Adequate Cycles for Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer - PDF(Slides)

EP07.05. Real-World Outcomes of Adjuvant Cisplatin/Vinorelbine vs Cisplatin/Pemetrexed in Resected Non-Squamous NSCLC - PDF(Slides)

EP07.05. Application of Neoadjuvant Chemoimmunotherapy in A Specific Group of Stage IB NSCLC - PDF(Slides)

EP07.05. Oncologic Outcomes of Stereotactic Body Radiotherapy in Early-Stage Non-Small Cell Lung Cancer Patients with Interstitial Lung Disease - PDF(Slides)

EP07.05. Efficacy and Safety of Osimertinib Therapy in High-Risk Stage I EGFRm NSCLC after R0 Resection(OSTAR): A Prospective, Single-Arm Study - PDF(Slides)

EP07.05. The Impact of COVID-19 on Both the Diagnosis and Surgical Outcomes of Lung Cancer in Korea - PDF(Slides)

EP07.05. The Efficacy of Neoadjuvant Chemoimmunotherapy versus Neoadjuvant Chemotherapy in Resectable NSCLC, a Comparison Research from Real World - PDF(Slides)

EP07.05. Prognostic Factors in Non-Small-Cell Lung Cancer Treated with Chemoimmunotherapy or Chemotherapy: A Real-World Data Study - PDF(Slides)

EP07.05. MPR and pCR Rates after Neoadjuvant Chemo-immunotherapy for Stage III Non small Cell Lung Cancer. - PDF(Slides)

EP07.05. Aumolertinib as Neoadjuvant Therapy for EGFR-mutated Non-Small Cell Lung Cancer: A Subcohort Analysis of the PURPOSE Trial - PDF(Slides)

EP07.05. Spontaneous Ventilation Video-assisted Thoracoscopic Surgery for Super-elderly NSCLC Patients: a Noninferiority Study. - PDF(Slides)

EP08.01. Subtyping EGFR-mutated NSCLC Patients with Adjuvant TKIs or Chemotherapy Using Deep Radiomic Signatures - PDF(Slides)

EP08.01. Single-Cell RNA Sequencing Reveals Unique Immune Landscape in Rare-Mutant Non-Small Cell Lung Cancer Undergoing Chemo-Immunotherapy - PDF(Slides)

EP08.01. Lymphocyte Count Pre-immunotherapy Predicts Progression-Free Survival in Stage III NSCLC Treated with Chemoradiotherapy and Immunotherapy - PDF(Slides)

EP08.02. Parameters of FDG PET/CT Predicting Pathological Response to Neoadjuvant Immunotherapy in Stage II/III Non-small Cell Lung Cancer Patients - PDF(Slides)

EP08.02. Real World Chemoradiotherapy Outcomes for Frail Older Adults with Unresectable Stage III Non Small Cell Lung Cancer (NSCLC) - PDF(Slides)

EP08.02. Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) - PDF(Slides)

EP08.02. Real-World Disease-Free Survival (DFS) in Non-metastatic Non-small Cell Lung Cancer (NSCLC): A German I-O Optimise Analysis - PDF(Slides)

EP08.02. Neoadjuvant Immunochemotherapy Combined with Probiotic Supplements in Stage IIB-IIIB NSCLC: A Real-World Prospective Study - PDF(Slides)

EP08.02. Neoadjuvant Therapy, Still a Contraindication to VATS Lobectomy or is it a New Indication? - PDF(Slides)

EP08.02. FDG PET Scan Based Response Assesment in Non-Small Cell Lung Cancer Treated With Chemoradiotherapy And Neoadjuvant Chemotherapy - PDF(Slides)

EP08.02. Lymphovascular Invasion Prediction with CT images in Patients with Non-Small Cell Lung Cancer (NSCLC) - PDF(Slides)

EP08.02. Comprehensive Assessment of Pulmonary Function in Patients Receiving Radical (Chemo)Radiotherapy for Carcinoma Lung - PDF(Slides)

EP08.02. Clinicopathological Analyses for Predicting Survival After Salvage Surgery for Initially Unresectable Lung Cancer - PDF(Slides)

EP08.02. Dosimetric Contribution of LAD Sparing Radiotherapy Plan in Patients with Postoperative Lung Cancer - PDF(Slides)

EP08.02. Dosimetric Contribution of LAD Artery Sparing RT Plan in Lung Cancer Patients Who Received Definitive RT - PDF(Slides)

EP08.02. Association of the Benefit of Durvalumab Consolidation Therapy and Driver Mutation Status for Locally Advanced Non-small Lung Cancer - PDF(Slides)

EP08.02. Prognostic Role of Baseline PET/CT Parameters in Frail Patients with Inoperable Node-Positive Stage IIB-IIIC/Recurrent NSCLC - PDF(Slides)

EP08.02. Moderately Hypofractionated PET/CT-Based Thoracic Radiotherapy in Elderly and Multimorbid Patients with Stage II/III NSCLC - PDF(Slides)

EP08.02. Higher Radiation Dose to Immune Cells is a Negative Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC) - PDF(Slides)

EP08.02. Comparison of Long-term Survival of Patients With Locally Advanced Lung Cancer After Video-Assisted Thoracoscopic Surgery Versus Thoracotomy - PDF(Slides)

EP08.02. The Value of Combined Immunotherapy in Neoadjuvant Regimen for Patients with Resectable Non-small Cell Lung Cancer - PDF(Slides)

EP08.02. Correlation of Quantified Metabolic Activity with Gross Tumor Volume in Patients with Non Small Cell Lung Cancer - PDF(Slides)

EP08.02. A Prospective Study of Gallium-68 Ventilation and Perfusion PET/CT Before, During, and After Radiotherapy in Patients with NSCLC - PDF(Slides)

EP08.02. Robot-Assisted Thoracic Surgery for Locally Advanced Non-small Cell Lung Cancer in a Japanese Single Institution - PDF(Slides)

EP08.02. Survival Outcome Comparison of Stage III and IV NSCLC Patients in Latvia and Israel: An Analysis of Treatment Approaches - PDF(Slides)

EP08.02. Is Early Cessation of Chemoradiotherapy Preventing Access to Adjuvant Immunotherapy for Patients with Stage III NSCLC? - PDF(Slides)

EP08.02. Neoadjuvant Immune Checkpoint Inhibitor plus Chemotherapy for Resectable Non-small Cell Lung Cancer in Real World - PDF(Slides)

EP08.02. A Case of Persistent Complete Response To Personalized Osimertinib and Concurrent Chemoradiation for Stage IIIC EGFRm NSCLC - PDF(Slides)

EP08.02. Trimodality Treatment of Superior Sulcus non-Small Cell Lung Cancer. An Institutional Series of 47 Consecutive Patients. - PDF(Slides)

EP08.02. Is Moderate-intensity Stereotactic Body Radiation Therapy for Ultra-central Lung Tumor a Feasible Option? - PDF(Slides)

EP08.02. Durvalumab as Maintenance in Patients who Received Chemoradiotherapy for Unresectable Stage III NSCLC: RWD from an EAP in Brazil (LACOG 0120) - PDF(Slides)

EP08.02. Long-Term Efficacy and Safety of Tislelizumab Plus Chemotherapy as Neoadjuvant/Adjuvant Therapy for IIB-III NSCLC: A Retrospective Study - PDF(Slides)

EP08.02. Optimal Planning Target Volume Margins for Spirometer-Based DIBH Radiotherapy for Lung Cancer - PDF(Slides)

EP08.02. Induction Immunochemotherapy Before Definitive Chemoradiotherapy for Unresectable Locally Advanced Non-small Cell Lung Cancer - PDF(Slides)

EP08.02. Evaluation of Treatment Strategies for Patients with Stage IIIA Non-Small Cell Lung Cancer in the Immunotherapy Era - PDF(Slides)

EP08.02. Prognostic Impacts of Lymphovascular Invasion of Resected Lung Adenocarcinoma after Induction Chemoradiotherapy - PDF(Slides)

EP08.02. Definitive Hypofractionated Radiation Therapy with or without Immunotherapy for Stage IIb-III NSCLC: An Institutional Experience - PDF(Slides)

EP08.02. Dosimetric Comparison of Free- Breathing versus Respiratory Motion-managed Radiotherapy with 4D-CT Based VMAT in Lung Cancer - PDF(Slides)

EP08.02. Management of Inoperable Locally Advanced Stage III ALK fusion Positive NSCLC: A Retrospective Multi-institutional Analysis - PDF(Slides)

EP08.03. Copy Number Variants and Late Somatic Mutations Underlying Tumor Progression in NADIM Clinical Trials - PDF(Slides)

EP08.03. Nivolumab Plus Ipilimumab in Relapsed Stage III Non-small Cell Lung Cancer after Durvalumab Following Chemoradiotherapy - PDF(Slides)

EP08.03. S-1 and CDDP with Concurrent TRT Followed by Durvalumab in Elderly Population with Unresectable, LA-NSCLC in Japan: Post-hoc Analysis of SAMURAI - PDF(Slides)

EP08.03. MicroDurva: A Prospective Study to Investigate the Role of Microbiome in Predicting the AEs from Durvalumab in Post-CCRT NSCLC Patients - PDF(Slides)

EP08.03. Role of DCE MRI in Predicting Treatment Response to Induction Immunochemotherapy in Locally Advanced NSCLC Patients - PDF(Slides)

EP08.04. Predictors and Outcomes of Pneumonitis in Non-Small Cell Lung Cancer Patients treated with Consolidative Durvalumab - PDF(Slides)

EP08.04. Evaluating Safety Profiles of Radiation-Related Toxicities in Thoracic Re-Irradiation - PDF(Slides)

EP08.04. Acute Postoperative Pain is the Most Severe at the Site of Chest Tube Insertion in Multiportal Video-assisted Thoracoscopic Surgery - PDF(Slides)

EP08.04. Development of a Risk Score to Predict Postoperative Complications in Patients with Non-small Cell Lung Cancer - PDF(Slides)

EP09.01. Feasibility and Survival Outcomes of “Salvage Surgery” for Initially Clinical Stage IV Non-small Cell Lung Cancer - PDF(Slides)

EP09.01. Clinical Outcome of Palliative Thoracic Radiotherapy in Advanced Lung Cancer in the Modern Era - A Single Institution Experience - PDF(Slides)

EP09.01. Hypofractionated Radiotherapy for Elderly Lung Cancer Patients - PDF(Slides)

EP09.01. Surgical Treatment in Non-small Cell Lung Cancer with Pulmonary Oligometastasis; 26 Years of Experience in a Single Center - PDF(Slides)

EP09.01. Is Palliative Thoracic Radiation Beneficial in Stage IV Non-small Cell Lung Cancer (NSCLC) In the Era of Modern Systemic Therapy? - PDF(Slides)

EP09.01. Outcomes of Surgical Treatment for Stage IV Non-Small Cell Lung Cancer (NSCLC) in a Population-Based Cohort - PDF(Slides)

EP09.01. Reverse Endobronchial Y-stent Implantation in Selected Cases of the Malignant Central Airway Obtruction - PDF(Slides)

EP09.02. Combination Of EGFR-TKIs And Radiotherapy In Stage IV LUAD - PDF(Slides)

EP09.02. Stereotactic Body Radiotherapy Synergizes Immunotherapy in Advanced or Recurrent NSCLC: A Single-center Experience - PDF(Slides)

EP09.02. A Phase II Study on Aggressive Local Consolidative Therapy in Combination With Chemotherapy for Oligometastic NSCLC: TORG1529 - PDF(Slides)

EP09.02. Operative and Mid-Term Oncologic Outcomes of the Surgery as a Form of Local Consolidation for Oncogenic-Driven Advanced NSCLC - PDF(Slides)

EP09.02. Fibrates Enhances Radiotherapy Efficacy by Elevating HDL Levels to Induce Tumor Cell Ferroptosis in NSCLC with Brain Metastasis - PDF(Slides)

EP09.02. Long-term Efficacy of Tumor Treating Fields (TTFields 150 kHz) in metastatic NSCLC: A Case Report - PDF(Slides)

EP09.03. Outcomes of Extracranial SBRT for Induced Oligopersistant and Oligoprogressive NSCLC Combined with Novel Systemic Therapies - PDF(Slides)

EP09.03. Local Ablation Induces Abscopal Effects and Improves the Efficacy of Continuous ICIs in Advanced NSCLC Patients with Oligo-progression - PDF(Slides)

EP09.04. Prognostic Factors for Patients With KRAS Mutated Non-Small Cell Lung Cancer and Brain Metastases - PDF(Slides)

EP09.04. Preoperative Circulating Tumor DNA Status Predicts Pathological Response in Advanced Non-small Cell Lung Cancer - PDF(Slides)

EP09.04. Survival of Non-small Cell Lung Cancer with and without Brain Metastasis - Shifting to a Merging Survival Curves Era - PDF(Slides)

EP09.05. Ionizing Radiation Induces Vascular Smooth Muscle Cell Senescence through Activating NF-κB/CTCF/p16 Pathway - PDF(Slides)

EP09.05. Changes in Pulmonary Function Following Single and Multi-Fraction Stereotactic Body Radiotherapy for Pulmonary Oligometastatic Disease - PDF(Slides)

EP10.01. DDR1 Mediated Glycolysis Regulates the Synergistic Effect of Anlotinib and Docetaxel in Lung Cancer - PDF(Slides)

EP10.01. Chemotherapy Outcomes in EGFR-TKI Resistant Patients: A Comparison of Common and Uncommon EGFR Mutation Subtypes - PDF(Slides)

EP10.01. A Phase 1/2 Study of REGN5093-M114, a METxMET Antibody-Drug Conjugate, in Patients with MET-Overexpressing NSCLC - PDF(Slides)

EP10.01. First-Line Treatment for Driver-Gene Negative Metastatic Lung Adenocarcinoma with MPE: A Multicenter Retrospectively Study - PDF(Slides)

EP10.01. Retrospective Analysis of Real-World Treatment Patterns and Survival Outcomes for Non-small Cell Lung Cancer Patients in Thailand - PDF(Slides)

EP10.01. Predictors of Survival for Docetaxel as a Subsequent Line after Progression to Platinum-Based Chemotherapy and Immunotherapy - PDF(Slides)

EP10.01. Clinical Features and Outcome Evaluation of Patients with Non-small-Cell Lung Cancer: A Single Center Study - PDF(Slides)

EP10.01. Relationship Between Age and Chemotherapy Regimen for Elderly Patients with Advanced Lung Cancer - PDF(Slides)

EP10.01. Added Serum Albumin to Lung-mol GPA Score Improves Prediction of Overall Survival in Non-Small Cell Lung Cancer Patients with Brain Metastasis - PDF(Slides)

EP10.01. Retrospective Study on Outcomes and Treatment Options for Patients with NSCLC Progression after Treatment with Durvalumab - PDF(Slides)

EP10.01. Efficacy of Intraventricular Chemotherapy with Pemetrexed for Leptomeningeal Metastasis from Lung Adenocarcinoma: A Retrospective Study - PDF(Slides)

EP10.01. Patterns of Systemic Anti-Cancer Therapy & Overall Survival of Stage IV NSCLC at Tertiary General Hospital - PDF(Slides)

EP10.01. Evaluating Osimertinib Induced Pneumonitis in EGFR Advanced Lung Cancer in a Real World Clinical Practice. - PDF(Slides)

EP10.01. Efficacy and Safety of Nintedanib and Docetaxel in Patients with Lung Adenocarcinoma: A Multicenter Real-world Analysis - PDF(Slides)

EP10.01. Sarcopenia as a Predictive Factor of Carboplatin Toxicity in Patients with Advanced Non-small Cell Lung Cancer - PDF(Slides)

EP10.01. Relationship between Impaired Fasting Glucose and Prognosis of the Disease in Patients with Advanced Stage Non-small Cell Lung Cancer. - PDF(Slides)

EP10.01. Treatment Patterns and Clinical Outcomes among Advanced NSCLC Patients with EGFR exon 20 Insertion Mutations in China - PDF(Slides)

EP11.01. Final Analysis of First-Line Chemo-Immunotherapy in Patients with Advanced Lung Adenocarcinoma: An Italian Real-World Study - PDF(Slides)

EP11.01. A Multicenter Study of the Association between TTF-1 and Immunochemotherapy in Lung Adenocarcinoma - PDF(Slides)

EP11.01. Neutrophil to Lymphocite Ratio in Patients Treated with Immunotherapy after Progression on Chemotherapy - PDF(Slides)

EP11.01. Does Tumor Microvessel Density Predict Response to Immune Checkpoint Inhibitors in Metastatic Non Small Cell Lung Cancer? - PDF(Slides)

EP11.01. ICTIS: A Novel Scoring System to Assess the Inclusivity of Metastatic Non-Small-Cell Lung Cancer Immunotherapy Trials - PDF(Slides)

EP11.01. SPD-CD40L Prevents Tumor Growth via Recruitment of Immune Cells to the Tumor Microenvironment - PDF(Slides)

EP11.01. Low NLR Predicted Overall Survival Benefit of Pembrolizumab and Chemotherapy Combination in Patients with NSCLC and Low PD-L1 Expression - PDF(Slides)

EP11.01. GSDME-dependent Pyroptosis Affects the Prognosis and Response to Immunotherapy in Lung Adenocarcinoma - PDF(Slides)

EP11.01. Study on Biomarkers for Predictive the Clinical Efficacy of Non-small Cell Lung Cancer Immunotherapy - PDF(Slides)

EP11.01. Immune Checkpoint Inhibitors in the Treatment of Non-Small Cell Lung Cancer: Does Histology Matter? - PDF(Slides)

EP11.01. Clinical Significance of Soluble PD-1 and PD-L1 in Plasma of NSCLC Patients Treated with Immune Checkpoint Inhibitors - PDF(Slides)

EP11.01. Prediction of NSCLC Immunotherapy Outcomes Across Multiple Clinical Indicators - PDF(Slides)

EP11.01. The Value of PD-L1 in Circulating Tumor Cells in Patients with Non-small Cell Lung Cancer Receiving Immunotherapy - PDF(Slides)

EP11.02. Nivolumab as Maintenance Therapy Following Platinum-Based Chemotherapy in EGFR-mutant Lung Cancer Patients After TKI Failure - PDF(Slides)

EP11.02. Phase I Study of Epacadostat in Combination with Sirolimus in Solid Tumors and PK Data. - PDF(Slides)

EP11.02. First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis - PDF(Slides)

EP11.02. Efficacy and Safety of Camrelizumab plus Famitinib in Previously Treated Patients with Advanced Non Small Cell Lung Cancer - PDF(Slides)

EP11.02. Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS - PDF(Slides)

EP11.02. Dostarlimab + CT vs Pembrolizumab + CT in Metastatic Non-Squamous NSCLC: Asian Subgroup Analyses of the PERLA Trial - PDF(Slides)

EP11.02. Predictive Toxicity and Response to Immunotherapy in Patients with Metastatic Non Small Cell Lung Cancer (IMMUNOPREDICT) - PDF(Slides)

EP11.02. Rh-endostatin Combined With PD-1 inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC - PDF(Slides)

EP11.02. Efficacy and Safety of Combining Envafolimab with Endostar in Advanced NSCLC : A Multi-Center Prospective Study (Endouble) - PDF(Slides)

EP11.03. Characterizing Neurologic Immune-related Adverse Events Using Consensus Disease Definitions - PDF(Slides)

EP11.03. Patient-Reported Fatigue in Lung Cancer Patients Undergoing Immunotherapy: A Real-Life Study - PDF(Slides)

EP11.03. Multi-Institutional Retrospective Study for the Efficacy of ICIs plus Platinum-Based Chemotherapy for EGFR Mutated NSCLC - PDF(Slides)

EP11.03. Molecular Characterization and Prognosis of Patients with KRAS Mutant Non-small Cell Lung Cancer - PDF(Slides)

EP11.03. Prognosis of Immunotherapy plus Whole Brain Radiotherapy for Non-Small Cell Lung Cancer Patients with Brain Metastases - PDF(Slides)

EP11.03. Long-term Outcomes and Toxicity in Patients with Metastatic Non Small Cell Lung Cancer Treated with Immunotherapy Containing Regimens - PDF(Slides)

EP11.03. Multicenter Pharmacokinetic Study of Pembrolizumab for Non-Small Cell Lung Cancer in Older Adults Aged Over 75 Years - PDF(Slides)

EP11.03. Profile of Patients with NSCLC Who Benefit from Immunochemotherapy. Real-World Data from the Multicenter Polish Lung Cancer Group Study - PDF(Slides)

EP11.03. ​Similar Efficacy Observed for Frontline Immunotherapy in Ethnic-Minority Patients with Metastatic NSCLC - PDF(Slides)

EP11.03. Site-Specific Response Patterns in Patients with Advanced NSCLC Treated with First-Line Systemic Therapy - PDF(Slides)

EP11.03. Real-World Efficacy of Atezolizumab in Patients with Previously Treated Advanced NSCLC in Spain - TRACKER Study - PDF(Slides)

EP11.03. The Economic Burden of Lung Cancer (NSCLC) In the County of Gävleborg - Sweden - PDF(Slides)

EP11.03. Sarcopenia Is a Poor Predictive Prognostic Factor for Non Small Cell Lung Cancer Patients Who Were Treated with Immune Check Point Inhibitors - PDF(Slides)

EP11.03. Re-immunotherapy with Nivolumab plus Ipilimumab in Advanced NSCLC Patients Previously Treated with Anti-PD-(L)1 Antibody - PDF(Slides)

EP11.03. Outcomes of Immunotherapy vs Chemotherapy as First-Line Treatment in Advanced NSCLC: A Meta-analysis of Randomized Clinical Trials - PDF(Slides)

EP11.03. Optimal Duration of Immune Checkpoint Inhbitors in Non-small Cell Lung Cancer: Less Is More? - PDF(Slides)

EP11.03. Anti-angiogenic Therapy or Immunotherapy? A Multicenter Study of Patients with Advanced NSCLC with EGFR / HER2 exon 20 Insertion Mutations - PDF(Slides)

EP11.03. Real World Experience of First Line Pembrolizumab for Non-Small Cell Lung Cancer (NSCLC) at a Tertiary Centre - PDF(Slides)

EP11.03. Incidence of Cardiotoxicity in Patients Treated for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors - PDF(Slides)

EP11.03. Proton Pump Inhibitors’ Impact on the Effectiveness of Immune Checkpoint Inhibitors in Metastatic Non-Small Cell Lung Cancer - PDF(Slides)

EP11.03. Efficacy of Nivolumab + Ipilimumab Vs other First-line Treatments for Metastatic NSCLC with PD-L1 <1%: a Network Meta-analysis - PDF(Slides)

EP11.03. The Efficacy of Immunotherapy and Chemoimmunotherapy in STK11, KEAP1 & KRAS Gene Mutations in Advanced Non-small Cell Lung Cancer (NSCLC) - PDF(Slides)

EP11.03. A Novel Approach for Personalized Strategy of Cancer Immunotherapy with Pattern Identification: From the Results of the HARMONY Study - PDF(Slides)

EP11.03. Real-World Outcomes with Immunotherapy Compared to Chemoimmunotherapy in Metastatic NSCLC with High PDL1 Expression - PDF(Slides)

EP11.03. Tislelizumab Plus Platinum-Based Chemotherapy as First-Line Treatment for Advanced Lung Cancer with KRAS Mutation in China - PDF(Slides)

EP11.03. Real World Outcomes after Chemotherapy and Immunotherapy in Patients with Metastatic Non-Small Cell Lung Cancer in Europe - PDF(Slides)

EP11.03. Immunotherapy and Overall Survival in Advanced NSCLC: A Systematic Review of Randomised Trials - PDF(Slides)

EP11.03. What Are Favorable Clinicopathological Factors and Types of Therapy for Postoperatively Recurrent NSCLC Patients? - PDF(Slides)

EP11.03. Quantification of Interstitial Lung Abnormality Using Deep Learning in Cancer Patients Who Underwent Immune Checkpoint Inhibitors - PDF(Slides)

EP11.03. Dose the Histological Subtype of NSCC-NOS Affect the Efficacy of 1st-Line PD-1/PD-L1 Inhibitors with or without Chemotherapy? - PDF(Slides)

EP11.03. Prognostic Value of Body Mass Index and Serum Lipid for First-line Immunotherapy in Patients with Advanced NSCLC: A Retrospective Study - PDF(Slides)

EP11.03. Clinical Impact of Immune Checkpoint Inhibitors Following Platinum Chemotherapy in Advanced or Metastatic Non-small Cell Lung Cancer Patients - PDF(Slides)

EP11.03. Impact of KRAS Mutation Subtype and Comutations across PD-L1 Levels in aNSCLC Patients Treated with (Chemo)Immunotherapy - PDF(Slides)

EP11.03. Clinical Outcomes of Immunotherapy with or without Radiation in Advanced Lung Cancer: a Real-World, Retrospective Study - PDF(Slides)

EP11.03. Efficacy and Safety of Chemotherapy Plus Immunotherapy and Recombinant Human Endostatin in Advanced Non-small-Cell Lung Cancer - PDF(Slides)

EP11.03. Comparison of Real-World Outcomes in aNSCLC Patients Receiving 1L Immunotherapy Alone or in Combination with Chemotherapy - PDF(Slides)

EP11.03. Platinum/Taxane versus Docetaxel +/- Ramucirumab for Metastatic Lung Cancers That Progressed on Platinum Doublets and Anti-PD1/PD-L1 - PDF(Slides)

EP11.03. An Observational Study to Identify Selection Criteria for Initiation of Different First Line Treatment Options in NSCLC Patients - PDF(Slides)

EP11.03. Successful Treatment with Pembrolizumab Alone for SMARCA4-deficient Lung Sarcomatoid with a High-TMB and PD-L1(+) A Case Report - PDF(Slides)

EP11.03. Superior Effectiveness of PD-1 Inhibitor Plus Chemotherapy vs Bevacizumab Plus Chemotherapy for NSCLC with Brain Metastases - PDF(Slides)

EP11.04. Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer - PDF(Slides)

EP11.04. Increasing Liquid Biopsy Sensitivity to the Next Level: Usability of Minimal Residual Disease Detection of Genomic Fusions by ddPCR - PDF(Slides)

EP12.01. The Safety and Efficacy of Aumolertinib in Advanced NSCLC Patients with EGFRm Who were Intolerant to Osimertinib: A Retrospective Clinical Study - PDF(Slides)

EP12.01. NGS Reveals Convergent Acquired Resistance and Newly Emerging Driver Involving MET Alterations in NSCLC: A Case Report - PDF(Slides)

EP12.01. Erlotinib and Ramucirumab Combination Therapy for Patients Previously Treated with EGFR-TKI: A Retrospective Observational Study - PDF(Slides)

EP12.01. Clinical Features and Progression Free Survival of Lung Adenocarcinoma Patients with EGFR sensitizing mutations with Dose Reduction of Afatinib - PDF(Slides)

EP12.01. Osimertinib in Epidermal Growth Factor Receptor-Mutated (EGFR+) Metastatic Non-Small-Cell Lung Cancer (NSCLC) Real-World Patients - PDF(Slides)

EP12.01. Metastatic NSCLC with G719X/S781I EGFR-mutations with acquired BRAF V600E mutation - response to Osimertinib, Dabrafenib and Trametinib - PDF(Slides)

EP12.01. Brigatinib Restores Disease Control at Second Progression on Osimertinib in Metastatic EGFR ex19del Mutated NSCLC with Acquired EML4-ALK Fusion - PDF(Slides)

EP12.01. Benefits of Afatinib and Osimertinib in a Patient with Lung Adenocarcinoma Harboring EGFR19Del/T790M/G724S Mutation - PDF(Slides)

EP12.01. Predictive and Prognostic Value of Early Skeletal Muscle Loss during First-Line EGFR-TKIs for Advanced Lung Adenocarcinoma - PDF(Slides)

EP12.01. Predictors of Poor Outcomes Among Patients Receiving 1st-Line Osimertinib for Advanced EGFR Mutated Non-Small Cell Lung Cancer - PDF(Slides)

EP12.01. Efficacy of Amivantamab in a Patient with EGFR ex20ins Lung Adenocarcinoma with Symptomatic Pleural Effusion after Platinum Doublet Failure - PDF(Slides)

EP12.01. Comparing Different Anti-angiogenic Agents and TKI Combinations in EGFR-mutated Advanced NSCLC: a Retrospective Study - PDF(Slides)

EP12.01. Educational Impact of A Clinical Advances Curriculum On EGFR Exon 20 Insertion Mutated NSCLC And EGFR TKI-Resistant NSCLC - PDF(Slides)

EP12.01. First-line Aumolertinib Treatment in Non-Small Cell Lung Cancer (NSCLC) with Primary EGFR T790M Mutation: A Report of two Cases - PDF(Slides)

EP12.01. Aumolertinib Combination SBRT Treated EGFR Co-mutation Patients with Symptomatic Brain Metastases: A Case Report - PDF(Slides)

EP12.01. The Safety and Efficacy of Aumolertinib in Advanced EGFR-mutant NSCLC Patients Who Were Intolerant to Osimertinib Treatment - PDF(Slides)

EP12.01. Association of CYP450 and Drug Efflux Transporters Polymorphism Influence Outcomes of Thai Non-small Cell Lung Cancer Treated with Osimertinib - PDF(Slides)

EP12.01. Validation of the ALK-Brain Prognostic Index (ALK-BPI) Model in Patients with ALK-rearranged Non-small Cell Lung Cancer and Brain Metastases - PDF(Slides)

EP12.01. Successful Aumolertinib Treatment of Activated EGFR Mutation NSCLC Patients with Interstitial Pneumonia Induced by Osimertinib - PDF(Slides)

EP12.01. Amivantamab: Prolonged Survivor in Post-TKI NSCLC with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutation (ex20ins) - PDF(Slides)

EP12.01. A Case of Brain Metastases from Lung Cancer with Epilepsy and ECOG Score of 4 Successfully Treated with Aumolertinib - PDF(Slides)

EP12.01. Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC - PDF(Slides)

EP12.01. Combination of Osimertinib plus Capmatinib in a Patient with EGFR-mutant, T790M positive and MET amplification: A Case Report - PDF(Slides)

EP12.01. High-Dose Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC with Meningeal Symptoms as the First Symptom - PDF(Slides)

EP12.01. Outcomes in NSCLC Patients with EGFR Co-Mutations Receiving Aumolertinib as First-Line Treatment: the Updated Results - PDF(Slides)

EP12.01. Aumolertinib as Neoadjuvant and Adjuvant Therapy for Unresectable Stage IIIA-IVA Non-Small Cell Lung Cancer with EGFR Mutations - PDF(Slides)

EP12.01. Final Report on Real World Effectiveness of Sequential Afatinib and Osimertinib in EGFR Positive Advanced Non-small Cell Lung Cancer - PDF(Slides)

EP12.01. A Case of Long PFS by Aumolertinib in Advanced Lung Cancer with Multiple Metastases lncluding Brain Metastasis - PDF(Slides)

EP12.01. Study on the Molecular Markers of Resistance in the First-line Treatment of NSCLC with EGFR Positive by Aumolertinib - PDF(Slides)

EP12.01. Treatment Strategies and Survival Outcomes of Patients with EGFR-mutated NSCLC and leptomeningeal metastasis - PDF(Slides)

EP12.01. Updated First-line Osimertinib in Asian patients with Advanced EGFR-mutated Lung Cancer - PDF(Slides)

EP12.01. Liquid Biopsy Reduce Time to Treatment for Patients with EGFR mutated Advanced Nonsquamous Non-small Cell Lung Cancer : A Mexican Unit Experience - PDF(Slides)

EP12.01. Autopsy and Next Generation Sequencing Report of First-Line Treatment with Osimertinib for EGFR-Mutated Squamous Cell Carcinoma of the Lung - PDF(Slides)

EP12.01. Skin Toxicity Associated with Targeted and Immune Therapies in Stage IV Lung Cancer Patients: A 14-year Cohort - PDF(Slides)

EP12.01. Heart Failure Incidence and Mortality With EGFR TKIs in Patients with NSCLC: Targeted Literature Review - PDF(Slides)

EP12.01. Exceptional Response to Aumolertinib in an Advanced NSCLC Patient With Rare EGFR Exon20 V774M and S768I Mutations - PDF(Slides)

EP12.01. Real-world Outcomes in a U.S. Asian Population with Stage IV NSCLC Treated with Osimertinib Stratified by EGFR Subtype - PDF(Slides)

EP12.01. Therapeutic or Prophylactic Targeting C797S in EGFR Mutant Lung Adenocarcinoma - PDF(Slides)

EP12.01. The Optimal Intervention Timing of Aumolertinib Combined with HFSRT for EGFR Mutated NSCLC Patients with Multiple Brain Metastasess - PDF(Slides)

EP12.01. Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort - PDF(Slides)

EP12.01. Case Report of Short-Term Gefitinib Induced IgA Nephropathy and Tubulointerstitial Nephritis in a Patient with Non-small Cell Lung Cancer - PDF(Slides)

EP12.01. A Lung Adenocarcinoma Patient with Co-mutations of MET Exon 14 Skipping and EGFR exon21 L858R responded to Aumolertinib - PDF(Slides)

EP12.01. L858R Exon 21 Mutation Is Associated with a Higher Risk of Brain Metastases in Patients with NSCLC Treated with TKI - PDF(Slides)

EP12.01. Lazertinib in Pretreated Epidermal Growth Factor Receptor T790M-Mutated Advanced Non-small Cell Lung Cancer: A Real-World Multicenter Study - PDF(Slides)

EP12.01. A Study of Aumolertinib Monotherapy or Combination Treated EGFR-mutated NSCLC Patients with Symptomatic Brain Metastases - PDF(Slides)

EP12.01. Molecular Characteristics and Response to TKIs in NSCLC Patients with EGFR Exon 19 Insertions - PDF(Slides)

EP12.01. Clinical Significance of Chronic Interstitial Pneumonia Induced by EGFR-TKI Administration - PDF(Slides)

EP12.01. A Multi-Center Observational Study of Effectiveness and Safety of First Line Afatinib in Major Uncommon EGFR mutated NSCLC - PDF(Slides)

EP12.01. The Contribution of Compound EGFR Mutations and Other Co-mutations to Efficacy of EGFR TKI in Lung Adenocarcinoma - PDF(Slides)

EP12.01. Single-Center Real-World Study of First Line Afatinib Treatment in Advanced EGFR-mutated Non-small Cell Lung Cancer in Vietnam - PDF(Slides)

EP12.01. Aumolertinib as First-line Treatment in EGFR-Mutant Pulmonary Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Study (ARISE) - PDF(Slides)

EP12.01. Successful Salvage Therapy Using High Dose Aumolertinib in T790M-negative EGFR-mutant NSCLC With Brain and Leptomeningeal Metastases - PDF(Slides)

EP12.01. Unresectable Advanced NSCLC Transformed to Resectable NSCLC through Effective Aumolertinib Neoadjuvant Therapy: A Case Report - PDF(Slides)

EP12.01. Continuous CR for EGFR-Mutated NSCLC with Brain Metastasis and Giant Lung Lesion Using Aumolertinib Plus Radiotherapy as First-Line Treatment - PDF(Slides)

EP12.01. Tepotinib and Capmatinib in Patients with MET exon 14 Skipping NSCLC: A Matching Adjusted Indirect Comparison (MAIC) - PDF(Slides)

EP12.01. An Observational Study Analyzing Progression Free Survival of Patients With EGFR Mutant NSCLC Treated with Osimertinib in South Carolina - PDF(Slides)

EP12.01. Clinical Features, Outcomes, and Biology of EGFR exon 20 Insertions in a Cohort of Hispanic Patients with Non-small Cell Lung Cancer - PDF(Slides)

EP12.01. Osteoblastic Bone Reaction in Non-small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations Treated with Osimertinib - PDF(Slides)

EP12.01. Conversion to Aumolertinib in NSCLC Patients with EGFR Mutations Who Are Safety Intolerant after Osimertinib Treatment: A Retrospective Study - PDF(Slides)

EP12.01. Metastatic Non-Small Cell Lung Cancer With EGFR Mutations: Treatment Pattern and Outcomes From a Systematic Literature Review - PDF(Slides)

EP12.01. Prognostic Value of Sequential Liquid Biopsy (LB) after Osimertinib Among Hispanic Patients with Advanced EGFR-Mutant NSCLC - PDF(Slides)

EP12.01. Long Survival in LM NSCLC Treated with Aumolertinib and Metronomic Intrathecal Pemetrexed under Dynamic Detection of CSF ctDNA - PDF(Slides)

EP12.01. A Real World Cohort Study of First Line Afatinib in Patients with EGFR mutant Advanced Non Small Cell Lung Cancer in Vietnam - PDF(Slides)

EP12.01. Durable Response to High-Dose Aumolertinib 165mg After Local Progression in EGFR-Mutated Non-Small Cell Lung Cancer with Brain Metastases - PDF(Slides)

EP12.01. Response Evaluation of Newly Diagnosed EGFR Mutated NSCLC in Tertiary Referral Cancer Center in Jakarta-Indonesia - PDF(Slides)

EP12.01. Anlotinib Combined with Osimertinib Reverses Acquired Osimertinib Resistance in NSCLC by Targeting the c-MET/MYC/AXL Axis - PDF(Slides)

EP12.01. Aumolertinib Combination Therapy for EGFR-Mutant NSCLC Patients with Refractory Leptomeningeal Metastasis Following Osimertinib Failure - PDF(Slides)

EP12.01. Real-World Study of First-Line Therapy with Aumolertinib for Elderly EGFR+ NSCLC Patients: The Updated Results - PDF(Slides)

EP12.01. Aumonertinib in EGFR-Mutant NSCLC Patients with Liver Dysfunction after TKI Treatment and NSCLC with Basic Hepatopathy as First-Line Therapy - PDF(Slides)

EP12.01. Increased Progression Free Survival of Patients with EGFR positive mutation NSCLC Treated with Afatinib in Regard to Toxicity - PDF(Slides)

EP12.01. Good Results of Osimertinib in a Patient with EGFR (L861Q) and MET Amplification NSCLC: A Case Report - PDF(Slides)

EP12.01. Adding Amivantamab as a Salvage Strategy Post EGFR TKI (Osimertinib/Mobocertinib) in EGFRm+ NSCLC - PDF(Slides)

EP12.01. Real-word Study of Aumolertinib Treatment for Advanced NSCLC Patients with Uncommon EGFR Mutations in Late Permian Coal Area - PDF(Slides)

EP12.02. Treatment Patterns and Economic Burden of Brain Metastases (BM) in Patients with ALK+ mNSCLC Receiving ALK TKIs - PDF(Slides)

EP12.02. Judith Tam ALK Lung Cancer Research Initiative - PDF(Slides)

EP12.02. The Response to First-line Therapies in Stage IV RET Fusion-Positive Non-small Cell Lung Cancer: a Multi-center Retrospective Study in China - PDF(Slides)

EP12.02. PD-L1 Expression Status Was Not Associated with Efficacy of Alectinib in Patients with ALK-positive Lung Cancer - PDF(Slides)

EP12.02. Comparative Efficacy and Safety of Lorlatinib vs Alectinib and Brigatinib Using Matching Adjusted Indirect Comparisons (MAIC) - PDF(Slides)

EP12.02. The Effectiveness of Lorlatinib for Previously Treated ROS1-rearranged NSCLC: Real world Experience in Taiwan - PDF(Slides)

EP12.02. Frequency and Outcomes of Leptomeningeal Metastases in Patients with Fusion-Positive Lung Cancers - PDF(Slides)

EP12.02. Prevalence and Treatment of Advanced NSCLC patients with REarranged During Transfection [RET]-fusion at a South Korean Centre - PDF(Slides)

EP12.02. Personalizing Care for Patients with Advanced ALK+ NSCLC through a Blended Continuing Education and Quality Improvement Initiative - PDF(Slides)

EP12.02. Sequencing Patterns and Treatment Effectiveness in ALK-positive aNSCLC Following First-Line Alectinib or Brigatinib - PDF(Slides)

EP12.02. Matching-Adjusted Indirect Comparison (MAIC): Entrectinib versus Crizotinib in Asian Patients with ROS1+ NSCLC - PDF(Slides)

EP12.03. Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy - PDF(Slides)

EP12.03. Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA) - PDF(Slides)

EP12.03. Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib. - PDF(Slides)

EP12.03. A Retrospective Analysis on the Lung Cancer Specimens for Multi-CDx System in Keio University Hospital - PDF(Slides)

EP12.03. A Case Report of Sustained Survival of NSCLC Treated with Combination of Cell Therapy and Immunotherapy - PDF(Slides)

EP13.01. pN Stage Predicts Survival Benefits of Postoperative Radiotherapy in Combined Small Cell Lung Cancer Patients after Surgery - PDF(Slides)

EP13.01. Patient-Specific Factors as Prognostic Biomarkers in Extensive Disease SCLC - PDF(Slides)

EP13.01. Does Oligometastases state exist in patients of Small Cell Lung Cancer? - A Small Retrospective Analysis from a Tertiary Cancer Centre - PDF(Slides)

EP13.01. Consolidative Radiotherapy for Extensive-Stage Small Cell Lung Cancer with an Emphasis on Oligo-Progressive Disease - PDF(Slides)

EP13.01. Prognostic Impact of Neutrophil-to-Lymphocyte Ratio (NLR) For Extensive-Stage Small Cell Lung Cancer (ES-SCLC) - PDF(Slides)

EP13.01. Immunohistochemical Classification of Patients with Small Cell Lung Cancer - A Single Center Study - PDF(Slides)

EP13.01. Stratified Control Study Of Neuroendocrine Differentiation and Potential Clinicopathologic Markers - PDF(Slides)

EP13.01. Single-Cell RNA Sequencing Reveals Immune Microenvironment of Small Cell Lung Cancer-associated Malignant Pleural Effusion - PDF(Slides)

EP13.01. Mitotic Counts and Phospho-Histone H3 Index in Grading Pulmonary Neuroendocrine Tumors: Assessment of Interobserver Variability and Utility - PDF(Slides)

EP13.01. Study of NLI Use in the First Line of Atezolizumab Plus Chemotherapy - PDF(Slides)

EP13.01. Validation of LIPI index in SCLC - PDF(Slides)

EP13.01. Prognostic Nutritional Index-Based immune Risk System for Prognosis and Immunotherapy Response Prediction in Small Cell Lung Cancer - PDF(Slides)

EP13.02. Minimally Invasive Surgery for Endobronchial Small Cell Lung Carcinoma following Neoadjuvant Chemotherapy - PDF(Slides)

EP13.02. Dynamic Transition of Molecular Subtypes in Relapsed Small Cell Lung Cancer Treated with Multimodal Therapy - PDF(Slides)

EP13.02. Entrectinib Amazing Efficacy in a Case of Lung Atypical Carcinoid with NTRK Gene Fusion - PDF(Slides)

EP13.03. Correlation of Immune-Related Adverse Events to Efficacy of PD-1/PD-L1 Inhibitors in Small Cell Lung Cancer: A Multi-center Retrospective Study - PDF(Slides)

EP13.03. Improved Long-Term Survival and Less Chemotherapy in Extended-SCLC Patients: A Real-World Study in the Immunotherapy Era - PDF(Slides)

EP13.03. RWD of Atezolizumab Plus Chemotherapy in First Line SCLC - PDF(Slides)

EP13.03. A Single Arm Phase II Study of Tislelizumab Plus Anlotinib as Maintenance Therapy in Patients with Extensive-stage Small Cell Lung Cancer - PDF(Slides)

EP13.03. Anlotinib as Maintenance Therapy for Extensive-stage Small-cell Lung Cancer: A Single-arm, Prospective, Phase II Study - PDF(Slides)

EP13.03. Small Cell Lung Cancer Immune Related Adverse Events, Survival Impacts - PDF(Slides)

EP13.03. Real-World Analysis of ICI Efficacy in ES-SCLC Patients with and without Brain Metastases: A Call for Inclusion in Clinical Trials - PDF(Slides)

EP13.03. Developing Strategies for Delivery of Patient-Centered Care for Small Cell Lung Cancer - PDF(Slides)

EP13.03. Outcomes of ES-SCLC Patients Treated with Platinum Doublet and Immunotherapy: A Western Australia Retrospective Review - PDF(Slides)

EP13.03. Clinical Effectiveness of First-Line Immunotherapy in Small Cell Lung Cancer - PDF(Slides)

EP13.03. Prophylactic Cranial and Consolidation Thoracic Radiation in Extensive Stage Small Cell (ES-SCLC) Lung Cancer in the Chemo-immunotherapy Era - PDF(Slides)

EP13.03. A Comparative Analysis between Real-World Data and Clinical Trials to Evaluate Differences in Outcomes for SCLC Patients - PDF(Slides)

EP13.03. Efficacy of First-Line Tislelizumab Plus Etoposide and Carboplatin in ES-SCLC - PDF(Slides)

EP13.04. Efficacy of Prophylactic Cranial Irradiation According to the Risk of Extracranial Recurrence in Limited-Stage Small Cell Lung Cancer - PDF(Slides)

EP13.04. Characterization of Limited-Stage Small Cell Lung Cancer: Molecular Subtypes, Tumor Microenvironment and Clinical Follow-up - PDF(Slides)

EP13.04. The Impact of PCI on the Prognosis of Limited-stage SCLC Patients in the Era of MRI Surveillance - PDF(Slides)

EP13.04. Preliminary Results of a Prospective Trial of Hypofractionated Radiotherapy Versus Hyperfractionated Radiotherapy for Limited-stage SCLC - PDF(Slides)

EP13.04. Outcomes of Limited-Stage Extrapulmonary Small Cell Carcinoma and Small Cell Lung Cancer - PDF(Slides)

EP13.05. Early ctDNA Changes and Clinical Outcomes in Extensive Stage Small Cell Lung Cancer Patients on Nivolumab and Temozolomide - PDF(Slides)

EP13.05. Temozolomide-associated Hypermutation and Response to Immunotherapy in Advanced Pulmonary Neuroendocrine Tumors. - PDF(Slides)

EP13.05. A Comparison of the Outcomes of Pulmonary versus Extrapulmonary Extensive Stage Small Cell Carcinoma - PDF(Slides)

EP13.05. Real-world Efficacy of PD-1/PD-L1 Inhibitors in Patients with Advanced Pulmonary Neuroendocrine Carcinoma - PDF(Slides)

EP13.05. Comparative Study of LCNEC and LCLC of the Lung Pathologically Diagnosed by Surgical Resection Specimens - PDF(Slides)

EP13.05. Effects and Outcomes Analysis of Immunotherapy for Patients with Pulmonary Large-Cell Neuroendocrine Carcinoma - PDF(Slides)

EP13.06. hSSB1 is Elevated and a Potential Target for Therapy in SCLC - PDF(Slides)

EP13.06. Real-World Outcomes in Patients with 3rd-Line Extensive Stage Small Cell Lung Cancer - PDF(Slides)

EP13.06. Radiotheranostics targeting Delta-Like Ligand 3 Expressing Small-Cell Lung Cancers. - PDF(Slides)

EP13.06. Phase II Study of Pembrolizumab, Plinabulin plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer - PDF(Slides)

EP13.06. Exploratory Clinical Study of Anlotinib Combined with Concurrent Chemoradiotherapy in the Treatment of Small Cell Lung Cancer(SCLC) - PDF(Slides)

EP13.07. Understanding Real-Life Response to Lurbinectedin as Second Line Therapy in Patients with Extensive Stage Small-Cell Lung Cancer - PDF(Slides)

EP13.07. Is Concept of Continuous Immunotherapy Beyond Progression Effective in Small Cell Lung Cancer? - PDF(Slides)

EP13.07. Treatment Patterns and Outcomes in Recent US Clinical Practice for SCLC Patients After Two Prior Lines of Therapy - PDF(Slides)

EP13.07. Immune Activation Effect of Different Irradiated Sites and Survival in ES-SCLC Patients Treated with Radioimmunotherapy: A Real-World Analysis - PDF(Slides)

EP13.07. RYZ101 (Ac-225 DOTATATE) Opportunity Beyond GEP-NETs: Preclinical Efficacy in Small Cell Lung Cancer - PDF(Slides)

EP13.07. Efficacy of Platinum Given after Lurbinectedin in Sensitive Relapsed SCLC Patients - PDF(Slides)

EP13.07. Exploring Outcomes in Second-line Therapy for Small Cell Lung Cancer with Brain Metastases: Lurbinectedin vs Others - PDF(Slides)

EP13.07. Canadian Consensus Recommendations: Use of Radiation Therapy among Patients with ES-SCLC receiving Immunotherapy - PDF(Slides)

EP13.07. A Study of Sintilimab Combined with Anlotinib and chemotherapy as Second-Line or Later Therapy in Extensive-Disease Small Cell Lung Cancer - PDF(Slides)

EP13.07. Efficacy and Safety of Antiangiogenic Therapy plus Immunotherapy as Later-line Treatment for Small Cell Lung Cancer - PDF(Slides)

EP14.01. Does Delaying Surgery Following Induction Chemotherapy Compromise Survival in Patients with Malignant Pleural Mesothelioma? - PDF(Slides)

EP14.01. Treatment Response in Malignant Pleural Mesothelioma Patients Can Be Predicted by Exhaled Breath Analysis - PDF(Slides)

EP14.01. Cytologic Predictors and Novel Markers of Malignant Mesothelial Proliferation (mesothelioma) in Pleural Effusion - PDF(Slides)

EP14.01. Risk Factors Influencing Postoperative Pleural Empyema in Patients with Pleural Mesothelioma after Multimodal Therapy - PDF(Slides)

EP14.01. Neo-Adjuvant Immunotherapy in Malignant Pleural Mesothelioma: Report on Three Cases Treated in a Single Institution - PDF(Slides)

EP14.01. Multimodal Treatment in Malignant Pleural Mesothelioma: An Institutional Experience of 432 Patients over a 29 Year Period - PDF(Abstract)

EP14.01. Patients Who Undergo Surgery Survive Longer than Those Who Refuse Surgery - PDF(Slides)

EP14.01. Low Ki-67 Positive Index is a Prognostic Factor for Better Survival Outcomes of Patients treated with Intracavitary Cisplatin-Fibrin - PDF(Slides)

EP14.01. Clinical Significance of BAP1 Expression in Malignant Mesothelioma Treated with Ipilimumab and Nivolumab. - PDF(Slides)

EP14.01. Feasibility of Near-Infrared Fluorescence-Guided Robotic-Assisted Minimally Invasive Esophagectomy with Indocyanine Green Dye - PDF(Slides)

EP14.01. Three-port Robot-assisted Thoracoscopic Surgery for Mediastinal Tumor with “Confronting View” at Our Hospital - PDF(Slides)

EP14.01. Forced Vital Capacity Is a Strong Predictor for Postoperative Survival of Patients with Malignant Pleural Mesothelioma - PDF(Slides)

EP14.02. Neoadjuvant Immune Checkpoint Inhibitor-Based Therapy Followed by Resection for Locally Advanced Thymic Malignancies - PDF(Slides)

EP14.02. Preoperative Steroid Pulse Therapy for Invasive Thymoma - PDF(Slides)

EP14.02. Open Versus Video-Assisted and Robotic-Assisted Thymectomy for the Treatment of Thymic Neoplasms - PDF(Slides)

EP14.02. Identification of Risk Factors for Postoperative Acute Exacerbation of Myasthenia Gravis after Total Thymectomy - PDF(Slides)

EP14.02. Mixed Feelings about Mixed Thymomas - PDF(Slides)

EP14.02. Atypical Response to Metronomic Chemotherapy in a Patient with Advanced Thymoma - PDF(Slides)

EP14.02. The Significance and Risk Factors of Lymph Node metastasis in Thymic Malignancies: A Large Population-based Database Analysis - PDF(Slides)

EP14.03. Is Subxiphoid Uniportal Video-Assisted Thoracoscopic Mediastinal Surgery Safe, Minimally Invasive, and Radical? - PDF(Slides)

EP14.03. The Impact of Expanded Indication of Robot-Assisted Thoracic Surgery for Mediastinal Tumors - PDF(Slides)

EP14.03. Pulmonary Blastoma is Successfully Treated with Immunotherapy and Targeted Therapy - PDF(Slides)

EP14.03. Rare but Aggressive: A Case of Primary Pulmonary Synovial Sarcoma - PDF(Slides)

EP14.03. Implant Associated Squamous Cell Carcinoma: An Emerging Chest Wall Malignancy - PDF(Slides)

EP14.03. PULS - An International Collaboration for Collection and Assessment of Data from Patients with PUL Monary Artery Sarcoma - PDF(Slides)

EP14.03. Three Cases of Mediastinal Teratoma Resulting in Thoracic Perforation - PDF(Slides)

EP14.03. Pulmonary Metastastasis of Dermatofibrosarcoma Protuberans of the Scalp : A Challenging Mesenchymal Tumor - PDF(Slides)

EP14.03. Expression of Fibroblast Activation Protein in Intrathoracic Solitary Fibrous Tumor - PDF(Slides)

EP14.03. Ebstein-Barr Virus-Associated Pulmonary Lymphomatoid Granulomatosis with Trigeminal Nerve Involvement - PDF(Slides)

EP14.03. Lung Epithelioid Hemangioendothelioma with Paraneoplastic Nail Clubbing and Hypertrophic Osteoarthropathy - PDF(Slides)

EP14.03. Anastomosing Hemangioma of Mediastinum and Pleura Mimicking Chest Malignancy - PDF(Slides)

EP14.04. BRCA-Associated Protein-1 (BAP1) Loss and Real-World Outcomes of Immune Checkpoint Inhibitor Therapy in Pleural Mesothelioma - PDF(Slides)

EP14.04. Expression of TILs and Patterns of Gene Expression from Paired Samples of Malignant Pleural Mesothelioma (MPM) Patients (p) - PDF(Slides)

EP15.01. Can Nurses Successfully Do Patient Advocacy : Need in Resource Poor Settings - PDF(Slides)

EP15.02. Improving the Lives of Patients Diagnosed with Lung Carcinoma: The Holistic Power of Palliative Care - PDF(Slides)

EP15.02. Starting Early Palliative Care for Lung Cancer as Soon as Possible: lesson learned from Resource-limited Setting in Indonesia - PDF(Slides)

EP15.03. Implementation of an Interdisciplinary Distress Assessment and Response Program for Family Caregivers - PDF(Slides)

EP15.03. Assessment of the Multidisciplinary Onco-thoracic Consultation Meeting of the University Hospital Center of Tangier - PDF(Slides)

EP15.03. Unscheduled Hospitalizations in Patients with Lung Cancer as a Frailty Event - PDF(Slides)

EP16.01. Virtual Educational Patient Meetings Empower, Unite Small Cell Lung Cancer Patients - PDF(Slides)

EP16.01. A Brief History of Lung Cancer in Canada: Care, Contributions and Challenges - PDF(Slides)

EP16.01. Optimizing Treatment Outcomes for L858R EGFR+ NSCLC - PDF(Slides)

EP16.01. Creation of Mental Health Support Materials for People with Lung Cancer and Healthcare Providers (HCPs) - PDF(Slides)

EP17.01. The Lung Cancer Clinical Quality Data Platform (LUCAP): Results from a Western Australia Pilot Study - PDF(Slides)

EP17.01. Data Mining to Build Metrics. A Feasible Assessment of Quality of Care for Stage III Non-small Cell Lung Cancer (NSCLC). - PDF(Slides)

EP17.01. Proposing Relevant Diagnosis Associated with Lung Cancer Based on Prior Diagnosis: Implementing Apriori Algorithm - PDF(Slides)

EP17.01. Lung Cancer Information System: Enabling Precision Oncology through Informatics - PDF(Slides)

EP17.01. Lung Cancer (Internet-Based) Delphi (LuCiD): a Delphi Consensus to Develop Australasian Thoracic Oncology Quality Indicators - PDF(Slides)

EP17.02. Concordance on Treatment Recommendations from Multidisciplinary Tumor Boards -Data from Driver-Mutated Lung Cancer in Focus - PDF(Slides)

EP17.03. Quantitative Findings from a Survey of Health Insurance in Patients Diagnosed as Advanced Lung Cancer in Japan - PDF(Slides)

EP17.03. Utilities Used in HTAs in mNSCLC Following Progression on or After Platinum-Based Chemotherapy - PDF(Slides)

EP17.03. Pharmacoeconomic Analysis of Brigatinib Versus Alectinib in Chinese Patients with ALK-Positive Non-Small Cell Lung Cancer - PDF(Slides)

EP17.03. The Economic Evaluation of The protein-Based Lung Cancer Biomarker Panel (LCBP):Evidencebased Onamulticenter Clinicaltrialin China - PDF(Slides)

EP17.04. The Impact of the Emergency Presentation of Patients Diagnosed with Lung Cancer on Treatment Outcomes in Wales. - PDF(Slides)

EP17.04. Global, Regional, National Burden of Lung Cancer Attributable to High Fasting Plasma Glucose - PDF(Slides)

EP17.04. Lung Cancer Care in Singapore: A review of the Healthcare Registry, 2013-2020 - PDF(Slides)

EP17.04. Survival Rate of Untreated Lung Cancer Patients at Dr. (H.C) Ir. Soekarno Hospital Bangka - PDF(Slides)

EP17.04. Research and Analysis on the Situation of Prevention and Treatment Capability of Cancer in County of China - PDF(Slides)

EP17.04. Clinical Outcomes and Lack of Health Equity in Minority Patients with Unresectable Non-small Cell Lung Cancer (NSCLC) Treated with Durvalumab - PDF(Slides)

EP17.04. Lung Stereotactic Body Radiation Therapy in a Developing Country: Patterns of Safety and Treatment Toxicities - PDF(Slides)

EP17.04. Changing Lung Cancer Incidence Trends and Risk Patterns Among Asian Americans in Los Angeles County, California, USA - PDF(Slides)

EP17.06. COVID-19 Long-Lasting Effect on Lung Cancer Diagnoses in Italy: Update of the Real-World Multicenter COVID-DELAY Study - PDF(Slides)

P1.01. Frequency of Germline Mutations in Patients with Non-small Cell Lung Cancer (NSCLC) Harboring Actionable DRIVER Alterations (G-DRIVER) - PDF(Slides)

P1.01. Diabetes as Prognostic and Predictive Factors in Resected Non-small Cell Lung Cancer, from a Large Chinese Cohort - PDF(Slides)

P1.01. Novel Anoikis-Related Prognostic Signatures of NSCLC Based on mRNA‑lncRNA Analysis and Primary Validation in CRISPR Screening - PDF(Slides)

P1.01. Clinical and Genetic Characteristics in Younger vs Older Lung Cancer Patients - PDF(Slides)

P1.01. A Phase IB Trial Of Nivolumab For Immunoprevention Of Bronchial Dysplasia Progression In High-risk Current And Former Smokers - PDF(Slides)

P1.01. Asbestos Exposure and Small Cell Lung Cancer. Systematic Review and Meta-Analysis - PDF(Slides)

P1.01. A Content Analysis E-cigarette Retailer Websites and Nicotine Addiction among E-cigarette Users- Mixed Methods Study from Malaysia - PDF(Slides)

P1.01. Assessing the Relationship Between Frailty and Lung Cancer Survival: A Systematic Review and Meta-Analysis - PDF(Slides)

P1.01. Peptic Ulcer and Long-Term Risk of Lung Cancer: A Prospective Cohort Study from UK Biobank - PDF(Slides)

P1.01. Lung Cancer Risk Prediction Model Incorporating Liver Function Markers: a Prospective Cohort Study from the UK Biobank - PDF(Slides)

P1.01. “A Core Part of the Whole Thing...”: Stakeholder Views on Offering Smoking Cessation Support in Lung Cancer Screening - PDF(Slides)

P1.01. Amelioration of the Toll of Air Pollution on Lung Cancer - PDF(Slides)

P1.02. HRA00129-C004, a Novel c-Met ADC with Promising Preclinical Anti-tumor Activity and Expanded Therapeutic Window - PDF(Slides)

P1.02. Co-inhibition of MEK/RTKs Pathways via Trametinib Plus Anlotinib forKRAS-Mutant NSCLC - PDF(Slides)

P1.02. Identifying Biomarkers of Response to Ensartinib, Lorlatinib, and Alectinib in an ALK+ Non-Small Cell Lung Cancer Preclinical Model (ResCu) - PDF(Slides)

P1.02. Targeting ATP7A by Elesclomol-Copper Derived Endoplasmic Reticulum Stress to Mediate Cuproptosis in KRAS-G12 Mutant LUAD - PDF(Slides)

P1.02. Glucose Deprivation Promotes Pseudo-Hypoxia and De-differentiation in Lung Adenocarcinoma - PDF(Slides)

P1.03. Dynamic Transcriptomic Characterization Changes of Early Stage Lung Adenocarcinoma as per the Incrassation of Consolidation Tumor Ratio - PDF(Slides)

P1.03. Combinationof Anlotinib and Tislelizumab for Lung Adenocarcinoma: Effects on Metabolic and Flora Microenvironment - PDF(Slides)

P1.04. CDK4/6 Inhibitor Improves Radioimmunotherapy Efficacy via Inducing PD-L1 Transcription through Increased c-Jun Activation in NSCLC - PDF(Slides)

P1.04. Ablative Radiation Induces Distinct Sequential Waves of Mitotic and Innate Immune Death Regulated through DNA Repair Pathways - PDF(Slides)

P1.05. Research on Specific DNA Methylation Regulatory Mechanism Based on Pan-Cancer Analysis - PDF(Slides)

P1.06. NIR-II Mediates Non-small Cell Lung Cancer Nanovaccines for Targeted Lymph Node Delivery and Anti-tumor Immune Activation - PDF(Slides)

P1.06. Trametinib Plus ANTI-PD-1 Immunotherapy Impairs Tumor Growth and Increases Survival of Lung Cancer through ID1 Downregulation - PDF(Slides)

P1.06. Effect and Mechanism of ASNS Remodeling the Metastatic Lymph Node Immune Microenvironment in Lung Cancer - PDF(Slides)

P1.06. Phenotype Mapping of Patient-Derived Small Cell Lung Cancer Organoids Illuminate Subtype-Specific Therapeutic Vulnerability - PDF(Slides)

P1.07. Collective Lung Cancer Migration Using a 3D Model - PDF(Slides)

P1.07. Patient-Derived Xenografts from Thoracic Malignancies as Promising Preclinical Models - PDF(Slides)

P1.08. CoxMoE: A Deep Learning Model Predicts Survival and Response in T790M Positive NSCLC Patients Treated with Third-Generation EGFR-TKI - PDF(Slides)

P1.08. Exploring Autophagy Flux-Related Molecules for Overcoming EGFR TKI Resistance - PDF(Slides)

P1.08. Hyper-Interferon Sensitive Influenza Virus Induces Immune Activation and Overcomes Resistance to Anti-PD-1 in Murine NSCLC - PDF(Slides)

P1.08. Delivery of ATRA and Gefitinib by Polyphenylalanine Nanosystem to Overcome EGFR-TKI Resistance in Lung Adenocarcinoma - PDF(Slides)

P1.08. On-Target Acquired Resistance to Mobocertinib and Strategy to Overcome It - In Vitro Study Using EGFR Ex20 Insertion Models - PDF(Slides)

P1.08. Impact of KRASG12D Subtype and Concurrent Pathogenic Mutations on Advanced Non-small Cell Lung Cancer Outcomes - PDF(Slides)

P1.09. Anti-Cancer Immune Activation Post Bronchoscopic Thermal Ablation in Non-Small Cell Lung Cancer - PDF(Slides)

P1.09. Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR Mutant NSCLC - PDF(Slides)

P1.09. SFRP2+ CAFs Hinder Abscopal Effect from Combined Radiotherapy and Immunotherapy by Forming a Hostile Perivascular Niche - PDF(Slides)

P1.09. Characterization of the Expression of BTN1A1 Exclusive to PD-L1/PD-1 Axis in Small Cell Lung Cancer Using Spatial Biology Approach - PDF(Slides)

P1.09. DCBLD2 Impacts Tumor Immune-Vascular Microenvironment of Lung Cancer by Inducing Pro-angiogenic Macrophages - PDF(Slides)

P1.10. Enrichment of FA/HR Aberrations inATM/ATR-mutated NSCLC Was Accompanied by Distinct Molecular Features and Poor Prognosis - PDF(Slides)

P1.11. Utility of ctDNA Monitoring during Surveillance in Surgically Resected NSCLC Patients - PDF(Slides)

P1.11. DYNAMALK: Dynamic ctDNA Profiling in ALK+ NSCLC. A Study of the Australian Registry and Biobank of Thoracic Cancers AURORA - PDF(Slides)

P1.11. Clinical Implication of Multi-Genomic Analysis about Compound and Uncommon EGFR Mutations in the Non-small Cell Lung Cancer - PDF(Slides)

P1.11. Application of the CRISPR/Cas9-based Gene Editing Technology for the Treatment of NUT Carcinoma - PDF(Slides)

P1.12. CD66c Activates EGFR Signalling Pathway and Promotes EMT in Lung Adenocarcinoma - PDF(Slides)

P1.12. Mechanism of Osteopontin Mediating Targeted Therapy Induced Interstitial Lung Disease Through Integrin αVβ3/Prostaglandin E2 - PDF(Slides)

P1.12. LP-184, a Tumor Site Activated Small Molecule Acylfulvene, Is Effective Preclinically in Subsets of Lung Cancer - PDF(Slides)

P1.12. In Vivo Efficacy of AZD9592, an EGFR-cMET Bispecific ADC, in a Broad Panel of NSCLC Patient-Derived Xenograft Models - PDF(Slides)

P1.12. Combining Anti-HER3 Antibody, HMBD-001, with EGFR Inhibition and Chemotherapy may Improve Treatment Outcomes in SqNSCLC - PDF(Slides)

P1.12. BiFeO3@PANI Sensitizes LKB1-Deficient LUAD to Radiotherapy via Induction of Tumoral Lipid Oxidation and Ferroptosis - PDF(Slides)

P1.12. Ferroptosis-induction Therapy Combined with Super-enhancers Inhibitors Selectively Target NRF2-activated Lung Cancer - PDF(Slides)

P1.12. Characterization of MET Exon 14 Skipping Analog (Y1003) in Non-Small Cell Lung Cancer (NSCLC) - PDF(Slides)

P1.12. APC-1, A Novel Aptamer-Cisplatin Conjugate, Exhibits Promising Anti-tumor Effect in Lung Cancer - PDF(Slides)

P1.12. Sensitization of Cancer Cells to Tumor Treating Fields (TTFields) via Inhibition of the PI3K/AKT Signaling Pathway - PDF(Slides)

P1.13. Deep Multi-omic Blood-Based Biomarker Discovery in People with Smoking History Demonstrates High Early Detection of Nsclc - PDF(Slides)

P1.13. Proof-of-mechanism for a Diagnostic Probe Generating D5-Ethanol Asan On-Breath Reporter Molecule for Lung Cancer - Evolution Phase 1. - PDF(Slides)

P1.13. The LuCID Study: Detection of Lung Cancer Breath Biomarkers via Breath Biopsy in a Multi-Centre Trial - PDF(Slides)

P1.13. Targeting SGLT2 for Early Diagnosis of Lung Adenocarcinoma - PDF(Slides)

P1.13. Plasma Cell-free RNA Sequencing Enables Sensitive Detection of Lung Cancer - PDF(Slides)

P1.13. A Novel Blood-Based DNAMethylation Panel for Detection of Lung Cancer at Very Early Stage - PDF(Slides)

P1.13. Detection of Lung Cancer in People Without a Smoking History Using Exhaled Breath as an Exogenous Probe - PDF(Slides)

P1.13. A Multi-Stage Imaging-Based Deep Learning Classifier for EGFR-TKI Response Prediction in EGFR mutant Non-small Cell Lung Cancer - PDF(Slides)

P1.14. Strengthening the Screening of Lung Cancer in Europe (SOLACE) Project - PDF(Slides)

P1.14. Validation of Lung Cancer Risk Prediction Models in an Asbestos Exposed Population - PDF(Slides)

P1.14. How Do Patients with Screening-Detected Pulmonary Nodules, Experience and React to Being under Surveillance? - PDF(Slides)

P1.14. European Lung Cancer Screening Implementation: 4-IN-THE-LUNG-RUN trial - PDF(Slides)

P1.15. Optimised Lung Cancer Screening to Prevent Cardiovascular and Pulmonary Diseases Coupled with Primary Prevention: Results of the Baseline Round - PDF(Slides)

P1.15. Cardiovascular implications of Lung Cancer Screening Program: The Smokers health Multiple Actions (SMAC) study - PDF(Slides)

P1.15. Dedicated Cardiovascular Screening in Lung Cancer Screening: Preliminary Results from the European 4-IN-THE-LUNG-RUN Trial - PDF(Slides)

P1.15. Awareness, Understanding, and Follow Up of Women with Dense Breasts Identified on Low-Dose CT Screening for Lung Cancer - PDF(Slides)

P1.16. Artificial Intelligence-Assisted Quantitative CT parameters in Predicting the Degree of Risk of Solitary Pulmonary Nodules - PDF(Slides)

P1.16. Three Dimensional Volumetric Analysis Is Useful to Improve Diagnostic Accuracy in Early-Stage Lung Adenocarcinoma. - PDF(Slides)

P1.16. Transbronchial Cryobiopsy Using 1.1 mm-Diameter Cryoprobe for the Diagnosis of Early Stage Lung Cancer - PDF(Slides)

P1.16. Differences in Incidentally Detected Versus Screening Detected Stage I Lung Cancer Surgery Patients - PDF(Slides)

P1.16. Quality Initiative to Improve Timeliness of Care in a Rapid Assessment Lung Cancer Clinic - PDF(Slides)

P1.17. Lung Cancer Screening in Low- and Middle-income Countries - Report on Status, Challenges and Perspectives from WCLC2022 and LALCA2023 - PDF(Slides)

P1.17. Interval of Computed Tomography after Lung Cancer Surgery Follow-Ups Did Not Affect Survival - PDF(Slides)

P1.17. Cost-effectiveness of Low-dose Computerized Tomography Lung Cancer Screening in High-risk Non-smokers and Smokers in Hong Kong - PDF(Slides)

P1.17. Lung-Cancer Screening: Is It Worth Investing? Evidence from a Population-Based Markov Study in Italy - PDF(Slides)

P1.17. Cost-Effectiveness of LDCT Screening in Never Smokers at High Lung-Cancer Risk - PDF(Slides)

P1.17. Integrated TB and Lung Cancer Screening in Viet Nam - PDF(Slides)

P1.17. Impact of Lung Cancer Screening with Low-Dose Chest Computed Tomography Scan in an Elderly Population: A Retrospective Cohort Study - PDF(Slides)

P1.17. Program Factors Associated with the Psychosocial Outcomes of Lung Cancer Screening: A Systematic Review - PDF(Slides)

P1.18. Association between Cognitive Impairment & Lung Cancer Screening Use among People with Significant Smoking History: Population-Based Study - PDF(Slides)

P1.18. Coordinating Lung Cancer Screening with Screening Mammography: The CALM Study - PDF(Slides)

P1.18. First Annual Lung Cancer Screening Day in the United States Saturday November 12 2022 - PDF(Slides)

P1.18. Te Oranga Pūkahukahu: Developing an Indigenous Māori Led Approach to Lung Cancer Screening - PDF(Slides)

P1.18. Barriers to Completing Low Dose CT Scan for Lung Cancer Screening - PDF(Slides)

P1.18. Systematic Enrolment Ensures High Participation Rate in Lung Cancer Screening - Results of Regional Pilot Study in Estonia - PDF(Slides)

P1.19. Pleural Invasion of Primary Lung Cancer Withinterstitial Lung Disease Treated by Surgical Resection. - PDF(Slides)

P1.20. Computed Tomography-based Deep Learning Model for Spread Through Air Spaces Prediction in Ground-Glass Predominant Lung Adenocarcinoma - PDF(Slides)

P1.20. Improved Diagnosis of Lung Neuroendocrine Tumors: Role of Proliferative Activity and Deep Learning - PDF(Slides)

P1.20. Predictability of Actionable Mutations in NSCLC using Attention-Based Multiple-Instance Learning on H&E Images - PDF(Slides)

P1.20. Leveraging NLP to Identify Biomarker-Eligible Patients - PDF(Slides)

P1.20. Mapping the Histopathological Landscape of Lung Adenocarcinoma using Self-Supervised Learning Artificial Intelligence - PDF(Slides)

P1.21. Major Pathologic Response after Neoadjuvant Therapy in NSCLC: Predicting Better Outcomes with High Interobserver Agreement - PDF(Slides)

P1.21. Genetic Susceptibility to Immune Checkpoints Blockade Resistance - PDF(Slides)

P1.21. Upregulation of HLA-I/II and Pro-inflammatory Cells in PBMCs Indicated Efficacy of Neoadjuvant Chemo-immunotherapy in Locally Advanced NSCLC - PDF(Slides)

P1.21. The Upregulated Expression of IGF2BP2 Predicts Poor Prognosis in Lung Adenocarcinoma and Affects Immune Microenvironment and Drug Sensitivity - PDF(Slides)

P1.21. Extracellular Vesicles and Radiomics Predict Durable Response to Immune-Checkpoint Inhibitors in Patients with Non-small Cell Lung Cancer - PDF(Slides)

P1.21. Quantitative Assessment of OX40L and Its Association with Sensitivity to First-Line Pembrolizumab in Non-small-Cell Lung Cancer - PDF(Slides)

P1.21. Eosinophil to Neutrophil Ratio Predicts Efficacy in Patients Receiving Immunotherapy in Metastatic Non-small Cell Lung Cancer (mNSCLC) - PDF(Slides)

P1.21. Radiomic Signature of Identifies Outcome and Prognosis to Immune Checkpoint Inhibitors (ICI) in PD-L1 Low Non-small Cell Lung Cancer (NSCLC) - PDF(Slides)

P1.21. PD-1 and Interleukin-10-Receptor Expression by T Lymphocytes in Malignant and Benign Pleural Effusions - PDF(Slides)

P1.21. Immunotherapy Response Score (IRS) Predicts Pembrolizumab Clinical Benefit in Patients with NSCLC in TPS≥50% - PDF(Slides)

P1.21. Microsatellite Instability Defines a Subset of Lung Cancers with Smoking Exposure, High Tumor Mutational Burden and MLH1 Inactivation. - PDF(Slides)

P1.21. LIPI-based Score Predicting OS Benefit for the Addition of Chemotherapy to Pembrolizumab in aNSCLC with PD-L1 TPS≥50% - PDF(Slides)

P1.21. Prognostic Value of Change in Platelet Volume for Patients with Metastatic Non-small Cell Lung Cancer Treated with Pembrolizumab - PDF(Slides)

P1.21. NSCLC Microenvironment Subtypes Correlate with Response and Survival to Immune Checkpoint Inhibitor Therapy - PDF(Slides)

P1.21. DOT1L Mutations as a Potential Predictor for Immune Checkpoint Inhibitor Efficacy in Non-Small-Cell Lung Cancer - PDF(Slides)

P1.21. Potential Role of Serum Glycoproteomics in Predicting irAEs in NSCLC Patients Treated with Immunotherapy - PDF(Slides)

P1.21. Potential Utilization of Serum Glycoproteomics as a Biomarker to Predict Survival Outcomes and irAEs in Advanced NSCLC Treated with ICI - PDF(Slides)

P1.21. Tertiary Lymphoid Structures Assessed by an AI-powered Analysis of H&E Images is Correlated with Favorable Outcomes of Immunotherapy in NSCLC - PDF(Slides)

P1.21. PD-L1 Expression in Surgically Resected Lung Pleomorphic Carcinoma - One-centre Study of 107 Patients - PDF(Slides)

P1.22. Clinical Characteristics and Biomarkers in Lung Cancer: A Comparison Between Screened and Non-Screened Cohorts - PDF(Slides)

P1.22. Whole Genome Sequencing Analysis of ALK-rearranged Non-small Cell Lung Cancer - PDF(Slides)

P1.22. Ventana ALK (D5F3) Immunohistochemistry Improves the Accuracy of Pathologic Assessment after Neoadjuvant ALK-TKIs for ALK-Positive NSCLC - PDF(Slides)

P1.22. Plasma-First to Accelerate Time to Treatment and Improve Target Detection in Advanced Lung Cancer: A Prospective Study - PDF(Slides)

P1.22. Prevalence of KRAS Subtype Alterations in Non-Small Cell Lung Cancer (NSCLC) with Brain Metastases - PDF(Slides)

P1.22. Patient Experiences of Biomarker Testing: Insights from a Global Patient Experience Survey - PDF(Slides)

P1.22. Predictive Biomarkers of Response to REGN5093 to Guide Patient Selection in MET-Altered Advanced Non-small Cell Lung Cancer - PDF(Slides)

P1.22. Biomarker Testing Trends from a Global Patient-Reported Outcomes Registry - PDF(Slides)

P1.22. Molecular Profiling Reveals Distinct Clinical and Genomic Features as Potential Therapeutic Targets in Pulmonary Spindle Cell Carcinoma - PDF(Slides)

P1.22. RET Fusion (RETfus+) Driven Non-Small Cell Lung Cancer (NSCLC): AComprehensive Genomic Profiling (CGP) Study with Histologic Correlation - PDF(Slides)

P1.22. Comparison of NGS and FISH Platforms to Test MET Amplification in Chinese Lung Cancer Patients: A Prospective Study - PDF(Slides)

P1.22. Nomogram Prediction for the Detection of Epidermal Growth Factor Receptor Mutation in Lung Adenocarcinoma Patients in Indonesia - PDF(Slides)

P1.22. Predominant Solid Patterns in Advanced EGFR Mutated Lung Adenocarcinoma Treated with TKI Is Associated with Worse Outcomes - PDF(Slides)

P1.22. A Phase 3 Multicenter Study to Evaluate the Feasibility of a New NGS Panel Using Cytological Specimens for NSCLC - PDF(Slides)

P1.22. Identification of MIF as a Multiple Primary Lung Cancer Related Gene Based on RNA Sequencing Technology and Study of Its Function - PDF(Slides)

P1.22. ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments - PDF(Slides)

P1.22. Addressing Lung Cancer Biomarker Testing Through the ECHO Model - Results from a 3-State Pilot in the United States - PDF(Slides)

P1.22. Immediate Biomarkers Profiling of Actionable NSCLC Panel from a Digitized H&E Biopsy Image - PDF(Slides)

P1.22. Determination of the Membranous Expression of cMET in Patients with Advanced NSCLC and RET Fusions. - PDF(Slides)

P1.22. High Incidence of Ischemic Stroke in Patients with Non-small cell lung cancer and RET fusions - PDF(Slides)

P1.22. Tertiary Lymphoid Structure Predicts Disease Free Survival in Patients with Resected Lung Adenocarcinoma Harboring Sensitizing EGFR Mutations - PDF(Slides)

P1.23. ctDNA Positivity Is a Clinical Prognosis Biomarker in Patients with EGFR ex20ins+ NSCLC - PDF(Slides)

P1.23. Circulating Tumour DNA as a Predictive Biomarker for Tumour Response and Prolonged Clinical Benefit with Nivolumab in NSCLC - PDF(Slides)

P1.23. Amplicon-Based Liquid Biopsy Prospectively Detects More Tissue-Confirmed Guideline-Recommended Biomarkers in Lung Cancer - PDF(Slides)

P1.23. Extracellular Small Vesicle Phosphorylated PD-L1 Liquid Biopsy Levels Correlate with Tumour Proportion Score (TPS) in NSCLC - PDF(Slides)

P1.23. Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer - PDF(Slides)

P1.23. Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study - PDF(Slides)

P1.23. Clinical Utility of Combined Plasma and Tissue NGS in Patients with Advanced, Treatment-Naïve, Non-small Cell Lung Cancer - PDF(Slides)

P1.23. Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study - PDF(Slides)

P1.24. Mortality Benefit of a 4-Protein Blood-Based Biomarker Panel for Lung Cancer - PDF(Slides)

P1.24. TAT3 Predicts Favourable Prognosis in Advanced Non Small Cell Lung Cancer - PDF(Slides)

P1.24. A Comparative Analysis of Secreted MiRNAs Reveals Candidate Biomarkers for Pleural Mesothelioma Detection - PDF(Slides)

P1.24. The Association of Acinar Pattern with Clinicopathological, Molecular Features, and Prognosis in Lung Adenocarcinoma Patients - PDF(Slides)

P1.24. Prognostic Value of DNA Ploidy and Nucleotyping in Early-stage Non-small Cell Lung Cancer - PDF(Slides)

P1.24. Association between Whole Blood ACTB methylation and Lung Cancer: A Case- Control Study - PDF(Slides)

P1.24. Effect of Gut Microbiome on Metastasis of Non-small Cell Lung Cancer - PDF(Slides)

P1.24. Spatially Defined Immune Response Signatures in 5µm Tumor Section of Resected T1-2N0M0 Lung Cancer Predict Clinical Outcome - PDF(Slides)

P1.24. Clinical Implication of Karyopherin a 2, Which Is a Nuclear Export Protein in Lung Adenocarcinoma - PDF(Slides)

P1.24. Single-Cell Profiling Reveals the Trajectory of FOLR2+TAMs to Tregs in the Progression of Lung Adenocarcinoma - PDF(Slides)

P1.24. Exploring the Stability of Gut Microbiome and Its Association with the Prognosis of NSCLC Treated with Chemoraditherapy - PDF(Slides)

P1.24. Clinicopathological Characteristics of Pulmonary Squamous Cell Carcinoma with KDM5D Copy Number Loss - PDF(Slides)

P1.24. Prognostic Molecular and Genetic Factors in Early Stage Non Small Cell Lung Cancer - PDF(Slides)

P1.24. Discovery of Novel Biomarkers of Small Cell Lung Cancer Using Highly Sensitive Quantitative Proteomic Analysis - PDF(Slides)

P1.24. The Paradoxical Behavior of Kappa When Quantifying Agreement in Histological Subtype Classification among Thoracic Pathologists - PDF(Slides)

P1.25. Real-World Data of Completely Resected Lung Adenocarcinoma Harboring Common EGFR Mutation in Japan (CReGYT-01 EGFR study) - PDF(Slides)

P1.25. Complete Pathologic Response (pCR) as a Surrogate Endpoint in Neoadjuvant Immunotherapy Clinical Trials for NSCLC: A Meta-analysis - PDF(Slides)

P1.25. Comparing Timeliness of Treatment for Surgery vs Radiation for Early-Stage Lung Cancer - PDF(Slides)

P1.25. Days Alive and Out of Hospital After Thoracoscopic Surgery and Exploratory Study the Correlation on the PRO of First Discharge Day - PDF(Abstract)

P1.25. Real-World Outcomes in Non-metastatic Non-small Cell Lung Cancer (NSCLC): An I-O Optimise Multi-Country Analysis - PDF(Slides)

P1.25. Prevalence of EGFR Mutations in Patients with Resected Stage I-III NSCLC: Results of the Asian Cohort of EARLY-EGFR - PDF(Slides)

P1.25. Surgical Outcomes in Patients with Resected Node-negative Lung Adenocarcinoma of 2 cm or Smaller - PDF(Slides)

P1.25. TARGET: A Phase II Study of 5-year Adjuvant Osimertinib in Completely Resected EGFR-mutated Stage II-IIIB NSCLC - PDF(Slides)

P1.25. Delays to Early-Stage Lung Cancer Surgery: Patient and Surgeon Perspectives - PDF(Slides)

P1.25. Phase 2 Trial of Neoadjuvant Camrelizumab Plus Chemotherapy or Apatinib for Resectable or Potentially Resectable NSCLC - PDF(Slides)

P1.25. Adequacy of Mediastinal Lymph Node Dissection in the Setting of New NCCN Guidelines: Simplified Method From A Rural Hospital - PDF(Slides)

P1.25. Enhanced Assessment Of Recurrence Risk Of Stage I NSCLC By Combined Adenocarcinoma Grading System And Serum Proteomic Testing - PDF(Slides)

P1.25. Delayed Recovery Time of Percutaneous Oxygen Saturation After Stair-climbing as a Predictor of Postoperative Complications - PDF(Slides)

P1.25. Trends and Disparities in Curative-Intent Treatment for Early-Stage Non-Small Cell Lung Cancer: A Population-Based Analysis of Surgery and SBRT - PDF(Slides)

P1.25. Outcomes by Age with Neoadjuvant Atezolizumab Treatment for Resectable Non-small Cell Lung Cancer in the Phase 2 LCMC3 Study - PDF(Slides)

P1.25. Stereotactic Ablative Body Radiotherapy for Early NSCLC: Changes in Pulmonary Function, Dyspnoea and Quality of Life - PDF(Slides)

P1.25. Prognostic Impact of Exon20 Insertion in Surgically Resected Lung Adenocarcinoma Harboring Atypical EGFR Single Mutation - PDF(Slides)

P1.25. Patient-Reported Outcomes and Exercise Capacity in a Real-Life Setting in Non-small Cell Lung Cancer Patients Undergoing Radiotherapy - PDF(Slides)

P1.26. A Real World Study of Perioperative Outcomes after Minimally Invasive Segmentectomy versus Lobectomy for Early-Stage Lung Cancer - PDF(Slides)

P1.26. Random Matrix Based Multiple Scattering Component Extraction Can Significantly Shorten the Time of Lung Segmentectomy - PDF(Slides)

P1.26. Retrospective Comparison of Robotic- and Video-assisted Thoracic Surgery after Neoadjuvant Therapy for Non-small Cell Lung Cancer - PDF(Slides)

P1.26. Increased Risk of Death from Other Causes After Lobectomy Compared with Sublober Resection in Lung Cancer Patients - PDF(Slides)

P1.26. Sublobar Resection is Equivalent to Lobectomy for Stage IA Adenocarcinoma Presenting as Subsolid Nodule - PDF(Slides)

P1.26. Harmonized Maximum Standardized Uptake Value as an Indicator for Sublobar Resection: A Multicenter Retrospective Study - PDF(Slides)

P1.26. Trisegmentectomy is Indicated for Non-Small Cell Lung Cancer in the Left Upper Division - PDF(Slides)

P1.26. Usefulness and Safety of Chest Tube Removal Regardless of Drainage Volume of Pleural Effusion in Patients Who Underwent Pulmonary Resection - PDF(Slides)

P1.26. Wedge Resection vs. Segmentectomy for NSCLC Size ≤2 CM, Consolidation Tumor Ratio >0.25, cN0: A Multicenter Propensity-Score Matching Analysis - PDF(Slides)

P1.26. Is Mediastinal Lymph Node Dissection Necessary in Segmentectomy for Peripheral Stage IA (≤2 CM) Non-small-Cell Lung Cancer? - PDF(Slides)

P1.27. Comparison of Physical and Mental Load Between VATS and RATS Based on NASA-Task Load Index: A Prospective Cohort Study - PDF(Slides)

P1.27. Artificial Intelligence Analysis Predicts Highly Malignant Potential in Small-Sized Lung Adenocarcinoma - PDF(Slides)

P1.27. Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis - PDF(Slides)

P1.27. Phase II Basket Trial of Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (DART) SWOG S1609: Bronchioloalveolar Carcinoma of the Lung - PDF(Slides)

P1.27. Two- and Three-dimensional Radiomic Measurements for Clinical Stage IA Lung Adenocarcinoma: Less is More - PDF(Slides)

P1.27. Construction of Postoperative Prediction Model Based on the New IASLC Grading System for Early Stage Lung Adenocarcinoma - PDF(Slides)

P1.27. BRAF Mutations Identify Non-small-Cell Lung Cancer Patients Who Benefit from Neoadjuvant Chemo-Immunotherapy - PDF(Slides)

P1.27. Immunotherapy versus Chemotherapy in the Management of Resectable Non-Small Cell Lung Cancer: A Meta-Analysis of Randomized Clinical Trials - PDF(Slides)

P1.27. Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I NSCLC with High-grade Patterns and EGFR Mutations (APPOINT) - PDF(Slides)

P1.27. NEOIPOWER: Icotinib plus Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-IIIB EGFR-mutant Lung Adenocarcinoma - PDF(Slides)

P1.28. Adherence to Post-treatment Surveillance Guidelines in Non-small Cell Lung Cancer - A Veteran’s Health Administration Cohort - PDF(Slides)

P1.28. EVs-miRNAs-Based Models in Predicting Radiosensitive Patients with Local Advanced-NSCLC Who Can Benefit from Adaptive Radiotherapy - PDF(Slides)

P1.28. Adjuvant CCRT Does Not Improve Survival Outcomes in Patients with ECE Positive Pathologic Stage III-N2 NSCLC After Upfront Surgery - PDF(Slides)

P1.28. Should Older Patients with Stage Iii Non-small-Cell Lung Cancer Be Treated with Concurrent Chemoradiotherapy? - PDF(Slides)

P1.28. Cessation of Marrow Proliferation on FLT-PET with Low RT Doses During ChemoRT for NSCLC Correlates with Lymphocyte Decline - PDF(Slides)

P1.28. Treatment Strategies for Locally-advanced NSCLC with Invasive T4 Tumors: A SEER Analysis in the Era of Precision Medicine - PDF(Slides)

P1.28. Dose-Response Relationship Between Radiotherapy and Loss in Lung Perfusion Determined From DECT and PET/CT in NSCLC - PDF(Slides)

P1.28. Definition of Resectable Stage III Non-Small Cell Lung Cancer: A Systematic Review from EORTC Lung Cancer Group - PDF(Slides)

P1.28. Definition of Resectable Stage III Non-small Cell Lung Cancer (NSCLC): A Clinical Case Review by a Pan-European Expert Panel - PDF(Slides)

P1.28. Differential Kinetics of Blood and Immune Subpopulations for Cisplatin vs. Sensitizing Paclitaxel Radiotherapy in Locally Advanced Lung Cancer - PDF(Slides)

P1.28. Recurrence Dynamics for Pathological N2 Non-small Cell Lung Cancer depending on the IASLC Residual Tumor Descriptor - PDF(Slides)

P1.28. Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy - PDF(Slides)

P2.01. Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT - PDF(Slides)

P2.01. Efficiency and Survival Data of Neoadjuvant PD-1 Inhibitor Combined With Chemotherapy in Potentially Resectable IIIA or IIIB NSCLC - PDF(Slides)

P2.01. An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC - PDF(Slides)

P2.01. The Safety and Efficacy of Induction Chemoimmunotherapy Followed by Radiotherapy and Consolidation Immunotherapy in Locally Advanced NSCLC - PDF(Slides)

P2.01. NAUTIKA1 Study: Preliminary Efficacy and Safety Data with Neoadjuvant Alectinib in Patients with Stage IB-III ALK+ NSCLC - PDF(Slides)

P2.01. Restoring Lymphocytes Using NKTR-255 after Chemoradiotherapy in Solid Tumors (RESCUE) - PDF(Slides)

P2.02. PROphylactic Pirfenidonefor Prevention of Radiation Induced Pneumonitis in Patients with Lung Cancer(PROPeR study) - PDF(Slides)

P2.02. Pneumonitis Rates Before Versus After Adoption of Immunotherapy Consolidation for Locally Advanced Non-Small Cell Lung Cancer - PDF(Slides)

P2.02. Neoadjuvant Immunotherapy Related Pneumonitis in Non-Small Cell Lung Cancer Patients: Incidence, Risk Factors, and Management - PDF(Slides)

P2.02. Comprehensive Pneumonitis Assessment Among Inoperable Stage III NSCLC Patients Treated with Chemoradiotherapy-Immunotherapy Regimen - PDF(Slides)

P2.03. Effectiveness and Safety of Combining Bevacizumab and Fractionated Stereotactic Radiotherapy for Brain Metastases in NSCLC Patients - PDF(Slides)

P2.03. Hybrid Immuno-RT (EclipseRT) for Bulky Tumors: Low-Dose Radiotherapy with Partial Tumor SBRT in Mice and Patients - PDF(Slides)

P2.03. Upfront or Delayed Cranial RT in Oncogene Mutated NSCLC with Asymptomatic Brain Metastases: A Phase III Randomized Controlled Trial - PDF(Slides)

P2.03. Predicting Risk of Distant Brain Failure with Radiosurgery and Systemic Therapy in a Diverse NSCLC Brain Metastasis Population - PDF(Slides)

P2.03. Clinical Impact of Genomic Characterization in Induced Oligometastatic Non-small Cell Lung Cancer - PDF(Slides)

P2.03. Treatment-related Pneumonitis in Non-small Cell Lung Cancer Treated with Thoracic RT plus TKI: A Systematic Review and Meta-Analysis - PDF(Slides)

P2.04. AVANZAR: Phase III Study of Datopotamab Deruxtecan (Dato-DXd) + Durvalumab + Carboplatin as 1L Treatment of Advanced/mNSCLC - PDF(Slides)

P2.04. EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours - PDF(Slides)

P2.05. Clinical impact of TTF-1 for Combined Chemoimmunotherapy Efficacy in Lung Adenocarcinoma: A Multicenter Prospective Study - PDF(Slides)

P2.05. MAPK1/MAPK3 Mutations Enhance Immunotherapy Efficacy in Lung Squamous Cell Carcinoma (LSCC): Results of the SQUINT Trial - PDF(Slides)

P2.05. Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort - PDF(Slides)

P2.05. Pharmacokinetics of Cemiplimab in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) - PDF(Slides)

P2.05. Genomic Variants Associated with Response to Immune Checkpoint Inhibitors Amongst Asian Patients with Advanced NSCLC - PDF(Slides)

P2.05. An Artificial Neural Network System to Predict the Immune-related Adverse Events Based on the RNA Data of ORIENT-3 Study - PDF(Slides)

P2.05. Immunotherapy Prognostication with Thoracic CT Contrastive Self-Supervised Learning in Patients with Non-Small Cell Lung Cancer - PDF(Slides)

P2.05. SIPS as a Prognostic Biomarker within Performance Status in Advanced Lung Cancer Patients Treated with Pembrolizumab - PDF(Slides)

P2.05. The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome - PDF(Slides)

P2.05. Serum Metabolomics to Determine Survival of Immunotherapy for Advanced Non-small Cell Lung Cancer: Metabolomic Analysis Based on Two Cohorts - PDF(Slides)

P2.05. Full Spectrum Flow Cytometry-powered Analysis of PBMC as Biomarkers for Immunotherapy in NSCLC with EGFR-TKI Resistance - PDF(Slides)

P2.05. Canakinumab with Standard of Care for Patients with Advanced NSCLC: T-cell Infiltration Analysis in CANOPY-1 - PDF(Slides)

P2.05. Understanding Genomic and Social Determinants of Cancer Immunotherapy Outcome across Ancestry - PDF(Slides)

P2.05. Distinct EGFR-driven Co-mutation Patterns Influence Atezolizumab Efficacy in NSCLC: Results from POPLAR and OAK Trials - PDF(Slides)

P2.05. Immune Suppressive Microenvironment in Liver Metastases Contributes to Organ-Specific Response of Immunotherapy - PDF(Slides)

P2.05. A Novel Autoantibodies Panel Predicted the Prognosis of Advanced Non-Small Cell Lung Cancer Receiving Anti-PD1 Combined With Chemotherapy - PDF(Slides)

P2.05. A Seven-Lnc RNA Signature for Prognosis Prediction of Patients with Lung Squamous Cell Carcinoma through Tumor Immune Escape - PDF(Slides)

P2.05. Prediction of Durable Response to Immunotherapy by Early Dynamic in ctDNA and Peripheral Immune Features in NSCLC - PDF(Slides)

P2.06. Cemiplimab-Based Treatment in Advanced NSCLC With Liver Metastases: Updated Analysis From EMPOWER-Lung 1 and EMPOWER-Lung 3 - PDF(Slides)

P2.06. DEnosumab plus PD-1 Inhibitor for MAINtenance Therapy of Advanced KRAS-Mutant NSCLC - A Prospective, Single-Arm, Phase II Study (DEMAIN) - PDF(Slides)

P2.06. Updated Analysis of Tislelizumab Plus Chemotherapy as First-Line Treatment for Elderly Advanced NSCLC Patients - PDF(Slides)

P2.06. First-Line Camrelizumab Plus Chemotherapy for Advanced Non-squamous NSCLC with Brain Metastases: Updated Data from CAP-BRAIN - PDF(Slides)

P2.06. Durvalumab ± Tremelimumab + Chemotherapy in 1L Metastatic NSCLC: Characterisation of patients with PFS ≥12 months in POSEIDON - PDF(Slides)

P2.06. Study Design to Assess Anti-TIGIT Mab Combination with Dostarlimab vs Pembrolizumab or Dostarlimab Monotherapy in NSCLC - PDF(Slides)

P2.06. PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901) - PDF(Slides)

P2.06. Phase I/II Study of Rucaparib and Pembrolizumab Maintenance in Stage IV NSCLC after Carboplatin, Pemetrexed, Pembrolizumab - PDF(Slides)

P2.06. Association of Clinical Response and HRQoL with Long-Term Survival with 1L Nivolumab + Ipilimumab in mNSCLC in CheckMate 227 - PDF(Slides)

P2.06. Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1 - PDF(Slides)

P2.06. Camrelizumab Plus Apatinib as First-Line Treatment for Advanced Squamous Non-small-Cell Lung Cancer: Updated Survival Results of a Phase 2 Trial - PDF(Slides)

P2.06. The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2 - PDF(Slides)

P2.07. Development of Postoperative Bronchopleural Fistula after Neoadjuvant Immunochemotherapy in Non-small Cell Lung Cancer: Case Reports - PDF(Slides)

P2.07. Association between OS and Subsequent ICI in Control Arm Patients of First Line ICI-based RCTs of Advanced/Metastatic NSCLC: FDA Analysis - PDF(Slides)

P2.07. Factors Associated with Disease Progression after Discontinuation of Immunotherapy for Immune-Related Toxicity in Non-small Cell Lung Cancer - PDF(Slides)

P2.07. Genomic Subtypes of EGFR-Mutant NSCLC and Real-World Progression-Free Survival (rwPFS) with Immunotherapy (IO) - PDF(Slides)

P2.07. Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry - PDF(Slides)

P2.07. Real World Efficacy of First-Line Immunotherapy +/- Chemotherapy in Advanced NSCLC Stratified by Serum Proteomics - PDF(Slides)

P2.07. Association of Completing 35 Cycles of Pembrolizumab and Further Progression-Free Survival among Durable Progression-Free Survivors - PDF(Slides)

P2.07. Checkpoint Inhibitor Pneumonitis Model for NSCLC based onPreexistingLung Ground Glass Opacities: Development and Validation - PDF(Slides)

P2.07. Stage 3 NSCLC Patients Progressing After Concurrent Chemo-Radiotherapy and Durvalumab- is There a Role for Another IO? - PDF(Slides)

P2.08. TROPION-Lung08: Datopotamab Deruxtecan Plus Pembrolizumab in Untreated Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC) - PDF(Slides)

P2.08. STAR-121: Phase 3 Study of DOM and ZIM plus Chemo vs Pembro plus Chemo in 1L mNSCLC with No Actionable Gene Alterations - PDF(Slides)

P2.08. A Phase 2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, Alone or in Combination with Nivolumab - PDF(Slides)

P2.08. A Phase 1/2 Dose Escalation and Dose Expansion Study of Ozuriftamab Vedotin (BA3021) Alone and in Combination with Nivolumab - PDF(Slides)

P2.08. IMRPrinter: A Phase 1/1b Trial of IMU‑201 (PD1-Vaxx) as Monotherapy or in Combination with Atezolizumab +/- Chemotherapy in NSCLC - PDF(Slides)

P2.08. A Phase II Study of Subcutaneous (SC) Atezolizumab in NSCLC Patients Using a Decentralized Clinical Trial Model - PDF(Slides)

P2.08. EDGE-Lung: A Phase 2 Open-Label Platform Study to Evaluate Immunotherapy-Based Combinations in Patients with Metastatic NSCLC - PDF(Slides)

P2.09. A Large Asian Real-World EGFR exon 20Insertion Mutated NSCLC Dataset with Deep Genomic Characterization - PDF(Slides)

P2.09. Lazertinib vs Gefitinib in Treatment-Naïve Patients with EGFR-mutated NSCLC: LASER301 Asian Subpopulation Analysis - PDF(Slides)

P2.09. Treatment Adherence Disparities and Clinical Outcomes of Osimertinib among Ethnic-Minority Patients with EGFR-Mutated NSCLC - PDF(Slides)

P2.09. Identification of Co-existing Genetic Alterations in Advanced Stage EGFR mutated NSCLC at Baseline and Disease Progression - PDF(Slides)

P2.09. Efficacy and Safety of Aumolertinib as Second- Or Third-Line Therapy in EGFR T790M Negative/Unknown Non-small Cell Lung Cancer - PDF(Slides)

P2.09. Safety and Efficacy of Aumolertinib in Patients with advanced NSCLC Harboring Uncommon EGFR Mutations: Cohort 2 Updated - PDF(Slides)

P2.09. Gefitinib Maintenance After Definitive CCRT in EGFR mutant Stage III NSCLC: Single Arm, Open Label, Multicenter Phase 2 Trial - PDF(Slides)

P2.09. A Phase 1, 2 Study to Evaluate the Safety and Anti-tumor Activity of JIN-A02 in Patients with EGFR Mutant Advanced NSCLC - PDF(Slides)

P2.09. JIN-A04, Highly Effective and Brain-penetrant Tyrosine Kinase Inhibitor Targeting HER2 Exon20 Insertion Mutations in NSCLC - PDF(Slides)

P2.09. Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations - PDF(Slides)

P2.09. QT-interval Prolongation and Torsades de Pointes With EGFR TKIs in NSCLC: Targeted Literature Review - PDF(Slides)

P2.09. Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations - PDF(Slides)

P2.09. Real World Efficacy and Safety of Sotorasib in U.S. Veterans with KRAS G12C Mutated Non-Small Cell Lung Cancer - PDF(Slides)

P2.09. Aumolertinib Combined Intrathecal Chemotherapy for LM from EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles - PDF(Slides)

P2.09. OSTARA: A Phase II Study of First-line Osimertinib Combined with Amivantamab in EGFRm Advanced Non-Small Cell Lung Cancer - PDF(Slides)

P2.09. FURVENT, Phase 3 Trial Testing Furmonertinib vs Chemotherapy as First-Line Treatment for Advanced NSCLC with EGFR exon 20 Insertions - PDF(Slides)

P2.09. Increased Dose of Aumolertinib Rechallenge in Advanced NSCLC with Gradual Progression - PDF(Slides)

P2.09. VRN110755, A New Therapeutic Option for EGFR Mutation-Driven NSCLC with Brain Metastasis or 1st-line Osimertinib-Resistant EGFR Mutations - PDF(Slides)

P2.09. A Multicentre, Real-World Observational Study of First-Line Osimertinib and Post Progression Patterns in EGFR Positive NSCLC (Reiwa Study) - PDF(Slides)

P2.09. Risk of Recurrent Interstitial Lung Disease (ILD) from EGFR TKI Rechallenge after Osimertinib Induced ILD - PDF(Slides)

P2.09. Inhibition of AXL and Mcl-1 Contributes to Eradicating Tolerance to EGFR-TKI Lazertinib in Lung Cancer Cells Expressing Mutant EGFR - PDF(Slides)

P2.09. Trials in Progress: Phase 1a/b study of ELVN-002, in Solid Tumors with HER2 Mutations, Amplification or Overexpression - PDF(Slides)

P2.09. Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC) - PDF(Slides)

P2.09. Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY) - PDF(Slides)

P2.09. Enhanced in Vivo Efficacy of Mobocertinib and Amivantamab Combination in EGFR ex20ins+ NSCLC PDX Models - PDF(Slides)

P2.09. A Phase II Trial of Anlotinib Plus Osimertinib in Advanced NSCLC with EGFR T790M Mutation After Failure of Prior EGFR TKIs - PDF(Slides)

P2.09. Design, Synthesis and Assessment of Novel Molecule against Drug-Resistant Dual Mutant EGFR (T790M/L858R) to Treat NSCLC - PDF(Slides)

P2.09. Amivantamab vs Real World Therapies for Advanced NSCLC with EGFR Exon20ins in China - PDF(Slides)

P2.09. Efficacy and Safety of Furmonertinib 160 mg as First-line Therapy for EGFR-mutated Advanced NSCLC Patients with CNS Metastases - PDF(Slides)

P2.09. Combined Multi-omics Explore the Resistance Mechanism of Third-generation EGFR-TKI BPI-7711 - PDF(Slides)

P2.09. MRI Radiomics Approach to Predict the Intracranial Efficacy of the Third Generation EGFR-TKI Osimertinib in NSCLC Patients with Brain Metastases - PDF(Slides)

P2.09. Racial Diversity and Co-Mutational Analysis of Biologically Relevant Alterations in EGFR Mutant Lung Cancers - PDF(Slides)

P2.09. Efficacy of Anlotinib in T790M-positive NSCLC Patients with Osimertinib Resistance: A Retrospective and Exploratory Study - PDF(Slides)

P2.09. Phase I/II Study Exploring Safety and Efficacy of Apl-101 Plus Frontline Osimertinib in EGFR-mutated Metastatic Non-small Cell Lung Cancer - PDF(Slides)

P2.09. Aumolertinib Combined with Carbamazepine and Intrathecal Pemetrexed for EGFR-mutated LM NSCLC with Symptomatic Epilepsy - PDF(Slides)

P2.10. ALKTERNATE: A Pilot Study Alternating Lorlatinib with Crizotinib in Patients with ALK+ NSCLC and ALK-inhibitor Resistance - PDF(Slides)

P2.10. Liquid Biopsy-based Umbrella Trial for Advanced NSCLC: Results of Phase 2 Plasma ALK-positive Cohort (A-Liquid) - PDF(Slides)

P2.10. Mechanisms of Acquired Resistance to ALK Inhibitors Using Plasma Sequencing - Preliminary Data from the ATORG004 Study - PDF(Slides)

P2.10. Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors - PDF(Slides)

P2.10. Cost of Managing Brain Metastases in Patients with ALK+ aNSCLC with First-Line Tyrosine Kinase Inhibitors (TKIs) in the UK - PDF(Slides)

P2.10. Brain Metastases in Patients with Fusion-Positive Lung Cancers - PDF(Slides)

P2.10. ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases - PDF(Slides)

P2.10. Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study - PDF(Slides)

P2.10. Co-occurring Loss of CDKN2A/2B Associated with Worse Survival and Increase Risk of Brain Metastasis in ALK-Rearranged Non-small Cell Lung Cancer - PDF(Slides)

P2.10. Comparative Effectiveness Analysis of Selpercatinib versus Standard Therapy in Patients with Non-small Cell Lung Cancer - PDF(Slides)

P2.10. Loss of EPHA2 Induces Primary Lorlatinib Resistance Through Sustained MAPK Activation - PDF(Slides)

P2.10. Characteristics and Outcomes of Hispanic Patients with RET-Fusion Positive NSCLC Treated in Real-World Practice - PDF(Slides)

P2.10. First-line (1L) Lorlatinib in Patients with ALK-Positive aNSCLC: Updated Network Meta-Analysis (NMA) and Review of Ten NMAs - PDF(Slides)

P2.10. Correlation Between Clinical and Health-related Quality-of-Life (HRQoL) Benefits in Patients With ALK+ NSCLC in ALTA-1L - PDF(Slides)

P2.11. A Phase II Study of Tepotinib in Advanced Solid Cancers with MET exon 14 Skipping Mutation or Amplification; Results of Non-small Cell Lung Cancer - PDF(Slides)

P2.11. Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION - PDF(Slides)

P2.11. Synergistic Co-Targeting Of MYC And KRAS In Lung Cancer By Novel Ligand-Directed Inverted Chimeric RNAi Molecules - PDF(Slides)

P2.11. A Phase 1B Trial of Tarloxotinib and Sotorasib in Lung Cancer Patients with KRAS G12C Mutations - PDF(Slides)

P2.11. SHERLOCK: Phase II Trial of Upfront Sotorasib with Chemotherapy and Bevacizumab for Advanced NSCLC with KRASG12C Mutation - PDF(Slides)

P2.12. Tumor Microenvironment Remodeling Contributes to the Resistance to EGFR-TKI in EGFR-mutated Non-small Cell Lung Cancer - PDF(Slides)

P2.12. Beware: Tyrosine Kinase Inhibitors for Lung Cancers that Inhibit MATE-1 can Lead to "False” Decreases in Renal Function - PDF(Slides)

P2.12. Cerebrospinal Fluid is an Alternative Medium of Liquid Biopsy for Patients with Brain Parenchymal Metastases from Non-Small Cell Lung Cancer - PDF(Slides)

P2.12. Real-World Data of Biomarker Diagnostics, Treatment Strategy, and Survival Outcome with Advanced or Recurrent NSCLC in Japan - PDF(Slides)

P2.12. Treatment Patterns and Clinical Outcomes in Patients with EGFR-mutant NSCLC after Progression on First-Line Osimertinib - PDF(Slides)

P2.12. Phase II Trial of LP-300 + Pemetrexed/Carboplatin in Patients Who Never Smoked with Lung Adenocarcinoma After TKI Progression - PDF(Slides)

P2.12. Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon Mutations - PDF(Slides)

P2.12. Targeted and Immunotherapy Associated Cardiotoxicity in Stage IV Lung Cancer Patients with and without Cardiac Comorbidities - PDF(Slides)

P2.13. Spatially Resolved Transcriptomics deciphers Inter- and Intra-Tumor Heterogeneity of Small Cell Lung Cancer - PDF(Slides)

P2.13. Molecular Subtyping of Small Cell Lung Carcinoma: An Attempt at Unravelling Its Biological Heterogeneity - PDF(Slides)

P2.13. Genomic Associations of Chemoimmunotherapy Outcomes in a Real-World Cohort of Small Cell Lung Cancer (SCLC) Patients - PDF(Slides)

P2.13. Pathological Images Machine Learning Predicts Long Term Effects for Immunotherapy in Small-Cell Lung Cancer - PDF(Slides)

P2.13. Spatiotemporal Heterogeneity of Transcription Factor-Based Subtype Assignment in Small Cell Lung Carcinoma - PDF(Slides)

P2.13. A Novel Clinical Scoring System (EAST score) for the Prediction of Treatment Response in Limited-Stage Small-Cell Lung Cancer - PDF(Slides)

P2.13. Biomarkers for Predicting the Efficacy of PD-L1 Inhibitors Combined with Chemotherapy in ES-SCLC - PDF(Slides)

P2.13. Integrated Clinical and Radiomics Approach to Assess the Treatment Outcome of Combined Chemoimmunotherapy in Extensive-Stage SCLC - PDF(Slides)

P2.14. Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC - PDF(Slides)

P2.14. First-Line Envafolimab plus Carboplatin-etoposide in Extensive-Stage Small-Cell Lung Cancer: a Single-Arm Phase II Study - PDF(Slides)

P2.14. Outcomes of Chemoimmunotherapy in Patients with ES-SCLC According to Liver Metastasis: A Multicenter Prospective Cohort Study - PDF(Slides)

P2.14. Treatment Beyond Progression with Atezolizumab in Extensive-Stage SCLC: Exploratory Analysis from the IMfirst Study - PDF(Slides)

P2.14. A Phase II Study of Sintilimab Combined with Concurrent Chemoradiotherapy in Patients with Limited-Stage Small Cell Lung Cancer:SINCE-01 Trial - PDF(Slides)

P2.14. Updated Results of Camrelizumab Plus Nab-Paclitaxel and Carboplatin as First-Line Treatment for ES-SCLC: A Phase II Trial - PDF(Slides)

P2.15. Priming SCLC Vasculature to Facilitate NK Cell Attack - PDF(Slides)

P2.15. Distinct Tumor Microenvironment in SCLC as compared with NSCLC by Single Cell Analysis - PDF(Slides)

P2.16. Sintilimab in Combination With Carboplatin/Cisplatin and Etoposide in the Treatment of Patients with Previously Untreated ES-SCLC - PDF(Slides)

P2.16. Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-Stage Small Cell Lung Cancer: PEERS Phase 2 Trial - PDF(Slides)

P2.16. RYZ101 + Carboplatin + Etoposide + Atezolizumab in Somatostatin Receptor Expressing Extensive-Stage Small-Cell Lung Cancer - PDF(Slides)

P2.16. Assessment of the Efficacy and Safety of Durvalumab Associated with Platinum-Etoposide in Previously Untreated ES-SCLC in Brazil - PDF(Slides)

P2.16. Durvalumab+EP in Advanced Large-Cell Neuroendocrine Carcinoma of Lung (aLCNEC): a Pilot Phase II study - PDF(Slides)

P2.16. A Phase 2 Study of Ifinatamab Deruxtecan (I-DXd; DS-7300) in Patients with Previously Treated ES-SCLC - PDF(Slides)

P2.17. Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer - PDF(Slides)

P2.17. EFfectiveness and Safety Profile of Lurbinectedin in Second-Line Small Cell Lung Cancer: A Real-World Study - PDF(Slides)

P2.17. CAN: A Phase II Trial of Combination of Niraparib and Anlotinib in Patients with Recurrent Small Cell Lung Cancer - PDF(Slides)

P2.17. Anti-PD-L1 Therapy Failed to Reduce the Risk of Developing Brain Metastases in Patients with ES-SCLC - PDF(Slides)

P2.17. Characterizing Mechanisms of Treatment Resistance in SCLC - PDF(Slides)

P2.17. Efficacy of Platinum after Lurbinectedin + DOX or Topotecan/CAV in Sensitive Relapsed SCLC Patients in the ATLANTIS Trial - PDF(Slides)

P2.17. Real-world Safety and Dosing of Lurbinectedin-Treated Patients with Small Cell Lung Cancer: Jazz EMERGE 402 Preliminary Analysis - PDF(Slides)

P2.18. Successful Generation of Tumor-Infiltrating Lymphocytes (TIL) for Adoptive Cell Therapy from Mesothelioma - PDF(Slides)

P2.18. Impact of Inclusion of Immunotherapy in National Treatment Guidelines on Survival Outcomes in Malignant Pleural Mesothelioma - PDF(Slides)

P2.18. Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso) - PDF(Slides)

P2.18. Impact of Evolving Treatment Paradigms on Survival Outcomes in Advanced Pleural Mesothelioma: A Real-World Analysis - PDF(Slides)

P2.18. Co-designing an Experience of Care and Quality of Life Survey for an Australian Mesothelioma Clinical Outcomes Registry - PDF(Slides)

P2.19. First-in-Human Phase 1 Trial of VT3989, a First-in-Class YAP/TEAD Inhibitor in Patients with Advanced Mesothelioma - PDF(Slides)

P2.19. [DREAM] Double Lung Transplant Registry Aimed for Lung-Limited Malignancies - A Prospective Registry Study for Medically Refractory Cancers - PDF(Slides)

P2.20. A Precision Medicine Approach by Performing Comprehensive Cancer Genome Profiling of Thymomas and Recurrent Thymomas - PDF(Slides)

P2.20. Thymomatous Myasthenia Gravis after Total Thymectomy at a Tertiary-Care Surgical Centre: a 20-Year Retrospective Review - PDF(Slides)

P2.20. Clinical Outcome of Patients with Thymic Carcinoma Treated with Preoperative Induction Therapy Followed by Surgical Resection - PDF(Slides)

P2.20. Differential Expression of Genes in Type A and B3 Thymomas and Thymic Carcinomas - PDF(Slides)

P2.20. The Impact of Preoperative Immunotherapy On Peri-Operative Outcomes After Thymectomy for Thymic Epithelial Tumors - PDF(Slides)

P2.20. Does Radical Thymectomy Influence the Neurological Outcome in Patients Aged over 65 with Thymoma and Myasthenia Gravis? - PDF(Slides)

P2.21. Inflammatory Biomarkers as Prognostic Factors for Malignant Pleural Mesothelioma - PDF(Slides)

P2.21. A Combination of PD-1 and TIGIT Checkpoint Blockade Elicits a Strong Antitumor Response in the Patient and Mouse Pleural Mesothelioma Model - PDF(Slides)

P2.21. Novel microRNAs are Associated with Presence of Pleural Mesothelioma and Response to Chemotherapy - PDF(Slides)

P2.21. The Significance of BAP1 and MTAP/CDKN2A Expression in Well-Differentiated Papillary Mesothelial TUmour: A Series of 21 Cases - PDF(Slides)

P2.21. CD47 as Biomarker of Prognosis in Patients with Malignant Pleural Mesothelioma - PDF(Slides)

P2.21. Characterization of the Genomic and Immune Landscape of Malignant Pleural Mesothelioma - PDF(Slides)

P2.21. A Novel Proteomic Technique Uncovers New Diagnostic Biomarkers for Malignant Pleural Mesothelioma - PDF(Slides)

P2.21. Mutant NF2-Driven De Novo Pyrimidine Synthesis is a Metabolic Vulnerability in Malignant Pleural Mesothelioma - PDF(Slides)

P2.21. Single-Cell Dissection Reveals Mesothelial Heterogeneity and Dysfunctional Immunity in Malignant Pleural Mesothelioma - PDF(Slides)

P2.22. Single-nuclei RNA Sequencing Reveals Heterogeneity and Malignancy in Pulmonary Sarcomatoid Carcinoma - PDF(Slides)

P2.22. Long-term Survival in Patients with Primitive Neuroectodermal Tumors of Thorax: Does Size Matter? - PDF(Slides)

P2.22. NUT Midline Carcinoma (NC) Deciphering the Standard of Care in an Ultra-rare Cancer - PDF(Slides)

P2.22. Is the Modified Frailty Index (mFI) a Reliable Predictor of Complications after Transthoracic Esophagectomy? - PDF(Slides)

P2.23. An Untold Story About Living with Low Muscle Mass and its Impact Throughout Curative Radiotherapy Treatment for Lung Cancer - PDF(Slides)

P2.23. Prospective Observational Study of Cachexia and Its Effect on Systemic Therapy in Patients with Previously-Untreated Advanced NSCLC (NEJ050A) - PDF(Slides)

P2.23. The Role of The Mesothelioma UK Nurse Increases the Number of Patients Accessing Legal Representation, Financial Entitlement. - PDF(Slides)

P2.23. Changes in Physical Activity, Fatigue, and Six-Minute Walk Distance Among Lung Cancer Patients Before and After Chemotherapy - PDF(Slides)

P2.23. Counseling & Rehabilitation of Lung-Cancer Sufferers by Nursing Personnel - PDF(Slides)

P2.23. Evaluation/Analysis of Opinions of Oncology Nurses , What We Need to Do ? - PDF(Slides)

P2.23. Determination of the Best Cut-off Point To Establish the Performance of a Mexican Cohort with Non-small Cell Lung Cancer in the 6-Minute Walk Test - PDF(Slides)

P2.25. Geriatric Assessment in Lung Cancer Surgery Patients and Caregivers - PDF(Slides)

P2.25. Resiliency among Older Adults Receiving Lung Cancer Treatment (ROAR-LCT): A Novel Pilot Supportive Care Intervention Study - PDF(Slides)

P2.25. Functional Independence of Older Adults after Lung Cancer Surgery: Final Analysis of a Prospective Observational Study - PDF(Slides)

P2.25. Unmet Social Needs and Spiritual Well-Being of Lung Cancer Surgery Patients and Family Caregivers from the United States - PDF(Slides)

P2.26. Managing Pain Lung Cancer Patients -- Contribution of Oncology Nurses - PDF(Slides)

P2.26. Patient-Reported Symptom Monitoring Improves 1-Year Quality of Life in Lung Cancer Patients; the SYMPRO-Lung Trial - PDF(Slides)

P2.27. Does Patient Experience with Robotic Thoracic Surgery Influence Their Willingness to Pay for It? - PDF(Slides)

P2.27. Stigma-Reducing Interventions for Lung Cancer and Other Smoking-Related Respiratory Diseases: A Systematic Review - PDF(Slides)

P2.27. Perception of Benefits and Risks of Treatments in Patients with Metastatic NSCLC with EGFRex20ins - PDF(Slides)

P2.27. Advocates Unite to Increase Lung Cancer Research Funding - PDF(Abstract)

P2.27. Everywhere Is Local: Applying Lessons from the Community to Areas across the Globe - PDF(Slides)

P2.28. Lung Cancer Mortality in Brazil: Temporal Trends, Regional Disparities and the Impact of the COVID-19 Pandemic - PDF(Slides)

P2.28. Impact of the Covid-19 Pandemic on Lung Cancer Diagnosis in a German Comprehensive Cancer Center. Are we still paying the debt? - PDF(Slides)

P2.28. Symptomatic vs. Asymptomatic SARS-CoV-2 Infection Rates in Lung Cancer: Longitudinal Nucleocapsid Antibody Analysis - PDF(Slides)

P2.29. Harnessing Artificial Intelligence to Expand Lung Cancer Clinical Trial Opportunities in Spain - PDF(Slides)

P2.29. The LungTrust Methodology - PDF(Slides)

P2.30. Cost Estimation of Radiotherapy for Local Control and Overall Survival Benefit of Lung Cancer in the Australian Population - PDF(Slides)

P2.30. Assessing the Impact of Using Disease-Specific Novel Value Elements on Cost-Effectiveness Results in Lung Cancer - PDF(Slides)

P2.31. Characterization of Survival Disparities among Asian Pacific Islander (API) Subgroups in Stage IV NSCLC in California - PDF(Slides)

P2.31. Real-World Survival Outcomes in NSCLC in Adults Ages 50 and Younger at a Large Academic Institution - PDF(Slides)

P2.31. Lambert-Eaton Myasthenic Syndrome is Underrecognized in Small Cell Lung Cancer: An Analysis of Real-World Data - PDF(Slides)

P2.31. Implementation of a Novel Chart Rounds Application to Facilitate Lung Radiotherapy Plan Peer-Review in a Virtual Environment - PDF(Slides)

P2.31. Determining Lines of Therapy in Patients with Metastatic Non-Small Cell Lung Cancer Using Real-World Data - PDF(Slides)

P2.31. Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy - PDF(Slides)

P2.31. Incidence and Survival Outcomes of Lung Cancer Post-Double Lung Transplant and its Association with Graft Rejection - PDF(Slides)

P2.31. Disparities in Representation of Older Adults, Women, Racial/Ethnic Minorities in Lung Cancer Clinical Trials: Meta-analysis - PDF(Slides)

P2.31. Missed Opportunities for Lung Cancer Personalized Medicine in a Brazilian Public Healthcare Service - PDF(Slides)

P2.31. Clinical Outcomes of Real-World Treatment for Metastatic EGFRm NSCLC after Osimertinib and Platinum-Based Chemotherapy - PDF(Slides)

P2.31. Impact of Stage-Specific Guideline Concordant Treatment in Small Cell Lung Cancer in Victoria, Australia - PDF(Slides)

P2.31. Sexual Dysfunction on Patients with Lung Cancer: Results from the CLARIFY Project. - PDF(Slides)

EP14.01. Multimodal Treatment in Malignant Pleural Mesothelioma: An Institutional Experience of 432 Patients over a 29 Year Period - PDF(Slides)